0001144204-12-030606.txt : 20120518 0001144204-12-030606.hdr.sgml : 20120518 20120518154713 ACCESSION NUMBER: 0001144204-12-030606 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 9 CONFORMED PERIOD OF REPORT: 20120331 FILED AS OF DATE: 20120518 DATE AS OF CHANGE: 20120518 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cellceutix CORP CENTRAL INDEX KEY: 0001355250 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 134303398 STATE OF INCORPORATION: NV FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-52321 FILM NUMBER: 12855418 BUSINESS ADDRESS: STREET 1: 100 CUMMING CENTER STREET 2: SUITE 151-B CITY: BEVERLY STATE: MA ZIP: 01915 BUSINESS PHONE: (978)-633-3623 MAIL ADDRESS: STREET 1: 100 CUMMING CENTER STREET 2: SUITE 151-B CITY: BEVERLY STATE: MA ZIP: 01915 FORMER COMPANY: FORMER CONFORMED NAME: EconoShare, Inc. DATE OF NAME CHANGE: 20060306 10-Q 1 v313755_10q.htm FORM 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10 – Q

x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2012

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934

Commission File Number: 000-52321

Cellceutix Corporation

(Exact name of registrant as specified in its charter)

Nevada		30-0565645

(State or Other Jurisdiction of		(I.R.S. Employer
Incorporation or Organization)		Identification Number)

100 Cumming Center, Suite 151-B

Beverly, MA 01915

(Address of principal executive offices and zip code)

(978)-633-3623

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by a check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of “accelerated filer and large accelerated filer” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ¨	Accelerated filer ¨
Non-accelerated filer ¨	Smaller reporting company x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ¨ No x

The number of shares outstanding of the Registrant's Common Stock as of May 10, 2012 was 91,476,067 shares.

CELLCEUTIX CORPORATION

FORM 10-Q

INDEX

TABLE OF CONTENTS

		PART I FINANCIAL INFORMATION

Item	1	Financial Statements

		Balance Sheets- March 31, 2012 (Unaudited) and June 30, 2010 (Audited)	3

		Statements of Operations (Unaudited) - For the Three and Nine Months Ended March 31, 2012 and 2011 and for the cumulative period from June 20, 2007 (Date of Inception) to March 31, 2012	4

		Statements of Changes in Stockholder’s Deficit (Unaudited) - For the cumulative period from June 20, 2007 (Date of Inception) to March 31, 2012	5

		Statement of Cash Flows (Unaudited) - For the Nine Months Ended March 31, 2012 and 2011, and for the cumulative period from June 20, 2007 (Date of Inception) to March 31, 2012	6

		Notes to Financial Statements (Unaudited)	7

Item	2	Management’s Discussion & Analysis of Financial Condition and Results of Operations	14
Item	3	Quantitative and Qualitative Disclosures About Market Risk	18
Item	4	Controls & Procedures	18

		PART II OTHER INFORMATION

Item	1	Legal Proceedings	18
Item	1a	Risk Factors	18
Item	2	Unregistered Sales of Equity Securities and Use of Proceeds	18
Item	3	Default Upon Senior Securities	19
Item	4	Mine Safety Disclosures	19
Item	5	Other Information	19
Item	6	Exhibits	19
		Signatures	20

Part 1. Financial Information

Item 1. Financial Statements

Cellceutix Corporation

(A Development Stage Enterprise)

Balance Sheets

	March 31, 2012			June 30, 2011
	(unaudited)			(audited)
Assets
Current assets:
Cash	$	93,660		$	68,661
Prepaid expenses		6,592			40,290
Other Receivables ( Grant)		-			204,144

Total current assets		100,252			313,095

Total assets	$	100,252		$	313,095

Liabilities and Stockholders' Deficit
Current liabilities:
Accounts payable, including related party payables of $1,695,683 and $1,789,818, respectively	$	1,997,364		$	2,139,527
Accrued expenses, including related party interest and rent accruals of $272,573 and $119,598, respectively		272,573			127,432
Accrued salaries and payroll taxes		2,604,188			2,030,621
Accrued settlement costs, current		261,046			300,859
Note payable to officer		2,022,264			2,002,264
Convertible debentures , current		-			167,099
Total current liabilities		7,157,435			6,767,802

Accrued settlement costs, less current portion		275,229			484,158
Convertible debentures, net of current		-			349,213

Total liabilities		7,432,664			7,601,173

Commitments and contingencies

Stockholders' deficit:
Preferred stock; $0.0001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding		-			-
Common stock Class A ; $0.0001 par value; 300,000,000 shares authorized; 94,238,151 and 91,720,646 shares issued and 91,476.067 and 87,578,562 outstanding, respectively		9,424			9,172
Class B (10 votes per share); $.0001 par value 100,000,000 shares authorized, -0- shares issued and outstanding		-			-
Additional paid in capital		7,893,202			4,838,968
Deficit accumulated during development stage		(14,707,305	)		(11,376,830	)
Treasury stock (2,762,084 and 4,142,084 shares at cost,)		(527,733	)		(759,388	)
Total stockholders' deficit		(7,332,412	)		(7,288,078	)

Total liabilities and stockholders' deficit	$	100,252		$	313,095

The accompanying notes are an integral part of these financial statements.

Cellceutix Corporation

(A Development Stage Enterprise)

Statements of Operations

(Unaudited)

	Three Months Ended						Nine Months Ended
	March 31, 2012			March 31, 2011			March 31, 2012			March 31, 2011			June 20, 2007 (Date of Inception) Through March 31, 2012

Revenues:	$	—		$	—		$	—		$	—		$	—

Operating Expenses:
Research and development, gross		269,043			933,382			478,909			1,679,420			4,738,972
Grants		—			—			—			(529,294	)		(529,294	)
Research and development, net of grants		269,043			933,382			478,909			1,150,126			4,209,678
General and administrative		159,710			23,373			178,779			75,683			507,763
Officers’ payroll and payroll tax		113,975			658,028			1,412,879			2,275,069			6,593,527
Patent expense		14,077			2,522			95,797			31,911			165,480
Professional fees		159,350			611,158			516,671			979,907			2,248,724

Total operating expenses		716,155			2,228,463			2,683,035			4,512,696			13,725,172
Loss from operations		(716,155	)		(2,228,463	)		(2,683,035	)		(4,512,696	)		(13,725,172	)

Interest expense-net		(62,462	)		(68,997	)		(207,548	)		(155,558	)		(533,162	)
Gain (loss) on financial instruments		470,000			-			(439,892	)		-			(439,892	)

Net loss before provision for income taxes		(308,617	)		(2,297,460	)		(3,330,475	)		(4,668,254	)		(14,698,226	)

Provision for income taxes		—			—			—			—			—

Net loss	$	(308,617	)	$	(2,297,460	)	$	(3,330,475	)	$	(4,668,254	)	$	(14,698,226	)

Basic and Diluted Loss per Share	$	(0.00	)	$	(0.03	)	$	(0.04	)	$	(0.05	)

Weighted average number of common shares used in basic and diluted per share calculations		91,256,613			89,714,469			89,649,308			91,207,738

The accompanying notes are an integral part of these financial statements.

Cellceutix Corporation

(A Development Stage Enterprise)

Statement of Changes in Stockholders' Deficit

For the Cumulative

Period June 20, 2007 (Date of Inception)

through March 31, 2012

(Unaudited)

										Deficit
										Accumulated
	Common Stock						Additional			During the
				Par Value			Paid-in			Development			Treasury Stock
	Shares			$0.0001			Capital			Stage			Shares			Amount			Total

Shares issued June 20, 2007 (Inception)		1,000,000		$	100		$	-		$	-			-		$	-		$	100

Net loss		-			-			-			(530	)		-						(530	)
Balance, June 30, 2007		1,000,000			100			-			(530	)		-			-			(430	)

Share exchange with CellceutixPharma, Inc. December 6, 2007		(1,000,000	)		(100	)		-			100			-			-			-

Share exchange in reverse merger with CellceutixPharma, Inc. December 6, 2007		82,000,000			8,200			-			(8,200	)		-			-			-

Shares exchanged in a reverse acquisition of CellceutixPharma, December 6, 2007		9,791,000			979			-			(979	)		-			-			-

Issuance of stock options		-			-			43,533			-			-			-			43,533

Forgiveness of debt from a stockholder		-			-			50			-			-			-			50

Capital contribution from a stockholder		-			-			50			-			-			-			50

Shares issued for services, April 28, 2008 at $1.05		100,000			10			104,990			-			-			-			105,000

Net loss		-			-			-			(510,193	)		-			-			(510,193	)
Balance, June 30, 2008		91,891,000			9,189			148,623			(519,802	)		-						(361,990	)

Cancellation of shares issued for services, December 31, 2008		(100,000	)		(10	)		(104,990	)		-			-			-			(105,000	)

Issuance of stock options		-			-			142,162			-			-			-			142,162

Shares issued for services, June 11, 2009 at $0.38		20,000			2			7,598			-			-			-			7,600

Shares issued for services, June 30, 2009 at $0.38		25,000			3			9,497			-			-			-			9,500

Net loss		-			-			-			(1,485,331	)		-			-			(1,485,331	)
Balance, June 30, 2009		91,836,000			9,184			202,890			(2,005,133	)		-			-			(1,793,059	)

Shares issued for services, July 6, 2009 at $0.43		25,000			2			10,748			-			-			-			10,750

Shares issued for services, February 5, 2010 at $0.30		3,500			-			1,050			-			-			-			1,050

Issuance of stock options		-			-			383,291			-			-			-			383,291

Shares issued for services, June 1, 2010 at $0.45		75,000			8			33,742			-			-			-			33,750

Net loss		-			-			-			(3,433,400	)		-			-			(3,433,400	)
Balance, June 30, 2010		91,939,500			9,194			631,721			(5,438,533	)		-			-			(4,797,618	)

Shares issued for services, July 6, 2010 at $0.55		50,000			5			27,495			-			-			-			27,500

Cancellation of shares issued		(75,000	)		(8	)		(33,742	)		-			-			-			(33,750	)

Issuance of stock options		-			-			3,060,691			-			-			-			3,060,691

Modification of stock options		-			-			237,098			-			-			-			237,098
								5
Forgiveness of liability in connection with settlement with stockholder		-			-			932,966			-			-			-			932,966

Repurchase of common stock in connection with settlement		-			-			-			-			4,602,313			(859,388	)		(859,388	)

Shares issued for services, March 1, 2011 at $0.32		184,375			18			58,982			-			-			-			59,000

Shares issued for services, February 8, 2011 at $0.20		70,000			7			13,993			-			-			-			14,000

Cancellation of treasury stock		(460,229	)		(45	)		(99,955	)		-			(460,229	)		100,000			-

Shares issued for services, May 26, 2011at $0.81		12,000			1			9,719			-			-			-			9,720

Net loss		-			-			-			(5,938,297	)		-			-			(5,938,297	)
Balance, June 30, 2011		91,720,646		$	9,172		$	4,838,968		$	(11,376,830	)		4,142,084		$	(759,388	)	$	(7,288,078	)

Issuance of stock options		-			-			1,175,445			-			-			-			1,175,445

Convertible Debentures converted to common stock		707,277			71			353,564			-			-			-			353,635

Shares issued for services, August 29, 2011at $0.38		100,000			10			37,990			-			-			-			38,000

Shares issued for services, November 8, 2011, at $0.41		125,000			13			51,236			-			-			-			51,249

Shares issued for services, January 11, 2012 at $0.45		200,000			20			89,980			-			-			-			90,000

Shares issued for charitable contributions, March 7, 2012 at $0.52		265,228			26			137,894			-			-			-			137,920

Issuance of capital stock		2,500,000			250			582,142												582,392

Reclassification of warrants into equity		-			-			857,500			-			-			-			857,500

Cancellation of treasury stock		(1,380,000	)		(138	)		(231,517	)		-			(1,380,000	)		231,655			-

Net loss for 9 months ended March 31,2012		-			-			-			(3,330,475	)		-			-			(3,330,475	)

		94,238,151		$	9,424		$	7,893,202	$		(14,707,305	)		2,762,084		$	(527,733	)	$	(7,332,412	)

The accompanying notes are an integral part of these financial statements.

Cellceutix Corporation

(A Development Stage Enterprise)

Statements of Cash Flows

(Unaudited)

	For the Nine Months Ended March 31, 2012			For the Nine Months Ended March 31, 2011			For the Cumulative Period June 20, 2007 (Date of Inception) through March 31, 2012

CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(3,330,475	)	$	(4,668,254	)	$	(14,698,226	)
Adjustments to reconcile net loss to net cash used in operating activities:
Common stock and stock options issued as payment for services compensation, services rendered and charitable contributions		1,527,323			2,585,387			5,512,508
Cancellation of stock for services		-			(11,250	)		(28,750	)
Amortization of accrued settlement costs		51,259			8,543			76,887
Gain (loss) on financial instruments		439,892						439,892
Changes in operating assets and liabilities:
Other receivable		204,144			—			—
Prepaid expenses		(1,010	)		12,778			8,160
Accounts payable		(142,163	)		693,624			1,997,414
Accrued expenses		149,562			145,140			489,984
Accrued salaries and payroll taxes		573,566			669,833			3,537,153
Net cash used in operating activities		(527,902	)		(564,199	)		(2,664,978	)

CASH FLOWS FROM FINANCING ACTIVITIES:
Capital contribution from a stockholder		—			—			50
Payment of settlement liabilities		(300,000	)		(100,000	)		(400,000	)
Loan from officer		20,000			750,370			1,925,587
Sale of common stock		—			—			100
Proceeds from convertible debentures		—			—			400,000
Redemption of convertible debentures		(167,099	)		—			(167,099	)
Proceeds from subscription		1,000,000						1,000,000
Net cash provided by financing activities		552,901			650,370			2,758,638

NET INCREASE (DECREASE) IN CASH		24,999			(86,171	)		93,660

CASH, BEGINNING OF PERIOD		68,661			3,994			—

CASH, END OF PERIOD	$	93,660		$	90,165		$	93,660

SUPPLEMENTAL DISCLOSURE OF NON-CASH FLOW FINANCING ACTIVITIES:
Common stock issued for acquisition	$	—		$	—		$	9,079
Forgiveness of debt	$	—		$	—		$	50
Cancellation of common stock for services	$	—		$	(33,750	)	$	(138,750	)
Settlement of accrued payroll and payroll taxes	$	—			932,966		$	932,966
Treasury stock as a result of settlement agreement	$	—			859,388		$	859,388
Reclassification of accrued interest to note payable and convertible debenture	$	—		$	137,964		$	197,964
Debt converted to common stock	$	353,635		$	—		$	353,635
Cancellation of treasury stock	$	(231,655	)	$	—		$	(231,655	)
Reclassification of warrants to equity	$	857,500		$	—		$	857,500

The accompanying notes are an integral part of these financial statements.

Cellceutix Corporation

(A Development Stage Enterprise)

Notes to Financial Statements

March 31, 2012

(Unaudited)

1. Background Information

Cellceutix Corporation, formerly known as EconoShare, Inc., (the “Company” or the “Registrant”) was incorporated on August 1, 2005 in the State of Nevada and was organized for the purpose of developing a B2B (Business to Business) website for an Asset Sharing market place and transaction system.

On December 6, 2007, the Company acquired CellceutixPharma, Inc., a privately owned Delaware corporation pursuant to an Agreement and Plan of Share Exchange (the “Exchange”). CellceutixPharma, Inc. was incorporated under the laws of the State of Delaware on June 20, 2007. Its assets consisted of rights assigned to it for six early stage pharmaceutical compounds by three different scientists.

Pursuant to the terms of the Exchange, the Company acquired CellceutixPharma, Inc. in exchange for an aggregate of 82,000,000 newly issued shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”). As a result of the Exchange, CellceutixPharma, Inc. became a wholly-owned subsidiary of the Company. The Company’s shares were issued to the CellceutixPharma, Inc. shareholders on a pro rata basis, on the basis of 82 shares of Common Stock for each share of CellceutixPharma, Inc. common stock held by such CellceutixPharma, Inc. shareholder at the time of the Exchange. This resulted in the former holders of CellceutixPharma, Inc. Common Stock, upon Exchange, owning approximately 89% of the outstanding shares of the Company’s Common Stock. Accordingly, the Exchange represented a change in control. For financial accounting purposes, the acquisition was a reverse acquisition of the Company by CellceutixPharma, Inc., under the purchase method of accounting, and was treated as a recapitalization with CellceutixPharma, Inc. as the legal acquirer. Upon consummation of the Exchange, the Company adopted the business plan of CellceutixPharma, Inc. We are an early stage developmental biopharmaceutical company. The Company has no customers, products or revenues to date, and may never achieve revenues or profitable operations.

On January 14, 2008, a majority of the shareholders of the Company approved an amendment to the Registrant’s articles of incorporation to change the name of the Registrant to Cellceutix Corporation. Upon the filing of a Definitive Information Statement and effectiveness of the name change on February 1, 2008, the Company applied to the National Association of Security Dealers (NASD) to change its stock symbol on the Over the Counter Bulletin Board which resulted in the Company’s stock symbol being changed to CTIX.

As of October 2011, the Company’s Common Stock is quoted on the Over the Counter Bulletin Board (OTCBB) with the symbol “CTIX”. Previously, the Company’s Common Stock was quoted on the OTC Markets Group, Inc.’s OTCQB.

On December 29, 2010 shareholders holding 51% of the Company’s outstanding common stock adopted and approved the 2010 Equity Incentive Plan and authorized an amendment to the Company’s Articles of Incorporation to authorize Class B common stock convertible into Class A common stock on a 1:1 basis, however the Class B Common Stock shall entitle ten votes for each share of Class B Common Stock. On February 8, 2011, the Company filed a Form 14C Information Statement with the Securities and Exchange Commission. This action became effective on May 10, 2011, approximately twenty (20) days from the date of mailing of the Definitive Information Statement. The Definitive Information Statement was mailed on April 20, 2011 to the shareholders of record as of February 9, 2011. All shares issued as of balance sheet dates are Class A common stock.

On September 21, 2011 Cellceutix reported that it had signed a Laboratory Services Research Support Agreement with Dana Farber/Partners CancerCare, Inc. The agreement outlines the collaborative and laboratory support for the planned clinical trials for Kevetrin™, Cellceutix’s novel compound as an indication for cancer.

In connection with an offering by the Company of a maximum of up to 2,500,000 shares at $0.40 per share (the “Offering”), a “Subscriber” on October 11, 2011, subscribed for 833,334 shares of the Company’s Class A common stock upon payment of $333,334 and on November 3, 2011, subscribed for 832,500 shares of the Company’s Class A common stock upon payment of $333,000 and on December 7, 2011, subscribed for 834,166 shares of the Company’s Class A common stock upon payment of $333,666. Subscriber is also entitled to one Stock Purchase Warrant exercisable at $1.00 for each share of Common Stock subscribed.

In November 2011, Dr. Paul Marks joined the Cellceutix Scientific Advisory Board. Dr. Marks served as President and Chief Executive Officer of Memorial Sloan-Kettering Cancer Center ("MSKCC") from 1980 to 1999 where he helped to establish the high standards for research and patient care that MSKCC is world renowned for. He remains a vital part of MSKCC as President Emeritus and Member of the Sloan-Kettering Institute.

In November 2011, Cellceutix filed its Investigational New Drug (IND) application for Kevetrin™, our novel anti-cancer drug, with the U.S. Food and Drug Administration (FDA). In December 2011, Cellceutix was notified by the FDA that the production manufactured by our vendor Formatech, Inc. for use in the clinical trials was not eligible because of GMP violations at Formatech. Cellceutix retained another formulation manufacturer and production was completed in March 2012. The manufactured product is now undergoing quality and stability testing. Once completed, Cellceutix will submit an amended IND to the FDA. The trials are planned at Dana Farber/ Harvard Cancer Center. The clinical trial will test Kevetrin™ against a variety of different cancer types in patients with advanced-stage cancers. Primary endpoints for the study will be safety, tolerable dosing levels and establishing the dose for a future Phase II clinical trial.

In December 2011,Cellceutix initiated a study in collaboration with Pioneer Valley Life Sciences Institute, a Baystate Medical Center/University of Massachusetts Amherst Research Partnership ("the Institute"), to collaborate on an innovative research project to investigate Kevetrin's antitumor activity related to risk factor aging. In February 2012, Cellceutix received data from this study that is helpful in further developing the potential of Kevetrin.

In January 2012,Cellceutix filed a patent application for KM-133, our compound to treat psoriasis and subsequently filed a request for a pre-IND meeting with the FDA. The meeting is now scheduled for mid June 2012.

In March 2012,Cellceutix entered into an agreement with Beth Israel Deaconess Medical Center(BIDMC), a teaching hospital of Harvard Medical School, on an innovative research project with Kevetrin. The Medical Center wishes to exploit the nuclear and/or mitochondrial pro-apoptotic function of p53 in melanoma and renal cell carcinoma, two types of cancer that are particularly resistant to therapy.BIDMChopes to improve therapy for melanoma and renal cell carcinoma, cancers that are particularly resistant to therapy.

BIDMC initiated combination studies with multikinaseinhibitors which activate pro-apoptotic activity by translocation of p53 in mitochondria thereby inducing apoptosis. Apoptosis is enhanced by MDM2 inhibitors by stabilizing p53. As presented at the American Association for Cancer Research (AACR) meeting in April, KevetrinphosphorylatesMDM2 which activates and stabilizes p53 by monoubiquitination inducing apoptosis. Prior data from the BIDMC laboratory showed that agents of this class can augment the pro-apoptotic and antitumor effects of MDM2 antagonists and is expected to have a synergistic effect with Kevetrin.

BIDMC will test the effects of Kevetrin alone and in combination with FDA-approved VEGFR antagonists in the renal cell carcinoma and melanoma studies. In vitro study endpoints include apoptosis by measuring caspase activation and PARP cleavage. In vivo endpoints include efficacy in a xenograft model, tumor vascularity, p53 levels, p21 expression and apoptosis.

This study will provide vital insight to exploit the nuclear and/or mitochondrial pro-apoptotic function by Kevetrin in combination with other multikinase inhibitors in treatment of these difficult to treat malignancies.

2. Financial Statements

In the opinion of management, all adjustments consisting only of normal recurring adjustments necessary for a fair statement of (a) the results of operations for the three and nine month periods ended March 31, 2012 and 2011, (b) the financial position at March 31, 2012 and (c) cash flows for the three and nine month periods ended March 31, 2012 and 2011, have been made.

The unaudited financial statements and notes are presented as permitted by Form 10-Q. Accordingly, certain information and note disclosures normally included in the financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted. The accompanying financial statements and notes should be read in conjunction with the Company’s Form 10K for the fiscal year ended June 30, 2011. The results of operations for the three and nine month periods ended March 31, 2012 are not necessarily indicative of those to be expected for the entire year.

The company has evaluated all subsequent events through the filing date of this form 10-Q with SEC, to ensure that this form 10-Q includes subsequent events that should be recognized in the financial statements as of March 31, 2012, and appropriate disclosure of subsequent events which were not recognized in the financial statements

3. Going Concern

The accompanying financial statements have been prepared assuming the Company will continue as a going concern. For the period since June 20, 2007 (date of inception) through March 31, 2012, the Company has had a cumulative net loss of $14,698,226and a working capital deficit of $7,057,183 at March 31, 2012. As of March 31, 2012, the Company has not emerged from the development stage. In view of these matters, the ability of the Company to continue as a going concern is dependent upon the Company’s ability to generate additional financing. Since inception, the Company has financed its activities principally from the use of equity securities, debt issuance and loans from an officer to pay for its operations. The Company intends on financing its future development activities and its working capital needs largely from the issuance of debt and the sale of equity securities, until such time that funds provided by operations are sufficient to fund working capital requirements. There can be no assurance that the Company will be successful at achieving its financing goals at reasonably commercial terms, if at all.

The economic downturn and market instability has made the business climate more volatile and more costly. If the current equity and credit markets deteriorate further or do not improve, it may make necessary debt or equity financing more difficult, more costly and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on the Company’s growth strategy, financial performance and stock price and could require the delay of new product development and clinical trial plans. Currently, the Company has not made any additional arrangements for equity or any other type of financing.

These factors raise substantial doubt about the Company's ability to continue as a going concern. The accompanying financial statements do not include any adjustments relating to the recoverability of the recorded assets or the classification of liabilities that may be necessary should the Company be unable to continue as a going concern.

4. Recent Accounting Pronouncements:

In May 2011, the FASB issued ASU No. 2011-04 (“ASU 2011-04”), Fair Value Measurement – amendments to achieve fair value measurements and disclosure requirements in US GAAP and IFRSs. The amendments change the wording used to describe many of the requirements in U.S. GAAP for measuring fair value and for disclosing information about fair value measurements. For many of the requirements, the Board does not intend for the amendments in this Update to result in a change in the application of the requirements in Topic 820. The amendments in this update are to be applied prospectively. The adoption of this guidance is not expected to have a material impact on the financial statements

In June 2011, the FASB issued guidance which eliminates the option to report other comprehensive income and its components in the statement of changes in stockholders’ equity and requires an entity to present the total of comprehensive income, the components of net income and the components of other comprehensive income either in a single continuous statement or in two separate but consecutive statements. This pronouncement is effective for fiscal years, and interim periods within those years, beginning after December 15, 2011. The adoption of this guidance is not expected to have a material impact on the financial statements.

Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material impact on the Company’s consolidated financial statements.

5. Commitments and Contingencies

Settlement Agreement

On February 14, 2011, the Company announced it reached a settlement agreement on all outstanding claims and issues between the Company and our former CEO, Mr. Evans. Each party dropped their respective claims and as a result all of Mr. Evans accrued salaries and options were cancelled. The terms of the agreement provide that the Company purchase 4,602,312 common shares held by Mr. Evans and/or Mr. Evans’ sons over a period of three years for a total sum of one million dollars. Payment by the Company in the amount of $100,000 was made upon the signing of the agreement and $300,000 was paid in February 2012. These payments resulted in the cancelation of 1,840,229 shares of common stock.2,762,084 shares of common stock remain in escrow until additional payments are made under the agreement and are shown as Treasury Stock on the Company’s Balance Sheet.

The Company had initially recorded this settlement at December 31, 2010 as a liability of the present value of the future payments and treasury stock. The Company had also recorded the forgiveness of Mr. Evans’ accrued payroll and related payroll taxes as a capital contribution of $932,966. As of March 31, 2012, the settlement liability was $ 536,275 of which $ 261,046 is due in February 2013 and recorded as current liability.

Pharmaceutical Compounds

On August 2, 2007, the Company was assigned all right, title, and interest to three pharmaceutical compounds;Kevetrin, KM 277 and KM 278, by their inventors. The Company was assigned all right, title, and interest to an additional three pharmaceutical compounds on October 17, 2007, KM 133 KM 362 and KM 3174. In July 2009, the Company was assigned all right, title, and interest to KM 732.In exchange for these compounds, the Company agreed to pay the inventors 5% of net sales of the compounds in countries where composition of matter patents have been issued and 3% of net sales in other countries. Kevetrin, KM 277, KM 278 and KM 362 were acquired from our President and director, Dr. Krishna Menon. The Company filed a patent application for Kevetrin and intends to file patent applications for each of the other six compounds as funds become available.

In December 2009, the Company was assigned all right, title and interest to a new compound, KM-391, which it intends to develop for the treatment of autism. In exchange for this compound, the Company agreed to pay the inventors $10,000 plus 4.5% of net sales the compound in countries where a composition of matter patent has been issued and 3% of net sales in other countries.

Employment Agreements

The Company’s accrued officers’ salaries and payroll taxes as of March 31, 2012 and June 30, 2011 are as follows:

	March 31, 2012		June 30, 2011

Krishna Menon	$	1,346,250	$	1,075,000
Leo Ehrlich	$	1,108,750	$	837,500
Accrued Payroll Taxes	$	149,188	$	118,121

	$	2,604,188	$	2,030,621

On December 29, 2010, the Company entered into employment agreements with its two executive officers, Leo Ehrlich, the Company’s Chief Executive Officer, and Krishna Menon, Chief Scientific Officer. Both agreements provide for a three year term with each executive receiving an annual base salary for $350,000 per year commencing January 1, 2011, with an annual increase of 10% for each year commencing January 2012. In addition, the Company’s Board awarded stock options exercisable at $0.11 per share pursuant to the Company’s 2010 Equity Incentive Plan to each executive officer as follows: a total of 18 million options with 6 million options vesting on December 29, 2010, 6 million options vesting on June 30, 2011 and 6 million options vesting on January 3, 2012.The Board, at its discretion, may increase the base salary based upon relevant circumstances.

Litigation

In the ordinary conduct of business, the Company is subject to lawsuits, arbitrations and administrative proceedings from time to time. The Company expenses legal costs as incurred.

Toxikon Corporation, a vendor, has initiated litigation with claims that it is owed a balance of approximately $100,000 plus interest and legal fees. Cellceutix has retained a lawyer and is disputing these claims and believes there is no balance owed.

6. Fair Value of Financial Assets and Financial Liabilities

The Company utilizes a hierarchy that prioritizes fair value measurements based on the types of inputs used for the various valuation techniques (market approach, income approach and cost approach). The levels of the hierarchy are described below:

•	Level 1: consists of financial instruments whose value is based on quoted market prices for identical financial instruments in an active market

•	Level 2: consists of financial instruments that are valued using models or other valuation methodologies. These models use inputs that are observable either directly or indirectly; Level 2 inputs include (i) quoted prices for similar assets or liabilities in active markets, (ii) quoted prices for identical or similar assets or liabilities in markets that are not active, (iii) pricing models whose inputs are observable for substantially the full term of the financial instrument and (iv) pricing models whose inputs are derived principally from or corroborated by observable market data through correlation or other means for substantially the full term of the financial instrument.

•	Level 3: consists of financial instruments whose values are determined using pricing models that utilize significant inputs that are primarily unobservable, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation

The assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the valuation of financial instruments and their classification within the fair value hierarchy. Financial instruments are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. There have been no changes in the classification of any financial instruments within the fair value hierarchy.

The Company’s remaining financial instruments consisted primarily of (level 1) cash and cash equivalents, accounts payable, accrued expenses and note payable. The carrying amounts of the Company’s financial instruments generally approximate their fair values as of March 31, 2012 and June 30, 2011 due to the short term nature of these instruments.

The Company did not have any level 3 instruments at March 31, 2012 but had convertible debentures as of June 30, 2011. The convertible debentures were paid in full in January 2012.

7. Related Party Transactions

Office Lease

Dr. Menon, the Company’s principal shareholder, President, and Director, also serves as the Chief Operating Officer and Director of Kard Scientific (“KARD”). On December 7, 2007, the Company began renting office space from KARD, on a month to month basis for $900 per month. At March 31, 2012 and June 30, 2011, payables of $46,800 and $38,700 to KARD were included in accrued expenses, respectively. For the three and nine months ended March 31, 2012and 2011 and the period June 20, 2007 (date of inception) through March 31, 2012, the Company has included $2,700, $8,100, $2,700, $8,100 and $46,800 in general and administrative expenses, respectively.

Clinical Studies

As of September 28, 2007 the Company engaged KARD to conduct specified pre-clinical studies necessary for the Company to prepare an IND submission to the Father Company does not have an exclusive arrangement with KARD. All work performed by KARD must have prior approval by the executive officers of the Company, and the Company retains all intellectual property resulting from the services by KARD. For the three and nine months ended March 31, 2012and 2011 and the period June 20, 2007 (date of inception) through March 31, 2012, the Company incurred $9,990, $9,990, $747,207, $1,032,867, and $2,601,110 of research and development expenses conducted by KARD, respectively. At March 31, 2012and June 30, 2011 the Company has included a total of $1,685,515 and $1,780,515 in accounts payable to Kard respectively.

8. Due To Officer

During the year ended June 30, 2010, Mr. Ehrlich, an officer of the Company, converted previous amounts provided in cash to the Company of $32,310 into a loan (the “Ehrlich Promissory Note A”).The Ehrlich Promissory Note A was an unsecured, 6% per annum simple interest bearing, demand note. During the same period, Mr. Ehrlich provided an additional $85,000 in cash in the form of a loan to the Company (the “Ehrlich Promissory Note B”).The Ehrlich Promissory Note B was an unsecured, 6% per annum simple interest bearing, demand note.

During the year ended June 30, 2010, Mr. Ehrlich, loaned the Company a total of $972,907.A condition for this loan was that the Ehrlich Promissory Note A and Ehrlich Promissory Note B be replaced with a new note, Ehrlich Promissory Note C. The Ehrlich Promissory Note C is an unsecured demand note that bears 9% simple interest per annum and is convertible into the Company’s common stock at $0.50 per share. The note requires that the interest rate on the amounts due on Ehrlich Promissory Notes A and B be changed retroactively, beginning October 1, 2009, to 9%.On April 1, 2011, the Company amended the Ehrlich Promissory Note C and agreed to retroactively convert accrued interest of $96,677 through December 31, 2010 into additional principal.

At March 31, 2012, $225,773 is accrued as interest expense on this note. During the nine months ended March 31, 2012, Mr. Ehrlich loaned the Company an additional $20,000 which brought the balance of the demand note to $2,022,264

9. Stock Options and Warrants:

On April 5, 2009 the Board of Directors of the Registrant adopted the 2009 Stock Option Plan ("the 2009 Plan"). The Plan permits the grant of 2,000,000 shares of both Incentive Stock Options ("ISOs"), intended to qualify under section 422 of the Code, and Non-Qualified Stock Options.

On December 29, 2010 shareholders holding 51% of the Company’s outstanding common stock adopted and approved the 2010 Equity Incentive Plan (“the 2010 Plan”). Under the 2010 Equity Incentive Plan the total number of shares of Common Stock reserved and available for issuance under the Plan shall be 45,000,000 shares. Shares of Common Stock under the Plan (“Shares”) may consist, in whole or in part, of authorized and unissued shares or treasury shares. The term of each Stock Option shall be fixed by the Committee; provided, however, that an Incentive Stock Option may be granted only within the ten-year period commencing from the Effective Date and may only be exercised within ten years of the date of grant (or five years in the case of an Incentive Stock Option granted to an optionee who, at the time of grant, owns Common Stock possessing more than 10% of the total combined voting power of all classes of voting stock of the Company (“10%Shareholder”).

On April 1, 2009, the Company entered into an agreement, subsequently amended, with a Consultant to assist the Company's Chief Scientific Officer to organize, manage and display data from animal studies as well as information relating to Active Pharmaceutical Ingredients and formulations of the Company's products through November 2010. The Consultant was compensated at the rate of $4,000 per month payable on the last day of each month. In addition, at the end of each month of services provided, the Consultant is granted options to purchase 10,000 shares of Company's common stock. Effective September 1, 2010, the Company has extended the current agreement and beginning in August 2010, the monthly fee was increased to $5,000. The remainder of the agreement remains unchanged. As of March 31, 2012, the Consultant has been awarded a total of 360,000 options to purchase common stock valued at $157,988, each grant is to be vested over one year from date of issuance. For the three and nine months ended March 31, 2012, the Company has expensed $18,251 and $50,029 to professional fees expense, related to these options.

On May 6, 2010, the Company entered into a two year agreement with an individual for consulting services. In exchange for these services, the Company granted the Consultant 200,000 options to purchase common stock. The options were valued using the Black-Scholes option model for $62,015, which includes the option modification expense. As of March 31, 2012, the Company has $2,621 remaining in prepaid expenses related to this agreement and expensed $7,863 and $23,589 for the three and nine months ended March 31, 2012.

On December 29, 2010 options to purchase 1,680,000 shares of the Company’s common stock were granted to a consultant for financial and administrative services rendered pursuant to the 2010 Company’s Equity Incentive Plan, of which 840,000 options were exercisable at the date of grant and 840,000 options vested on June 30, 2011. The options are exercisable at $0.10 per share.

On December 29, 2010, the Company entered into employment agreements with its two executive officers, Leo Ehrlich, the Company’s Chief Executive Officer, and Krishna Menon, Chief Scientific Officer. Both agreements provide for a three year term with each executive receiving an annual base salary for $350,000 per year commencing January 1, 2011, with an annual increase of 10% for each year commencing January 2012. In addition, the Company’s Board awarded stock options exercisable at $0.11 per share pursuant to the Company’s 2010 Equity Incentive Plan to each executive officer as follows: Option Group A, a total of 18 million options with 6 million options vesting on December 29, 2010, 6 million options vesting on June 30, 2011 and 6 million options vesting on January 3, 2012. The Board, at its discretion, may increase the base salary based upon relevant circumstances. The Company recorded $0.0 and $1,093,416 in stock based compensation for the three and nine months ended March 31, 2012 and a cumulative total of $3,292,248 in stock based compensation as of March 31, 2012.

In July 2011 we issued options to purchase 50,000 shares of our common stock to a consultant for services rendered to the Company valued at $28,000.

The fair value of each option for the nine months ended March 31, 2012 and 2011 was estimated on the date of grant or grant modification using the Black Scholes model that uses assumptions noted in the following table.

	Nine Months Ended March 31, 2012	Nine Months Ended March 31, 2011
Expected term (in years)	5 – 10	5 – 10
Expected stock price volatility	142.51% – 148.15%	121.23% – 152.05%
Risk-free interest rate	1.97% – 3.0%	0.88% – 3.75%
Expected dividend yield	0%	0%

Stock Options

The following table summarizes all stock option activity:

	Number of Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (Years)		Aggregate Intrinsic Value
Outstanding at June 30, 2010		3,355,430		$	0.25		1.36		—
Granted		38,442,500			0.11		9.24		—
Exercised		—			—		—		—
Forfeited/expired		(2,755,430	)		0.25		—		—
Outstanding at June 30, 2011		39,042,500		$	0.12		9.15	$	24,003,475
Granted		140,000			0.58		7.00	$	4,300
Exercised		—			—		—		—
Forfeited/expired		—			—		—		—
Outstanding at March 31, 2012		39,182,500		$	0.12		8.64	$	15,819,150
Exercisable at March 31, 2012		39,117,623		$	0.11		8.63	$	15,816,685

The Company recognized of $1,175,445 and $2,481,150 of compensation costs related to option awards granted during the nine months ended March 31, 2012 and 2011, $18,251 and $1,042,151 for the three months ended March 31, 2012 and 2011 and $5,042,046 for the period from inception to March 31, 2012, respectively, and there is $28,401 of unamortized compensation cost expected to be recognized through December 31, 2012. This includes the additional compensation costs related to the Board of Director’s approval to extend the term of all outstanding options an additional two years.

As of December 31, 2010, there were 2,964,000 warrants issued and outstanding with a weighted average exercise price of $0.81. The warrants were to expire in September 2010, however in September 2010; the Company approved the extension of these warrants to December 31, 2013.

During the months of October, November and December 2011, warrants to purchase 2,500,000 shares of the Company’s Class A common stock were issued to an investor pursuant to his purchase of 2,500,000 shares of the Company’s Class A common stock at $0.40 per share. Under ASC 815-40-25, the fair value of these warrants should be reported as a liability, Pursuant to the Warrant Agreement, because there is currently no effective registration statement covering the shares of common stock underlying these warrants, these warrants are currently subject to a cashless exercise whereby the warrant holders may surrender their warrants to the company in exchange for shares of common stock. The number of shares of common stock into which a warrant would be exchangeable in such a cashless exercise depends on both the exercise price of the warrants and the market price of the common stock, each at or near the time of exercise. Because both of these factors are variable, it is possible that the company could have insufficient authorized shares to satisfy a cashless exercise. In this scenario, if the company were unable to obtain shareholder approval to increase the number of authorized shares, the company could be obligated to settle such a cashless exercise with cash rather than by issuing shares of common stock. Further, ASC 815-40-25 requires that we record the potential settlement obligation at each reporting date using the current estimated fair value of the warrants, with any changes being recorded through our statement of operations. The warrants were valued at $417,608 at the time of issuance and recorded as a liability. At December 31, 2011, the warrants were valued at $1,327,500 and the warrant liability was increased by $909,892. On January 12, 2012, the subscription agreement was modified to remove the cashless exercise provision, and provide for “piggy-back” registration rights. The warrants were valued as of January 12, 2012 and the value reduced by $470,000. The remaining $857,000 of warrant value was reclassified from a liability to equity. As of March 31, 2012, these 2,500,000 warrants are outstanding with an exercise price of $1.00 and expire in October, November and December 2014.

10. Equity Transactions

On August 29, 2011, the Company issued 100,000 shares of Class A common stock to consultants for services rendered in the first quarter of fiscal year 2012.The 100,000 shares of common stock are valued at a total of $38,000.

On September 9, 2011, the company issued 471,518 common shares of the company stock to White Star LLC and 235,759 common shares to Dahlia Nordlicht upon conversion of convertible debentures. (see note 11)

On November 8, 2011, the Company issued a total of 125,000 shares of Class A common stock to two consultants and a member of its scientific advisory board valued at $51,250.

On January 11, 2012, the Company issued a total of 200,000 shares of Class A common stock to a consultant valued at $90,000.

On March 7, 2012 the Company issued a total of 265,228 shares of Class A common stock as charitable contributions valued at $137,920.

11. Convertible Debentures

On May 7, 2008, the Company issued Convertible Debentures, at 9% per annum, for a total amount of $400,000.The principal and related accrued interest were due December 2009, and secured by the Company’s assets. The Debentures and any accrued and unpaid interest were convertible into the Company’s common stock, at the holder’s request, at a conversion price of $1.50.In January 2010, the Company extended and amended the original Convertible Debenture agreements by extending the original maturity date to December 31, 2010. The conversion price of the principal and any unpaid interest was changed to $0.50 per share. The Company and debenture holders also agreed to convert accrued interest of $60,000 into additional principal. On February 10, 2011, the Company extended and amended the Convertible Debenture agreements by extending the original maturity date to December 31, 2011.The conversion price of the principal balance remains at $0.50 per share. The Company and debenture holders also agreed to convert accrued interest of $41,287 through December 31, 2010 into additional principal resulting in a note balance of $501,287.

On September 9, 2011, the company issued 471,518 common shares of the company stock to White Star LLC upon conversion of $222,791 of the principal on our existing outstanding debentures and $12,965 for interest; and the company issued 235,759 common shares to Dahlia Nordlicht upon conversion of $111,397 of the principal on our existing outstanding debentures and $6,482 for interest. Each of the Notes was converted at the price of $.50 per share. The shares were issued pursuant to the exemption from registration provided for under Rule 506 of Regulation D, promulgated under the United States Securities Act of 1933, as amended.

The Company paid off the remaining Convertible Debenture balance in the amount of $167,100 plus interest of $14,826 on January 3, 2012.

12. Subsequent Events

Cellceutix has been advised that a “Notice of Intent to Sell” 184,375 shares of the Company’ Class A Common Stock issued to Formatech, Inc. for services that were not completed (See Note 1), has been filed by Formatech’s Bankruptcy trustee. Cellceutix has engaged an attorney with the aim of recovering these shares. A court hearing for this Motion is scheduled for June 28, 2012.

On April 26, 2012, the Company issued 300,000 shares of Class A common stock to consultants for services. The 300,000 shares of common stock are valued at a total of $138,000 based on the closing bid price as quoted on the OTC Bulletin Board on April 25, 2012 of $0.46 per share. On May 3, 2012, the Company issued a total of 100,000 shares of Class A common stock to two consultants for services. The 100,000 shares of common stock are valued at a total of $48,000 based on the closing bid price as quoted on the OTC Bulletin Board on May 2, 2012 of .46 per share. In addition a total of 50,000 three (3) year stock purchase options exercisable at $0.54 were issued. The options vest on June 30, 2012.

On May 7, 2012 the Company announced that Syracuse University’s basketball coach Jim Boeheim joined Cellceutix as an advisor to the Company.

On May 8, 2012, the Company entered into a subscription agreement for Series A Convertible Preferred shares with an accredited investor for an aggregate of $1,000,000. Initial funding was One Hundred Thousand USD ($100,000) for the purchase 10,000 Series A Convertible Preferred Shares, and was closed on May 8, 2012. Subscription Agreement provides for installment Funding Amounts to take place every thirty days after initial closing date for an amount of the lesser of (i) $75,000 or (ii) twenty five (25% ) per cent of the dollar value of the total volume traded during the preceding 22 trading days. The Series A Preferred Shares are convertible into common stock at the lesser of 85% of the closing bid price on the date of prior to each closing, or 85% of the lowest bid price for the fifteen (15) days prior to conversion. Additionally, for each common share issued upon conversion of Series A preferred share, a five year common stock purchase warrants shall be issued to the Subscriber which warrant shall be exercisable at the conversion price of the common shares issued. The Series A Convertible Preferred shares do not pay dividends. The Common shares underlying the Series A Preferred Shares and the common stock purchase warrants are subject to piggy back registration rights.

On May 8, 2012, the Company renegotiated the terms of the outstanding balance of principle and interest $2,248,037, as of March 31, 2012, represented by the Ehrlich Promissory Note C issued to Leo Ehrlich for funds he loaned to the company. In connection therewith, the Company renegotiated the interest on the loan from 9% simple interest to 10% simple interest and issued 2,000,000 Equity Incentive Options exercisable at $0.51 per share equal to 110% of the closing bid price of $0.46 per share on May 7, 2012. Options are valid for ten (10) years from the date of issuance.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion of the Company’s financial condition and the results of operations should be read in conjunction with the Financial Statements and Notes thereto appearing elsewhere in this document.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements. In order to comply with the terms of the safe harbor, the Company notes that in addition to the description of historical facts contained herein, this report contains certain forward-looking statements that involve risks and uncertainties as detailed herein and from time to time in the Company’s other filings with the Securities and Exchange Commission and elsewhere. Such statements are based on management’s current expectations and are subject to a number of factors and uncertainties, which could cause actual results to differ materially from those, described in the forward-looking statements. These factors include, among others: (a) the Company’s fluctuations in sales and operating results; (b) risks associated with international operations; (c) regulatory, competitive and contractual risks; (d) product development risks; (e) the ability to achieve strategic initiatives, including but not limited to the ability to achieve sales growth across the business segments through a combination of enhanced sales force, new products, and customer service; and (f) pending litigation.

Management’s Plan of Operation

We are a developmental stage biopharmaceutical company. We plan to transition to a clinical stage company in mid 2012. In November 2011, Cellceutix filed an Investigational New Drug (IND) application for Kevetrin™, our novel anti-cancer drug, with the U.S. Food and Drug Administration (FDA). In December 2011, Cellceutix was notified by the FDA that the production manufactured by our vendor Formatech, Inc. for use in the clinical trials, was not eligible because of GMP violations at Formatech. Cellceutix retained another formulation manufacturer and production was completed in March 2012. The manufactured product is now undergoing quality and stability testing. Once completed, Cellceutix will submit an amended IND to the FDA. The trials are planned for at Dana Farber/ Harvard Cancer Center. The clinical trial will test Kevetrin™ against a variety of different cancer types in patients with advanced-stage cancers. Primary endpoints for the study will be safety, tolerable dosing levels and establishing the dose for a future Phase II clinical trial.

Kevetrin™, the Company’s flagship compound against cancers, has demonstrated the potential for a major breakthrough in cancer research by exhibiting an activation of p53 in both wild and mutant types of p53. p53, often referred to as the “Guardian Angel Gene” or the “Guardian Angel of the Human Genome” due its crucial role in controlling cell mutations, is a tumor suppressor protein that is encoded by the TP53 gene in humans and has been widely regarded as possibly holding a key to the future of cancer therapies. Additional studies have shown that Kevetrin™ has potent anticancer activity in a wide range of tumor types by targeting histonedeacetylase (HDAC).

In January 2012,Cellceutix filed a patent application for KM-133, our compound to treat psoriasis and subsequently filed a request for a pre-IND meeting with the FDA. The Company now has a meeting scheduled in mid June 2012 with the FDA.

We have no product sales to date and we will not receive any product revenue until we receive approval from the FDA or equivalent foreign regulatory bodies to begin selling our pharmaceutical candidates. Developing pharmaceutical products, however, is a lengthy and very expensive process. Assuming we do not encounter any unforeseen safety issues during the course of developing our product candidates, we do not expect to complete the development of a product candidate for several years, if ever.

We acquired exclusive rights to a total of eight (8) pharmaceutical compound candidates that are designed for treatment of diseases which may be either existing or diseases identified in the future. The Company has spent most of its efforts and resources on its anti-cancer compound, Kevetrin, for the treatment of certain cancers. Based on the experimental studies results to date, the Company has decided to advance Kevetrin along the regulatory and clinical pathway. We anticipate using our expertise to manage and perform what we believe are the most critical aspects of the product development process which include: (i) the design and oversight of clinical trials; (ii) the development and execution of strategies for the protection and maintenance of intellectual property rights; and (iii) the interaction with regulatory authorities internationally. We expect to concentrate on product development and engage in a limited way in product discovery, avoiding the significant investment of time and financial resources that is generally required before a compound is identified and brought into clinical trials.

Subsequent Events

On May 3, 2012, the Company issued a total of 100,000 shares of Class A common stock to two consultants for services. The 100,000 shares of common stock are valued at a total of $48,000 based on the closing bid price as quoted on the OTC Bulletin Board on May 2, 2012 of $0.46 per share. In addition a total of 50,000 three (3) year stock purchase options exercisable at $0.54 were issued. The options vest on June 30, 2012.

On May 7, 2012 the Company announced that Syracuse University’s basketball coach Jim Boeheim joined Cellceutix as an advisor to the Company.

Significant Milestones In Kevetrin’s Development

The following are studies completed and incorporated into our investigational new drug application (IND) filed on November 7, 2011 which is presently on hold.

cGMP synthesis

In-vitro studies

In vivo studies

Pharmacodynamics of Kevetrin- the study of the physiological effects of drugs on the body.

Pharmacokinetic (PK) -Pharmacokinetics includes the study of the mechanisms of absorption and distribution of an administered drug, the rate at which a drug action begins and the duration of the effect, the chemical changes of the substance in the body and the effects and routes of excretion of the metabolites of the drug.

GLP safety pharmacology studies

GLP toxicology studies

Formulation

Bio Markers

The Phase I clinical protocol- Primary endpoints for the study will be safety, tolerable dosing levels and establishing the dose for a future Phase II clinical trial.

We have incurred $4,738,972 in research and development expenses from inception through March 31, 2012.We have not obtained sufficient funding for our drug development business plan, nor have we generated any revenues, nor do we not expect to generate revenues in the near future. We may not be successful in developing our drugs and start selling our products when planned, or that we will become profitable in the future. We have incurred net losses in each fiscal period since inception of our operations.

Summaries and graphs of the results of experiments with Kevetrin in animal models of drug resistant lung cancer, breast cancer, colon cancer and other cancers are available on the Company’s website atwww.cellceutix.com.

KM-391- compound in development for the treatment of autism

We announced positive results in animal studies of our autism compound, KM-391. KM-391 demonstrated significant improvements in the test animals when compared to both the “no treatment” group and the “active control” (fluoxetine) group on the parameters of brain plasticity, serotonin levels and behavioral function. These parameters were selected as important indicators of the effect needed to successfully treat autism.

Presently the project is delayed due to our focus on Kevetrin.

KM-133- Psoriasis

KM-133, a small molecule compound, acting on the principles of foliate mechanism, is in development for Psoriasis. After a series of chemical optimization exercises, the Company has completed an animal study in a xenograft model of psoriasis.

KM-133 was studied in mice that were irradiated then engrafted with human psoriatic tissue. Groups of ten mice were treated orally for 14 days with either 10 mg/kg KM-133 once/day, 10 mg/kg KM-133 twice/day, 7.5 mg/kg methotrexate once/day or acted as controls. The mice were followed for 180 days. Endpoints were skin appearance, histological observations, and blood levels of PRINS, IL-20 and 12-R lipoxygenase.For these parameters, KM-133 was compared to controls and methotrexate. CD4+ and CD8+ lymphocyte counts were also measured and compared to efalizumab.

KM-133 significantly reduced all psoriatic endpoints measured relative to controls (p<0.01). The higher dose of KM-133 reduced psoriatic endpoints more than methotrexate (p<0.01). In addition, there was no recurrence of psoriasis in animals treated with KM-133, whereas psoriasis recurred after an average of 61 days in animals treated with methotrexate.Immunosuppression in animals treated with KM-133 was less severe than in those treated with efalizumab.

The Company believes that this compound meets the requirements of FDA 505 (b) (2).This would allow the clinical study to begin at an advanced stage of clinical testing. The Company filed a request with the FDAfor a pre-IND meeting thatisnow scheduled for mid June 2012.

Liquidity and Capital Resources

As of March 31, 2012, the Company had a cash balance of $93,660. The Company will need to raise substantial funds in order to execute its product development plan. Based upon our expected rate of expenditures, we currently do not have sufficient cash reserves to meet all of our anticipated obligations through our fiscal year end of June 30, 2012. The Company may seek to raise capital through an offering of our common stock or other securities of the Company. However, there can be no assurance that we will be successful in securing the capital we require or that we may obtain financing on terms and conditions that are acceptable to the Company.

During October, November, and December 2011, in connection with an offering by the Company of a maximum of up to 2,500,000 shares at $0.40 per share (the “Offering”), a “Subscriber” subscribed for 2,500,000 shares of the Company’s Class A common stock upon payment of$1,000,000. Subscriber is also entitled to one Stock Purchase Warrant exercisable at $1.00 for each share of Common Stock subscribed.

On January 12, 2012 we amended the terms of the 2,500,000 Warrants issued to Subscriber. The amended terms eliminated the provision allowing for cashless exercise and provided for 'Piggy Back Registration Rights”.

On November 8, 2011, the Company issued a total of 125,000 shares of Class A common stock to two consultants and a member of its scientific advisory board valued at $51,250.

Requirement for Additional Capital

Research and Development Costs. The Company has engaged in limited research and development activities. We currently do not have sufficient funds to meet our planned drug development for the next twelve (12) months and we may not be able to obtain the necessary financing on terms and conditions acceptable to the Company. Assuming that we are successful in raising additional financing, we plan to incur the following expenses over the next twelve (12) months:

1	Research and Development of $900,000: Includes planned costs for Kevetrin of $150,000, and $750,000 in preclinical development costs for our other compounds.

2	Clinical trials – We have budgeted $2,500,000 for our planned Phase 1 trials of Kevetrin

3	Corporate overhead of $1,250,000: Budgeted office salaries, legal, accounting and other costs expected to be incurred.

4	Capital costs of $100,000: Estimated cost for equipment and laboratory improvements.

The Company will be unable to proceed with its full planned drug development program (s), meet its administrative expense requirements, capital costs, or staffing costs without obtaining additional financing of approximately$4,750,000 (as per current management’s budgets). The Company does not have any arrangements at this time for equity or other financings towards meeting this financing requirement. If we are unable to obtain additional financing on terms and conditions acceptable to the Company, our business plan will be significantly delayed.

Off-Balance Sheet Arrangements.

The Company does not have any off-balance sheet arrangements, as defined in Item 304(a) (4) (ii) of Regulation S-K under the Securities Exchange Act of 1934, as amended.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Not applicable

Item 4. Controls and Procedures

The Company’s Chief Executive Officer and Chief Financial Officer have evaluated the effectiveness of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of March 31, 2012 covered by this Quarterly Report on Form 10-Q.Based upon such evaluation, the Chief Executive Officer andChief Financial Officer have concluded that, as of the end of such period, the Company’s disclosure controls and procedures were not effective as required under Rules 13a-15(e) and 15d-15(e) under the Exchange Act. This conclusion by the Company’s Chief Executive Officer and Chief Financial Officer does not relate to reporting periods after March 31, 2012.

Changes in Internal Control over Financial Reporting

No change in the Company’s internal control over financial reporting occurred during the quarter ended March 31, 2012, that materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

Cellceutix has been advised that a “Notice of Intent to Sell” 184,375 shares of the Company’ Class A Common Stock issued to Formatech, Inc. for services that were not completed has been filed by Formatech’s Bankruptcy trustee. Cellceutix has engaged an attorney with the aim of recovering these shares. A court hearing for this Motion is scheduled for June 28, 2012.

Item 1a. Risk Factors

We are a "smaller reporting company" as defined by Regulation S-K and, as such, we are not required to provide the information contained in this item.

Item 2. Unregistered Sales Of Equity Securities

On November 8, 2011, the Company issued a total of 125,000 shares of Class A common stock to two consultants and a member of its scientific advisory board valued at $51,250.

In connection with an offering by the Company of a maximum of up to 2,500,000 shares at $0.40 per share (the “Offering”), a “Subscriber” during the months of October, November and December 2011, subscribed for 2,500,000 shares of the Company’s Class A common stock upon payment of$1,000,000. Subscriber is also entitled to one Stock Purchase Warrant exercisable at $1.00 for each share of Common Stock subscribed.

On January 11, 2012, the Company issued a total of 200,000 shares of Class A common stock to a consultant valued at $90,000.

On March 7, 2012 ,the Company issued a total of 265,228 shares of Class A common stock as charitable contributions valued at $122,005.

On May 3, 2012, the Company issued a total of 100,000 shares of Class A common stock to two consultants for services. The 100,000 shares of common stock are valued at a total of $48,000 based on the closing bid price as quoted on the OTC Bulletin Board on May 2, 2012 of .46 per share. In addition a total of 50,000 three (3) year stock purchase options exercisable at $.54 were issued. The options vest on June 30, 2012.

Item 3. Defaults Upon Senior Securities

None

Item 4. Mine Safety Disclosures

None

Item 5. Other Information

None

Item 6. Exhibits

(a) Exhibit index

31-1	Certification of Chief Executive Officer, Chief Financial Officer, and Chief Accounting Officer required by Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended.
32-1	Certification of Chief Executive Officer, Chief Financial Officer, Chief Accounting Officer required by Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended

(b) Reports on Form 8-K

(1)	The Company filed a Form 8-K on January 25, 2012 related to Item 3.02 Unregistered Sales of Equity Securities on the conversion of debt to Class A common stock.

(2)	The Company filed a Form 8-K on April 20, 2012 related to Item 8.01 Other Events, related to a Notice of Intent to Sell” 184,375 shares of the Company’ Class A Common Stock by the Bankruptcy Trustee of Formatech, a past vendor of Cellceutix

(3)	The Company filed a Form 8-K on January 25, 2012 related to Item 3.02 Unregistered Sales of Equity Securities; Item 5.03 Amendments to Articles of Incorporation or Bylaws, or Change of Fiscal Year; and Item 8.01: Other Events , related to various corporate matters

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

CELLCEUTIX CORPORATION

/s/ Leo Ehrlich

Leo Ehrlich, Interim Chief Executive Officer and Chief Financial Officer and Chairman of the Board of Directors

(Principal Executive, Accounting and Financial Officer)

/s/ Krishna Menon

Krishna Menon,

President and Director

Dated: May 21, 2012

EX-31.1 2 v313755_ex31-1.htm EXHIBIT 31.1

Exhibit 31-1

CERTIFICATION PURSUANT TO RULE 13a-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

I, Leo Ehrlich, certify that:

1. I have reviewed this report on Form 10-Q of Cellceutix Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a – 15(f) and 15d – 15(f)) for the registrant and we have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.

c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and

d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the small business issuer 's auditors and the audit committee of registrant 's board of directors (or persons performing the equivalent function):

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect registrant 's ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

	CELLCEUTIX CORPORATION

Date: May 21, 2012	By:	/s/ Leo Ehrlich
		Leo Ehrlich
		Interim Chief Executive Officer, Chief Financial Officer,

		Chairman of the Board of Directors
		(Principal Executive, Accounting and Financial Officer)

EX-32.1 3 v313755_ex32-1.htm EXHIBIT 32.1

Exhibit 32-1

CERTIFICATION PURSUANT TO

18 U.S.C. §1350, AS

ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Leo Ehrlich, Interim Chief Executive Officer and Chief Financial Officer of Cellceutix Corporation, hereby certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002:

(1)	the Quarterly Report on Form 10-Q of Cellceutix Corporation for the quarter ended March 31, 2012 as filed with the Securities and Exchange Commission on the date hereof, fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and

(2)	the information contained in the such Quarterly Report on Form 10-Q of Cellceutix Corporation for the quarter ended March 31, 2012 fairly presents, in all material respects, the financial condition and results of operations of Cellceutix Corporation

	CELLCEUTIX CORPORATION

Date: May 21, 2012	By:	/s/ Leo Ehrlich
		Leo Ehrlich
		Interim Chief Executive Officer, Chief Financial Officer,

		Chairman of the Board of Directors
		(Principal Executive, Accounting and Financial Officer)

EX-101.INS 4 ctix-20120331.xml XBRL INSTANCE DOCUMENT 91476067

90165

261046

527733

7157435

272573

100252

1695683

10000000

100252

14707305

6592

272573

275229

7893202

100252

-7332412

0.0001

7432664

2762084

2022264

1997364

2604188

93660

0.38

0.41

0.45

0.52

94238151

9424

2762084

-527733

7893202

-14707305

0.0001

100000000

9424

91476.067

0.0001

94238151

300000000

-430

1000000

100

-530

-361990

91891000

9189

148623

-519802

1.05

-1793059

0.38

91836000

9184

202890

-2005133

-4797618

3994

0.43

0.30

0.45

91939500

9194

631721

-5438533

300859

167099

759388

6767802

127432

313095

204144

1789818

10000000

313095

11376830

349213

40290

119598

484158

4838968

313095

-7288078

0.0001

7601173

4142084

2002264

2139527

2030621

68661

0.55

0.32

0.20

0.81

91720646

9172

4142084

-759388

4838968

-11376830

0.0001

100000000

9172

87578562.000

0.0001

91720646

300000000

-530

100

2007-06-20

100

1000000

-530

1000000

1925587

-400000

13725172

-2664978

-439892

353635

2248724

-14698226

-8160

489984

-14698226

4738972

-533162

859388

5512508

167099

6593527

-13725172

28750

1997414

529294

100

400000

93660

3537153

507763

2758638

76887

932966 9079 857500 197964 50 165480 4209678 138750 -231655

750370

-100000

4512696

-564199

979907

-4668254

-12778

145140

-4668254

1679420

-155558

859388

2585387

2275069

-4512696

11250

693624

529294

-86171

669833

75683

650370

8543

-0.05

932966 137964 91207738 31911 1150126 33750 Q3 CTIX CELLCEUTIX CORP false Smaller Reporting Company 2012 10-Q 2012-03-31 0001355250 --06-30

1000000

20000

-300000

<div style="FONT: 10pt Times New Roman, Times, Serif"> 10.           Equity Transactions   On August 29, 2011, the Company issued 100,000 shares of Class A common stock to consultants for services rendered in the first quarter of fiscal year 2012.The 100,000 shares of common stock are valued at a total of $38,000.   On September 9, 2011, the company issued 471,518 common shares of the company stock to White Star LLC and 235,759 common shares to Dahlia Nordlicht upon conversion of convertible debentures. (see note 11)   On November 8, 2011, the Company issued a total of 125,000 shares of Class A common stock to two consultants and a member of its scientific advisory board valued at $51,250.   On January 11, 2012, the Company issued a total of 200,000 shares of Class A common stock to a consultant valued at $90,000.    On March 7, 2012 the Company issued a total of 265,228 shares of Class A common stock as charitable contributions valued at $137,920. </div>

<div style="FONT: 10pt Times New Roman, Times, Serif"> 5.          Commitments and Contingencies   Settlement Agreement   On February 14, 2011, the Company announced it reached a settlement agreement on all outstanding claims and issues between the Company and our former CEO, Mr. Evans. Each party dropped their respective claims and as a result all of Mr. Evans accrued salaries and options were cancelled. The terms of the agreement provide that the Company purchase 4,602,312 common shares held by Mr. Evans and/or Mr. Evans’ sons over a period of three years for a total sum of one million dollars. Payment by the Company in the amount of $100,000 was made upon the signing of the agreement and $300,000 was paid in February 2012. These payments resulted in the cancelation of 1,840,229 shares of common stock.2,762,084 shares of common stock remain in escrow until additional payments are made under the agreement and are shown as Treasury Stock on the Company’s Balance Sheet.   The Company had initially recorded this settlement at December 31, 2010 as a liability of the present value of the future payments and treasury stock. The Company had also recorded the forgiveness of Mr. Evans’ accrued payroll and related payroll taxes as a capital contribution of $932,966. As of March 31, 2012, the settlement liability was $ 536,275 of which $ 261,046 is due in February 2013 and recorded as current liability.   Pharmaceutical Compounds   On August 2, 2007, the Company was assigned all right, title, and interest to three pharmaceutical compounds;Kevetrin, KM 277 and KM 278, by their inventors. The Company was assigned all right, title, and interest to an additional three pharmaceutical compounds on October 17, 2007, KM 133 KM 362 and KM 3174. In July 2009, the Company was assigned all right, title, and interest to KM 732.In exchange for these compounds, the Company agreed to pay the inventors 5% of net sales of the compounds in countries where composition of matter patents have been issued and 3% of net sales in other countries. Kevetrin, KM 277, KM 278 and KM 362 were acquired from our President and director, Dr. Krishna Menon. The Company filed a patent application for Kevetrin and intends to file patent applications for each of the other six compounds as funds become available.   In December 2009, the Company was assigned all right, title and interest to a new compound, KM-391, which it intends to develop for the treatment of autism. In exchange for this compound, the Company agreed to pay the inventors $10,000 plus 4.5% of net sales the compound in countries where a composition of matter patent has been issued and 3% of net sales in other countries.    Employment Agreements   The Company’s accrued officers’ salaries and payroll taxes as of March 31, 2012 and June 30, 2011 are as follows:   <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">March 31, 2012</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">June 30, 2011</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td> </td> <td> </td> <td style="TEXT-ALIGN: center" colspan="2"> </td> <td> </td> <td> </td> <td style="TEXT-ALIGN: center" colspan="2"> </td> <td> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; WIDTH: 68%">Krishna Menon</td> <td style="WIDTH: 2%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 12%">1,346,250</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 2%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 12%">1,075,000</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">Leo Ehrlich</td> <td> </td> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">1,108,750</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">837,500</td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">Accrued Payroll Taxes</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">$</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 149,188</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">$</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 118,121</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 2,604,188</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 2,030,621</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> </tr> </table>   On December 29, 2010, the Company entered into employment agreements with its two executive officers, Leo Ehrlich, the Company’s Chief Executive Officer, and Krishna Menon, Chief Scientific Officer. Both agreements provide for a three year term with each executive receiving an annual base salary for $350,000 per year commencing January 1, 2011, with an annual increase of 10% for each year commencing January 2012. In addition, the Company’s Board awarded stock options exercisable at $0.11 per share pursuant to the Company’s 2010 Equity Incentive Plan to each executive officer as follows: a total of 18 million options with 6 million options vesting on December 29, 2010, 6 million options vesting on June 30, 2011 and 6 million options vesting on January 3, 2012.The Board, at its discretion, may increase the base salary based upon relevant circumstances.   Litigation   In the ordinary conduct of business, the Company is subject to lawsuits, arbitrations and administrative proceedings from time to time. The Company expenses legal costs as incurred.   Toxikon Corporation, a vendor, has initiated litigation with claims that it is owed a balance of approximately $100,000 plus interest and legal fees. Cellceutix has retained a lawyer and is disputing these claims and believes there is no balance owed. </div>

2683035

<div style="FONT: 10pt Times New Roman, Times, Serif"> 8.           Due To Officer   During the year ended June 30, 2010, Mr. Ehrlich, an officer of the Company, converted previous amounts provided in cash to the Company of $32,310 into a loan (the “Ehrlich Promissory Note A”).The Ehrlich Promissory Note A was an unsecured, 6% per annum simple interest bearing, demand note. During the same period, Mr. Ehrlich provided an additional $85,000 in cash in the form of a loan to the Company (the “Ehrlich Promissory Note B”).The Ehrlich Promissory Note B was an unsecured, 6% per annum simple interest bearing, demand note.   During the year ended June 30, 2010, Mr. Ehrlich, loaned the Company a total of $972,907.A condition for this loan was that the Ehrlich Promissory Note A and Ehrlich Promissory Note B be replaced with a new note, Ehrlich Promissory Note C. The Ehrlich Promissory Note C is an unsecured demand note that bears 9% simple interest per annum and is convertible into the Company’s common stock at $0.50 per share. The note requires that the interest rate on the amounts due on Ehrlich Promissory Notes A and B be changed retroactively, beginning October 1, 2009, to 9%.On April 1, 2011, the Company amended the Ehrlich Promissory Note C and agreed to retroactively convert accrued interest of $96,677 through December 31, 2010 into additional principal.   At March 31, 2012, $225,773 is accrued as interest expense on this note. During the nine months ended March 31, 2012, Mr. Ehrlich loaned the Company an additional $20,000 which brought the balance of the demand note to $2,022,264 </div>

-527902

-439892

353635

516671

-3330475

<div style="FONT: 10pt Times New Roman, Times, Serif"> 2.          Financial Statements   In the opinion of management, all adjustments consisting only of normal recurring adjustments necessary for a fair statement of (a) the results of operations for the three and nine month periods ended March 31, 2012 and 2011, (b) the financial position at March 31, 2012 and (c) cash flows for the three and nine month periods ended March 31, 2012 and 2011, have been made.   The unaudited financial statements and notes are presented as permitted by Form 10-Q. Accordingly, certain information and note disclosures normally included in the financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted. The accompanying financial statements and notes should be read in conjunction with the Company’s Form 10K for the fiscal year ended June 30, 2011.  The results of operations for the three and nine month periods ended March 31, 2012 are not necessarily indicative of those to be expected for the entire year.   The company has evaluated all subsequent events through the filing date of this form 10-Q with SEC, to ensure that this form 10-Q includes subsequent events that should be recognized in the financial statements as of March 31, 2012, and appropriate disclosure of subsequent events which were not recognized in the financial statements </div>

1010

149562

<div style="FONT: 10pt Times New Roman, Times, Serif"> 12.           Subsequent Events   Cellceutix has been advised that a “Notice of Intent to Sell” 184,375 shares of the Company’ Class A Common Stock issued to Formatech, Inc. for services that were not completed (See Note 1), has been filed by Formatech’s Bankruptcy trustee. Cellceutix has engaged an attorney with the aim of recovering these shares. A court hearing for this Motion is scheduled for June 28, 2012.     On April 26, 2012, the Company issued 300,000 shares of Class A common stock to consultants for services. The 300,000 shares of common stock are valued at a total of $138,000 based on the closing bid price as quoted on the OTC Bulletin Board on April 25, 2012 of $0.46 per share. On May 3, 2012, the Company issued a total of 100,000 shares of Class A common stock to two consultants for services. The 100,000 shares of common stock are valued at a total of $48,000 based on the closing bid price as quoted on the OTC Bulletin Board on May 2, 2012 of .46 per share. In addition a total of 50,000 three (3) year stock purchase options exercisable at $0.54 were issued. The options vest on June 30, 2012.   On May 7, 2012 the Company announced that Syracuse University’s basketball coach Jim Boeheim joined Cellceutix as an advisor to the Company.   On May 8, 2012, the Company entered into a subscription agreement for Series A Convertible Preferred shares with an accredited investor for an aggregate of $1,000,000. Initial funding was One Hundred Thousand USD ($100,000) for the purchase 10,000 Series A Convertible Preferred Shares, and was closed on May 8, 2012. Subscription Agreement provides for installment Funding Amounts to take place every thirty days after initial closing date for an amount of the lesser of (i) $75,000 or (ii) twenty five (25% ) per cent of the dollar value of the total volume traded during the preceding 22 trading days. The Series A Preferred Shares are convertible into common stock at the lesser of 85% of the closing bid price on the date of prior to each closing, or 85% of the lowest bid price for the fifteen (15) days prior to conversion. Additionally, for each common share issued upon conversion of Series A preferred share, a five year common stock purchase warrants shall be issued to the Subscriber which warrant shall be exercisable at the conversion price of the common shares issued. The Series A Convertible Preferred shares do not pay dividends. The Common shares underlying the Series A Preferred Shares and the common stock purchase warrants are subject to piggy back registration rights.    On May 8, 2012, the Company renegotiated the terms of the outstanding balance of principle and interest $2,248,037, as of March 31, 2012, represented by the Ehrlich Promissory Note C issued to Leo Ehrlich for funds he loaned to the company. In connection therewith, the Company renegotiated the interest on the loan from 9% simple interest to 10% simple interest and issued 2,000,000 Equity Incentive Options exercisable at $0.51 per share equal to 110% of the closing bid price of $0.46 per share on May 7, 2012. Options are valid for ten (10) years from the date of issuance. </div>

-3330475

478909

353635

-204144

-207548

1527323

582392

<div style="FONT: 10pt Times New Roman, Times, Serif"> 1.         Background Information   Cellceutix Corporation, formerly known as EconoShare, Inc., (the “Company” or the “Registrant”) was incorporated on August 1, 2005 in the State of Nevada and was organized for the purpose of developing a B2B (Business to Business) website for an Asset Sharing market place and transaction system.   On December 6, 2007, the Company acquired CellceutixPharma, Inc., a privately owned Delaware corporation pursuant to an Agreement and Plan of Share Exchange (the “Exchange”). CellceutixPharma, Inc. was incorporated under the laws of the State of Delaware on June 20, 2007. Its assets consisted of rights assigned to it for six early stage pharmaceutical compounds by three different scientists.   Pursuant to the terms of the Exchange, the Company acquired CellceutixPharma, Inc. in exchange for an aggregate of 82,000,000 newly issued shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”). As a result of the Exchange, CellceutixPharma, Inc. became a wholly-owned subsidiary of the Company. The Company’s shares were issued to the CellceutixPharma, Inc. shareholders on a pro rata basis, on the basis of 82 shares of Common Stock for each share of CellceutixPharma, Inc. common stock held by such CellceutixPharma, Inc. shareholder at the time of the Exchange. This resulted in the former holders of CellceutixPharma, Inc. Common Stock, upon Exchange, owning approximately 89% of the outstanding shares of the Company’s Common Stock. Accordingly, the Exchange represented a change in control. For financial accounting purposes, the acquisition was a reverse acquisition of the Company by CellceutixPharma, Inc., under the purchase method of accounting, and was treated as a recapitalization with CellceutixPharma, Inc. as the legal acquirer. Upon consummation of the Exchange, the Company adopted the business plan of CellceutixPharma, Inc. We are an early stage developmental biopharmaceutical company. The Company has no customers, products or revenues to date, and may never achieve revenues or profitable operations.   On January 14, 2008, a majority of the shareholders of the Company approved an amendment to the Registrant’s articles of incorporation to change the name of the Registrant to Cellceutix Corporation. Upon the filing of a Definitive Information Statement and effectiveness of the name change on February 1, 2008, the Company applied to the National Association of Security Dealers (NASD) to change its stock symbol on the Over the Counter Bulletin Board which resulted in the Company’s stock symbol being changed to CTIX.   As of October 2011, the Company’s Common Stock is quoted on the Over the Counter Bulletin Board (OTCBB) with the symbol “CTIX”. Previously, the Company’s Common Stock was quoted on the OTC Markets Group, Inc.’s OTCQB.   On December 29, 2010 shareholders holding 51% of the Company’s outstanding common stock adopted and approved the 2010 Equity Incentive Plan and authorized an amendment to the Company’s Articles of Incorporation to authorize Class B common stock convertible into Class A common stock on a 1:1 basis, however the Class B Common Stock shall entitle ten votes for each share of Class B Common Stock. On February 8, 2011, the Company filed a Form 14C Information Statement with the Securities and Exchange Commission. This action became effective on May 10, 2011, approximately twenty (20) days from the date of mailing of the Definitive Information Statement. The Definitive Information Statement was mailed on April 20, 2011 to the shareholders of record as of February 9, 2011. All shares issued as of balance sheet dates are Class A common stock.   On September 21, 2011 Cellceutix reported that it had signed a Laboratory Services Research Support Agreement with Dana Farber/Partners CancerCare, Inc. The agreement outlines the collaborative and laboratory support for the planned clinical trials for Kevetrin™, Cellceutix’s novel compound as an indication for cancer.   In connection with an offering by the Company of a maximum of up to 2,500,000 shares at $0.40 per share (the “Offering”), a “Subscriber” on October 11, 2011, subscribed for 833,334 shares of the Company’s Class A common stock upon payment of $333,334 and on November 3, 2011, subscribed for 832,500 shares of the Company’s Class A common stock upon payment of $333,000 and on December 7, 2011, subscribed for 834,166 shares of the Company’s Class A common stock upon payment of $333,666. Subscriber is also entitled to one Stock Purchase Warrant exercisable at $1.00 for each share of Common Stock subscribed.   In November 2011, Dr. Paul Marks joined the Cellceutix Scientific Advisory Board. Dr. Marks served as President and Chief Executive Officer of Memorial Sloan-Kettering Cancer Center ("MSKCC") from 1980 to 1999 where he helped to establish the high standards for research and patient care that MSKCC is world renowned for. He remains a vital part of MSKCC as President Emeritus and Member of the Sloan-Kettering Institute.    In November 2011, Cellceutix filed its Investigational New Drug (IND) application for Kevetrin™, our novel anti-cancer drug, with the U.S. Food and Drug Administration (FDA). In December 2011, Cellceutix was notified by the FDA that the production manufactured by our vendor Formatech, Inc. for use in the clinical trials was not eligible because of GMP violations at Formatech. Cellceutix retained another formulation manufacturer and production was completed in March 2012. The manufactured product is now undergoing quality and stability testing. Once completed, Cellceutix will submit an amended IND to the FDA. The trials are planned at Dana Farber/ Harvard Cancer Center. The clinical trial will test Kevetrin™ against a variety of different cancer types in patients with advanced-stage cancers. Primary endpoints for the study will be safety, tolerable dosing levels and establishing the dose for a future Phase II clinical trial.   In December 2011,Cellceutix initiated a study in collaboration with Pioneer Valley Life Sciences Institute, a Baystate Medical Center/University of Massachusetts Amherst Research Partnership ("the Institute"), to collaborate on an innovative research project to investigate Kevetrin's antitumor activity related to risk factor aging. In February 2012, Cellceutix received data from this study that is helpful in further developing the potential of Kevetrin.   In January 2012,Cellceutix filed a patent application for KM-133, our compound to treat psoriasis and subsequently filed a request for a pre-IND meeting with the FDA. The meeting is now scheduled for mid June 2012.   In March 2012,Cellceutix entered into an agreement with Beth Israel Deaconess Medical Center(BIDMC), a teaching hospital of Harvard Medical School, on an innovative research project with Kevetrin. The Medical Center wishes to exploit the nuclear and/or mitochondrial pro-apoptotic function of p53 in melanoma and renal cell carcinoma, two types of cancer that are particularly resistant to therapy.BIDMChopes to improve therapy for melanoma and renal cell carcinoma, cancers that are particularly resistant to therapy.   BIDMC initiated combination studies with multikinaseinhibitors which activate pro-apoptotic activity by translocation of p53 in mitochondria thereby inducing apoptosis. Apoptosis is enhanced by MDM2 inhibitors by stabilizing p53. As presented at the American Association for Cancer Research (AACR) meeting in April, KevetrinphosphorylatesMDM2 which activates and stabilizes p53 by monoubiquitination inducing apoptosis. Prior data from the BIDMC laboratory showed that agents of this class can augment the pro-apoptotic and antitumor effects of MDM2 antagonists and is expected to have a synergistic effect with Kevetrin.   BIDMC will test the effects of Kevetrin alone and in combination with FDA-approved VEGFR antagonists in the renal cell carcinoma and melanoma studies. In vitro study endpoints include apoptosis by measuring caspase activation and PARP cleavage. In vivo endpoints include efficacy in a xenograft model, tumor vascularity, p53 levels, p21 expression and apoptosis.   This study will provide vital insight to exploit the nuclear and/or mitochondrial pro-apoptotic function by Kevetrin in combination with other multikinase inhibitors in treatment of these difficult to treat malignancies. </div>

167099

1412879

-2683035

-142163

1175445

<div style="FONT: 10pt Times New Roman, Times, Serif"> 6.       Fair Value of Financial Assets and Financial Liabilities   The Company utilizes a hierarchy that prioritizes fair value measurements based on the types of inputs used for the various valuation techniques (market approach, income approach and cost approach). The levels of the hierarchy are described below: <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="TEXT-ALIGN: justify; WIDTH: 0.25in">•</td> <td style="TEXT-ALIGN: justify">Level 1: consists of financial instruments whose value is based on quoted market prices for identical financial instruments in an active market</td> </tr> <tr style="VERTICAL-ALIGN: top"> <td style="TEXT-ALIGN: justify"> </td> <td style="TEXT-ALIGN: justify"> </td> </tr> <tr style="VERTICAL-ALIGN: top"> <td style="TEXT-ALIGN: justify">•</td> <td style="TEXT-ALIGN: justify">Level 2: consists of financial instruments that are valued using models or other valuation methodologies. These models use inputs that are observable either directly or indirectly; Level 2 inputs include (i) quoted prices for similar assets or liabilities in active markets, (ii) quoted prices for identical or similar assets or liabilities in markets that are not active, (iii) pricing models whose inputs are observable for substantially the full term of the financial instrument and (iv) pricing models whose inputs are derived principally from or corroborated by observable market data through correlation or other means for substantially the full term of the financial instrument.</td> </tr> <tr style="VERTICAL-ALIGN: top"> <td style="TEXT-ALIGN: justify"> </td> <td style="TEXT-ALIGN: justify"> </td> </tr> <tr style="VERTICAL-ALIGN: top"> <td>•</td> <td style="TEXT-ALIGN: justify">Level 3: consists of financial instruments whose values are determined using pricing models that utilize significant inputs that are primarily unobservable, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation</td> </tr> </table>   The assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the valuation of financial instruments and their classification within the fair value hierarchy. Financial instruments are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. There have been no changes in the classification of any financial instruments within the fair value hierarchy.   The Company’s remaining financial instruments consisted primarily of (level 1) cash and cash equivalents, accounts payable, accrued expenses and note payable. The carrying amounts of the Company’s financial instruments generally approximate their fair values as of March 31, 2012 and June 30, 2011 due to the short term nature of these instruments.   The Company did not have any level 3 instruments at March 31, 2012 but had convertible debentures as of June 30, 2011. The convertible debentures were paid in full in January 2012. </div>

24999

<div style="FONT: 10pt Times New Roman, Times, Serif"> 9.         Stock Options and Warrants:   On April 5, 2009 the Board of Directors of the Registrant adopted the 2009 Stock Option Plan ("the 2009 Plan"). The Plan permits the grant of 2,000,000 shares of both Incentive Stock Options ("ISOs"), intended to qualify under section 422 of the Code, and Non-Qualified Stock Options.   On December 29, 2010 shareholders holding 51% of the Company’s outstanding common stock adopted and approved the 2010 Equity Incentive Plan (“the 2010 Plan”). Under the 2010 Equity Incentive Plan the total number of shares of Common Stock reserved and available for issuance under the Plan shall be 45,000,000 shares. Shares of Common Stock under the Plan (“Shares”) may consist, in whole or in part, of authorized and unissued shares or treasury shares. The term of each Stock Option shall be fixed by the Committee; provided, however, that an Incentive Stock Option may be granted only within the ten-year period commencing from the Effective Date and may only be exercised within ten years of the date of grant (or five years in the case of an Incentive Stock Option granted to an optionee who, at the time of grant, owns Common Stock possessing more than 10% of the total combined voting power of all classes of voting stock of the Company (“10%Shareholder”).   On April 1, 2009, the Company entered into an agreement, subsequently amended, with a Consultant to assist the Company's Chief Scientific Officer to organize, manage and display data from animal studies as well as information relating to Active Pharmaceutical Ingredients and formulations of the Company's products through November 2010. The Consultant was compensated at the rate of $4,000 per month payable on the last day of each month. In addition, at the end of each month of services provided, the Consultant is granted options to purchase 10,000 shares of Company's common stock.  Effective September 1, 2010, the Company has extended the current agreement and beginning in August 2010, the monthly fee was increased to $5,000.  The remainder of the agreement remains unchanged.  As of March 31, 2012, the Consultant has been awarded a total of 360,000 options to purchase common stock valued at $157,988, each grant is to be vested over one year from date of issuance.  For the three and nine months ended March 31, 2012, the Company has expensed $18,251 and $50,029 to professional fees expense, related to these options.    On May 6, 2010, the Company entered into a two year agreement with an individual for consulting services.  In exchange for these services, the Company granted the Consultant 200,000 options to purchase common stock.  The options were valued using the Black-Scholes option model for $62,015, which includes the option modification expense.  As of March 31, 2012, the Company has $2,621 remaining in prepaid expenses related to this agreement and expensed $7,863 and $23,589 for the three and nine months ended March 31, 2012.   On December 29, 2010 options to purchase 1,680,000 shares of the Company’s common stock were granted to a consultant for financial and administrative services rendered pursuant to the 2010 Company’s  Equity Incentive Plan, of which 840,000 options were exercisable at the date of grant and 840,000  options vested on June 30, 2011.  The options are exercisable at $0.10 per share.      On December 29, 2010, the Company entered into employment agreements with its two executive officers, Leo Ehrlich, the Company’s Chief Executive Officer, and Krishna Menon, Chief Scientific Officer. Both agreements provide for a three year term with each executive receiving an annual base salary for $350,000 per year commencing January 1, 2011, with an annual increase of 10% for each year commencing January 2012. In addition, the Company’s Board awarded stock options exercisable at $0.11 per share pursuant to the Company’s 2010 Equity Incentive Plan to each executive officer as follows:   Option Group A, a total of 18 million options with 6 million options vesting on December 29, 2010, 6 million options vesting on June 30, 2011 and 6 million options vesting on January 3, 2012.    The Board, at its discretion, may increase the base salary based upon relevant circumstances.  The Company recorded $0.0 and $1,093,416 in stock based compensation for the three and nine months ended March 31, 2012 and a cumulative total of $3,292,248 in stock based compensation as of March 31, 2012.   In July 2011 we issued options to purchase 50,000 shares of our common stock to a consultant for services rendered to the Company valued at $28,000.   The fair value of each option for the nine months ended March 31, 2012 and 2011 was estimated on the date of grant or grant modification using the Black Scholes model that uses assumptions noted in the following table.   <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="TEXT-ALIGN: center; WIDTH: 60%" nowrap="nowrap">  </td> <td style="TEXT-ALIGN: center; WIDTH: 2%; FONT-WEIGHT: bold" nowrap="nowrap"> </td> <td style="BORDER-BOTTOM: black 1pt solid; WIDTH: 18%" nowrap="nowrap"> Nine Months Ended March 31, 2012 </td> <td style="TEXT-ALIGN: center; WIDTH: 2%; FONT-WEIGHT: bold" nowrap="nowrap"> </td> <td style="BORDER-BOTTOM: black 1pt solid; WIDTH: 18%" nowrap="nowrap"> Nine Months Ended March 31, 2011 </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: top"> <td>Expected term (in years)</td> <td style="TEXT-ALIGN: center"> </td> <td style="TEXT-ALIGN: center">5 – 10</td> <td style="TEXT-ALIGN: center"> </td> <td style="TEXT-ALIGN: center">5 – 10</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: top"> <td>Expected stock price volatility</td> <td style="TEXT-ALIGN: center"> </td> <td style="TEXT-ALIGN: center">142.51% – 148.15%</td> <td style="TEXT-ALIGN: center"> </td> <td style="TEXT-ALIGN: center">121.23% – 152.05%</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: top"> <td>Risk-free interest rate</td> <td style="TEXT-ALIGN: center"> </td> <td style="TEXT-ALIGN: center">1.97% – 3.0%</td> <td style="TEXT-ALIGN: center"> </td> <td style="TEXT-ALIGN: center">0.88% – 3.75%</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: top"> <td>Expected dividend yield</td> <td style="TEXT-ALIGN: center"> </td> <td style="TEXT-ALIGN: center">0%</td> <td style="TEXT-ALIGN: center"> </td> <td style="TEXT-ALIGN: center">0%</td> </tr> </table>    Stock Options   The following table summarizes all stock option activity: <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2">Number of Options</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2">Weighted Average Exercise Price</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2">Weighted Average Remaining Contractual Life (Years)</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2">Aggregate Intrinsic Value</td> <td style="PADDING-BOTTOM: 1pt"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="WIDTH: 48%">Outstanding at June 30, 2010</td> <td style="WIDTH: 2%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 9%">3,355,430</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 2%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 9%">0.25</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 2%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 9%">1.36</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 2%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 9%">—</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td>Granted</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">38,442,500</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">0.11</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">9.24</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">—</td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td>Exercised</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">—</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">—</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">—</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">—</td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 1pt">Forfeited/expired</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> (2,755,430</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">)</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 0.25</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> —</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> —</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td>Outstanding at June 30, 2011</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">39,042,500</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">0.12</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">9.15</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">24,003,475</td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td>Granted</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">140,000</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">0.58</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">7.00</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">4,300</td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td>Exercised</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">—</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">—</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">—</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">—</td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 1pt">Forfeited/expired</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> —</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> —</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> —</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> —</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 1pt">Outstanding at March 31, 2012</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 39,182,500</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">$</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 0.12</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 8.64</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">$</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 15,819,150</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 1pt">Exercisable at March 31, 2012</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 39,117,623</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">$</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 0.11</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 8.63</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">$</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 15,816,685</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> </tr> </table>   The Company recognized of $1,175,445 and $2,481,150 of compensation costs related to option awards granted during the nine months ended March 31, 2012 and 2011, $18,251 and $1,042,151 for the three months ended March 31, 2012 and 2011 and $5,042,046 for the period from inception to March 31, 2012, respectively, and there is $28,401 of unamortized compensation cost expected to be recognized through December 31, 2012.  This includes the additional compensation costs related to the Board of Director’s approval to extend the term of all outstanding options an additional two years.    As of December 31, 2010, there were 2,964,000 warrants issued and outstanding with a weighted average exercise price of $0.81.  The warrants were to expire in September 2010, however in September 2010; the Company approved the extension of these warrants to December 31, 2013.     During the months of October, November and December 2011, warrants to purchase 2,500,000 shares of the Company’s Class A common stock were issued to an investor pursuant to his purchase of 2,500,000 shares of the Company’s Class A common stock at $0.40 per share. Under ASC 815-40-25, the fair value of these warrants should be reported as a liability, Pursuant to the Warrant Agreement, because there is currently no effective registration statement covering the shares of common stock underlying these warrants, these warrants are currently subject to a cashless exercise whereby the warrant holders may surrender their warrants to the company in exchange for shares of common stock. The number of shares of common stock into which a warrant would be exchangeable in such a cashless exercise depends on both the exercise price of the warrants and the market price of the common stock, each at or near the time of exercise. Because both of these factors are variable, it is possible that the company could have insufficient authorized shares to satisfy a cashless exercise. In this scenario, if the company were unable to obtain shareholder approval to increase the number of authorized shares, the company could be obligated to settle such a cashless exercise with cash rather than by issuing shares of common stock. Further, ASC 815-40-25 requires that we record the potential settlement obligation at each reporting date using the current estimated fair value of the warrants, with any changes being recorded through our statement of operations. The warrants were valued at $417,608 at the time of issuance and recorded as a liability. At December 31, 2011, the warrants were valued at $1,327,500 and the warrant liability was increased by $909,892. On January 12, 2012, the subscription agreement was modified to remove the cashless exercise provision, and provide for “piggy-back” registration rights. The warrants were valued as of January 12, 2012 and the value reduced by $470,000. The remaining $857,000 of warrant value was reclassified from a liability to equity. As of March 31, 2012, these 2,500,000 warrants are outstanding with an exercise price of $1.00 and expire in October, November and December 2014. </div>

573566

<div style="FONT: 10pt Times New Roman, Times, Serif"> 7.           Related Party Transactions   Office Lease   Dr. Menon, the Company’s principal shareholder, President, and Director, also serves as the Chief Operating Officer and Director of Kard Scientific (“KARD”). On December 7, 2007, the Company began renting office space from KARD, on a month to month basis for $900 per month. At March 31, 2012 and June 30, 2011, payables of $46,800 and $38,700 to KARD were included in accrued expenses, respectively. For the three and nine months ended March 31, 2012and 2011 and the period June 20, 2007 (date of inception) through March 31, 2012, the Company has included $2,700, $8,100, $2,700, $8,100 and $46,800 in general and administrative expenses, respectively.   Clinical Studies   As of September 28, 2007 the Company engaged KARD to conduct specified pre-clinical studies necessary for the Company to prepare an IND submission to the Father Company does not have an exclusive arrangement with KARD. All work performed by KARD must have prior approval by the executive officers of the Company, and the Company retains all intellectual property resulting from the services by KARD. For the three and nine months ended March 31, 2012and 2011 and the period June 20, 2007 (date of inception) through March 31, 2012, the Company incurred $9,990, $9,990, $747,207, $1,032,867, and $2,601,110 of research and development expenses conducted by KARD, respectively. At March 31, 2012and June 30, 2011 the Company has included a total of $1,685,515 and $1,780,515 in accounts payable to Kard respectively. </div>

178779

552901

51259

-0.04

857500 89649308 <div style="FONT: 10pt Times New Roman, Times, Serif"> 11.          Convertible Debentures   On May 7, 2008, the Company issued Convertible Debentures, at 9% per annum, for a total amount of $400,000.The principal and related accrued interest were due December 2009, and secured by the Company’s assets. The Debentures and any accrued and unpaid interest were convertible into the Company’s common stock, at the holder’s request, at a conversion price of $1.50.In January 2010, the Company extended and amended the original Convertible Debenture agreements by extending the original maturity date to December 31, 2010. The conversion price of the principal and any unpaid interest was changed to $0.50 per share. The Company and debenture holders also agreed to convert accrued interest of $60,000 into additional principal. On February 10, 2011, the Company extended and amended the Convertible Debenture agreements by extending the original maturity date to December 31, 2011.The conversion price of the principal balance remains at $0.50 per share. The Company and debenture holders also agreed to convert accrued interest of $41,287 through December 31, 2010 into additional principal resulting in a note balance of $501,287.   On September 9, 2011, the company issued 471,518 common shares of the company stock to White Star LLC upon conversion of $222,791 of the principal on our existing outstanding debentures and $12,965 for interest; and the company issued 235,759 common shares to Dahlia Nordlicht upon conversion of $111,397 of the principal on our existing outstanding debentures and $6,482 for interest. Each of the Notes was converted at the price of $.50 per share. The shares were issued pursuant to the exemption from registration provided for under Rule 506 of Regulation D, promulgated under the United States Securities Act of 1933, as amended.   The Company paid off the remaining Convertible Debenture balance in the amount of $167,100 plus interest of $14,826 on January 3, 2012. </div> <div style="FONT: 10pt Times New Roman, Times, Serif"> 4.          Recent Accounting Pronouncements:    In May 2011, the FASB issued ASU No. 2011-04 (“ASU 2011-04”), Fair Value Measurement – amendments to achieve fair value measurements and disclosure requirements in US GAAP and IFRSs. The amendments change the wording used to describe many of the requirements in U.S. GAAP for measuring fair value and for disclosing information about fair value measurements. For many of the requirements, the Board does not intend for the amendments in this Update to result in a change in the application of the requirements in Topic 820. The amendments in this update are to be applied prospectively. The adoption of this guidance is not expected to have a material impact on the financial statements   In June 2011, the FASB issued guidance which eliminates the option to report other comprehensive income and its components in the statement of changes in stockholders’ equity and requires an entity to present the total of comprehensive income, the components of net income and the components of other comprehensive income either in a single continuous statement or in two separate but consecutive statements. This pronouncement is effective for fiscal years, and interim periods within those years, beginning after December 15, 2011. The adoption of this guidance is not expected to have a material impact on the financial statements.   Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material impact on the Company’s consolidated financial statements. </div> <div style="FONT: 10pt Times New Roman, Times, Serif"> 3.         Going Concern   The accompanying financial statements have been prepared assuming the Company will continue as a going concern. For the period since June 20, 2007 (date of inception) through March 31, 2012, the Company has had a cumulative net loss of $14,698,226and a working capital deficit of $7,057,183 at March 31, 2012.  As of March 31, 2012, the Company has not emerged from the development stage. In view of these matters, the ability of the Company to continue as a going concern is dependent upon the Company’s ability to generate additional financing. Since inception, the Company has financed its activities principally from the use of equity securities, debt issuance and loans from an officer to pay for its operations. The Company intends on financing its future development activities and its working capital needs largely from the issuance of debt and the sale of equity securities, until such time that funds provided by operations are sufficient to fund working capital requirements. There can be no assurance that the Company will be successful at achieving its financing goals at reasonably commercial terms, if at all.    The economic downturn and market instability has made the business climate more volatile and more costly.  If the current equity and credit markets deteriorate further or do not improve, it may make necessary debt or equity financing more difficult, more costly and more dilutive.  Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on the Company’s growth strategy, financial performance and stock price and could require the delay of new product development and clinical trial plans.  Currently, the Company has not made any additional arrangements for equity or any other type of financing.   These factors raise substantial doubt about the Company's ability to continue as a going concern. The accompanying financial statements do not include any adjustments relating to the recoverability of the recorded assets or the classification of liabilities that may be necessary should the Company be unable to continue as a going concern. </div> 95797 857500 478909

100000

37990

38000

2011-08-29

125000

51236

51249

2011-11-08

200000

89980

90000

2012-11-01

265228

137894

137920

2012-07-03

138

250

2500000

-1380000

707277

-231655

-1380000

231517

353564

582142

1175445

857500

-3330475

-231655

-1485331

142162

20000

7598

7600

2009-06-11

25000

9497

9500

2009-06-30

10 100000

142162

104990

-1485331

105000 2008-12-31

-3433400

383291

25000

10748

10750

2009-07-06

3500

1050

2010-02-05

75000

33742

33750

2010-06-01

383291

-3433400

-5938297

-932966

3060691

237098 859388 33750

50000

27495

27500

2010-07-06

184375

58982

59000

2011-03-01

70000

13993

14000

2011-02-08

12000

9719

9720

2011-05-26

460229

8 75000

-100000

-460229

859388 4602313

99955

-932966

3060691

237098 33742

-5938297

-510193

43533

50 2007-12-06 2007-12-06 2007-12-06

9791000

979

8200 82000000 -100 1000000

100000

43533

104990

-510193

-979

-8200 100

105000

2008-04-28

2228463

611158

-2297460

933382

-68997

658028

-2228463

23373

-0.03

89714469 2522 933382

716155

470000

159350

-308617

269043

-62462

113975

-716155

159710

0.00

91256613 14077 269043 0001355250 2012-01-01 2012-03-31 0001355250 2011-01-01 2011-03-31 0001355250 us-gaap:GoodsAndServicesExchangedForEquityInstrumentMember 2007-07-01 2008-06-30 0001355250 ctix:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStageMember 2007-07-01 2008-06-30 0001355250 us-gaap:AdditionalPaidInCapitalMemberus-gaap:GoodsAndServicesExchangedForEquityInstrumentMember 2007-07-01 2008-06-30 0001355250 us-gaap:AdditionalPaidInCapitalMember 2007-07-01 2008-06-30 0001355250 us-gaap:CommonStockMemberus-gaap:GoodsAndServicesExchangedForEquityInstrumentMember 2007-07-01 2008-06-30 0001355250 us-gaap:CommonStockMember 2007-07-01 2008-06-30 0001355250 ctix:TransactionDate03Member 2007-07-01 2008-06-30 0001355250 ctix:TransactionDate02Member 2007-07-01 2008-06-30 0001355250 ctix:TransactionDate01Member 2007-07-01 2008-06-30 0001355250 2007-07-01 2008-06-30 0001355250 ctix:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStageMember 2010-07-01 2011-06-30 0001355250 us-gaap:AdditionalPaidInCapitalMember 2010-07-01 2011-06-30 0001355250 us-gaap:TreasuryStockMember 2010-07-01 2011-06-30 0001355250 us-gaap:CommonStockMember 2010-07-01 2011-06-30 0001355250 ctix:IssuanceDuringPeriod4thMemberus-gaap:GoodsAndServicesExchangedForEquityInstrumentMember 2010-07-01 2011-06-30 0001355250 ctix:IssuanceDuringPeriod4thMemberus-gaap:AdditionalPaidInCapitalMemberus-gaap:GoodsAndServicesExchangedForEquityInstrumentMember 2010-07-01 2011-06-30 0001355250 ctix:IssuanceDuringPeriod4thMemberus-gaap:CommonStockMemberus-gaap:GoodsAndServicesExchangedForEquityInstrumentMember 2010-07-01 2011-06-30 0001355250 ctix:IssuanceDuringPeriod3rdMemberus-gaap:GoodsAndServicesExchangedForEquityInstrumentMember 2010-07-01 2011-06-30 0001355250 ctix:IssuanceDuringPeriod3rdMemberus-gaap:AdditionalPaidInCapitalMemberus-gaap:GoodsAndServicesExchangedForEquityInstrumentMember 2010-07-01 2011-06-30 0001355250 ctix:IssuanceDuringPeriod3rdMemberus-gaap:CommonStockMemberus-gaap:GoodsAndServicesExchangedForEquityInstrumentMember 2010-07-01 2011-06-30 0001355250 ctix:IssuanceDuringPeriod2ndMemberus-gaap:GoodsAndServicesExchangedForEquityInstrumentMember 2010-07-01 2011-06-30 0001355250 ctix:IssuanceDuringPeriod2ndMemberus-gaap:AdditionalPaidInCapitalMemberus-gaap:GoodsAndServicesExchangedForEquityInstrumentMember 2010-07-01 2011-06-30 0001355250 ctix:IssuanceDuringPeriod2ndMemberus-gaap:CommonStockMemberus-gaap:GoodsAndServicesExchangedForEquityInstrumentMember 2010-07-01 2011-06-30 0001355250 ctix:IssuanceDuringPeriod1stMemberus-gaap:GoodsAndServicesExchangedForEquityInstrumentMember 2010-07-01 2011-06-30 0001355250 ctix:IssuanceDuringPeriod1stMemberus-gaap:AdditionalPaidInCapitalMemberus-gaap:GoodsAndServicesExchangedForEquityInstrumentMember 2010-07-01 2011-06-30 0001355250 ctix:IssuanceDuringPeriod1stMemberus-gaap:CommonStockMemberus-gaap:GoodsAndServicesExchangedForEquityInstrumentMember 2010-07-01 2011-06-30 0001355250 2010-07-01 2011-06-30 0001355250 ctix:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStageMember 2009-07-01 2010-06-30 0001355250 us-gaap:AdditionalPaidInCapitalMember 2009-07-01 2010-06-30 0001355250 ctix:IssuanceDuringPeriod3rdMemberus-gaap:GoodsAndServicesExchangedForEquityInstrumentMember 2009-07-01 2010-06-30 0001355250 ctix:IssuanceDuringPeriod3rdMemberus-gaap:AdditionalPaidInCapitalMemberus-gaap:GoodsAndServicesExchangedForEquityInstrumentMember 2009-07-01 2010-06-30 0001355250 ctix:IssuanceDuringPeriod3rdMemberus-gaap:CommonStockMemberus-gaap:GoodsAndServicesExchangedForEquityInstrumentMember 2009-07-01 2010-06-30 0001355250 ctix:IssuanceDuringPeriod2ndMemberus-gaap:GoodsAndServicesExchangedForEquityInstrumentMember 2009-07-01 2010-06-30 0001355250 ctix:IssuanceDuringPeriod2ndMemberus-gaap:AdditionalPaidInCapitalMemberus-gaap:GoodsAndServicesExchangedForEquityInstrumentMember 2009-07-01 2010-06-30 0001355250 ctix:IssuanceDuringPeriod2ndMemberus-gaap:CommonStockMemberus-gaap:GoodsAndServicesExchangedForEquityInstrumentMember 2009-07-01 2010-06-30 0001355250 ctix:IssuanceDuringPeriod1stMemberus-gaap:GoodsAndServicesExchangedForEquityInstrumentMember 2009-07-01 2010-06-30 0001355250 ctix:IssuanceDuringPeriod1stMemberus-gaap:AdditionalPaidInCapitalMemberus-gaap:GoodsAndServicesExchangedForEquityInstrumentMember 2009-07-01 2010-06-30 0001355250 ctix:IssuanceDuringPeriod1stMemberus-gaap:CommonStockMemberus-gaap:GoodsAndServicesExchangedForEquityInstrumentMember 2009-07-01 2010-06-30 0001355250 2009-07-01 2010-06-30 0001355250 us-gaap:GoodsAndServicesExchangedForEquityInstrumentMember 2008-07-01 2009-06-30 0001355250 ctix:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStageMember 2008-07-01 2009-06-30 0001355250 us-gaap:AdditionalPaidInCapitalMemberus-gaap:GoodsAndServicesExchangedForEquityInstrumentMember 2008-07-01 2009-06-30 0001355250 us-gaap:AdditionalPaidInCapitalMember 2008-07-01 2009-06-30 0001355250 us-gaap:CommonStockMemberus-gaap:GoodsAndServicesExchangedForEquityInstrumentMember 2008-07-01 2009-06-30 0001355250 ctix:IssuanceDuringPeriod2ndMemberus-gaap:GoodsAndServicesExchangedForEquityInstrumentMember 2008-07-01 2009-06-30 0001355250 ctix:IssuanceDuringPeriod2ndMemberus-gaap:AdditionalPaidInCapitalMemberus-gaap:GoodsAndServicesExchangedForEquityInstrumentMember 2008-07-01 2009-06-30 0001355250 ctix:IssuanceDuringPeriod2ndMemberus-gaap:CommonStockMemberus-gaap:GoodsAndServicesExchangedForEquityInstrumentMember 2008-07-01 2009-06-30 0001355250 ctix:IssuanceDuringPeriod1stMemberus-gaap:GoodsAndServicesExchangedForEquityInstrumentMember 2008-07-01 2009-06-30 0001355250 ctix:IssuanceDuringPeriod1stMemberus-gaap:AdditionalPaidInCapitalMemberus-gaap:GoodsAndServicesExchangedForEquityInstrumentMember 2008-07-01 2009-06-30 0001355250 ctix:IssuanceDuringPeriod1stMemberus-gaap:CommonStockMemberus-gaap:GoodsAndServicesExchangedForEquityInstrumentMember 2008-07-01 2009-06-30 0001355250 2008-07-01 2009-06-30 0001355250 us-gaap:TreasuryStockMember 2011-07-01 2012-03-31 0001355250 ctix:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStageMember 2011-07-01 2012-03-31 0001355250 us-gaap:AdditionalPaidInCapitalMember 2011-07-01 2012-03-31 0001355250 us-gaap:TreasuryStockMember 2011-07-01 2012-03-31 0001355250 us-gaap:CommonStockMember 2011-07-01 2012-03-31 0001355250 ctix:IssuanceDuringPeriod4thMemberus-gaap:ContributionOfNonmonetaryAssetsToCharitableOrganizationMember 2011-07-01 2012-03-31 0001355250 ctix:IssuanceDuringPeriod4thMemberus-gaap:AdditionalPaidInCapitalMemberus-gaap:ContributionOfNonmonetaryAssetsToCharitableOrganizationMember 2011-07-01 2012-03-31 0001355250 ctix:IssuanceDuringPeriod4thMemberus-gaap:CommonStockMemberus-gaap:ContributionOfNonmonetaryAssetsToCharitableOrganizationMember 2011-07-01 2012-03-31 0001355250 ctix:IssuanceDuringPeriod3rdMemberus-gaap:GoodsAndServicesExchangedForEquityInstrumentMember 2011-07-01 2012-03-31 0001355250 ctix:IssuanceDuringPeriod3rdMemberus-gaap:AdditionalPaidInCapitalMemberus-gaap:GoodsAndServicesExchangedForEquityInstrumentMember 2011-07-01 2012-03-31 0001355250 ctix:IssuanceDuringPeriod3rdMemberus-gaap:CommonStockMemberus-gaap:GoodsAndServicesExchangedForEquityInstrumentMember 2011-07-01 2012-03-31 0001355250 ctix:IssuanceDuringPeriod2ndMemberus-gaap:GoodsAndServicesExchangedForEquityInstrumentMember 2011-07-01 2012-03-31 0001355250 ctix:IssuanceDuringPeriod2ndMemberus-gaap:AdditionalPaidInCapitalMemberus-gaap:GoodsAndServicesExchangedForEquityInstrumentMember 2011-07-01 2012-03-31 0001355250 ctix:IssuanceDuringPeriod2ndMemberus-gaap:CommonStockMemberus-gaap:GoodsAndServicesExchangedForEquityInstrumentMember 2011-07-01 2012-03-31 0001355250 ctix:IssuanceDuringPeriod1stMemberus-gaap:GoodsAndServicesExchangedForEquityInstrumentMember 2011-07-01 2012-03-31 0001355250 ctix:IssuanceDuringPeriod1stMemberus-gaap:AdditionalPaidInCapitalMemberus-gaap:GoodsAndServicesExchangedForEquityInstrumentMember 2011-07-01 2012-03-31 0001355250 ctix:IssuanceDuringPeriod1stMemberus-gaap:CommonStockMemberus-gaap:GoodsAndServicesExchangedForEquityInstrumentMember 2011-07-01 2012-03-31 0001355250 2011-07-01 2012-03-31 0001355250 us-gaap:CommonStockMember 2010-07-01 2011-03-31 0001355250 2010-07-01 2011-03-31 0001355250 us-gaap:TreasuryStockMember 2007-06-20 2012-03-31 0001355250 us-gaap:CommonStockMember 2007-06-20 2012-03-31 0001355250 2007-06-20 2012-03-31 0001355250 ctix:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStageMember 2007-06-20 2007-06-30 0001355250 us-gaap:CommonStockMember 2007-06-20 2007-06-30 0001355250 2007-06-20 2007-06-30 0001355250 us-gaap:CommonClassAMember 2011-06-30 0001355250 us-gaap:CommonClassBMember 2011-06-30 0001355250 ctix:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStageMember 2011-06-30 0001355250 us-gaap:AdditionalPaidInCapitalMember 2011-06-30 0001355250 us-gaap:TreasuryStockMember 2011-06-30 0001355250 us-gaap:CommonStockMember 2011-06-30 0001355250 ctix:IssuanceDuringPeriod4thMemberus-gaap:GoodsAndServicesExchangedForEquityInstrumentMember 2011-06-30 0001355250 ctix:IssuanceDuringPeriod3rdMemberus-gaap:GoodsAndServicesExchangedForEquityInstrumentMember 2011-06-30 0001355250 ctix:IssuanceDuringPeriod2ndMemberus-gaap:GoodsAndServicesExchangedForEquityInstrumentMember 2011-06-30 0001355250 ctix:IssuanceDuringPeriod1stMemberus-gaap:GoodsAndServicesExchangedForEquityInstrumentMember 2011-06-30 0001355250 2011-06-30 0001355250 ctix:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStageMember 2010-06-30 0001355250 us-gaap:AdditionalPaidInCapitalMember 2010-06-30 0001355250 us-gaap:CommonStockMember 2010-06-30 0001355250 ctix:IssuanceDuringPeriod3rdMemberus-gaap:GoodsAndServicesExchangedForEquityInstrumentMember 2010-06-30 0001355250 ctix:IssuanceDuringPeriod2ndMemberus-gaap:GoodsAndServicesExchangedForEquityInstrumentMember 2010-06-30 0001355250 ctix:IssuanceDuringPeriod1stMemberus-gaap:GoodsAndServicesExchangedForEquityInstrumentMember 2010-06-30 0001355250 2010-06-30 0001355250 ctix:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStageMember 2009-06-30 0001355250 us-gaap:AdditionalPaidInCapitalMember 2009-06-30 0001355250 us-gaap:CommonStockMember 2009-06-30 0001355250 ctix:IssuanceDuringPeriod2ndMemberus-gaap:GoodsAndServicesExchangedForEquityInstrumentMember 2009-06-30 0001355250 ctix:IssuanceDuringPeriod1stMemberus-gaap:GoodsAndServicesExchangedForEquityInstrumentMember 2009-06-30 0001355250 2009-06-30 0001355250 us-gaap:GoodsAndServicesExchangedForEquityInstrumentMember 2008-06-30 0001355250 ctix:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStageMember 2008-06-30 0001355250 us-gaap:AdditionalPaidInCapitalMember 2008-06-30 0001355250 us-gaap:CommonStockMember 2008-06-30 0001355250 2008-06-30 0001355250 ctix:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStageMember 2007-06-30 0001355250 us-gaap:CommonStockMember 2007-06-30 0001355250 2007-06-30 0001355250 us-gaap:CommonClassAMember 2012-03-31 0001355250 us-gaap:CommonClassBMember 2012-03-31 0001355250 ctix:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStageMember 2012-03-31 0001355250 us-gaap:AdditionalPaidInCapitalMember 2012-03-31 0001355250 us-gaap:TreasuryStockMember 2012-03-31 0001355250 us-gaap:CommonStockMember 2012-03-31 0001355250 ctix:IssuanceDuringPeriod4thMemberus-gaap:ContributionOfNonmonetaryAssetsToCharitableOrganizationMember 2012-03-31 0001355250 ctix:IssuanceDuringPeriod3rdMemberus-gaap:GoodsAndServicesExchangedForEquityInstrumentMember 2012-03-31 0001355250 ctix:IssuanceDuringPeriod2ndMemberus-gaap:GoodsAndServicesExchangedForEquityInstrumentMember 2012-03-31 0001355250 ctix:IssuanceDuringPeriod1stMemberus-gaap:GoodsAndServicesExchangedForEquityInstrumentMember 2012-03-31 0001355250 2012-03-31 0001355250 2011-03-31 0001355250 2012-05-10 shares iso4217:USD iso4217:USD shares pure

EX-101.SCH 5 ctix-20120331.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 103 - Statement - Balance Sheets link:calculationLink link:presentationLink link:definitionLink 104 - Statement - Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 105 - Statement - Statements of Operations link:calculationLink link:presentationLink link:definitionLink 106 - Statement - Statement of Changes in Stockholders' Deficit link:calculationLink link:presentationLink link:definitionLink 107 - Statement - Statement of Changes in Stockholders' Deficit (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 108 - Statement - Statements of Cash Flows link:calculationLink link:presentationLink link:definitionLink 109 - Disclosure - Background Information link:calculationLink link:presentationLink link:definitionLink 110 - Disclosure - Financial Statements link:calculationLink link:presentationLink link:definitionLink 111 - Disclosure - Going Concern link:calculationLink link:presentationLink link:definitionLink 112 - Disclosure - Recent Accounting Pronouncements link:calculationLink link:presentationLink link:definitionLink 113 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 114 - Disclosure - Fair Value of Financial Assets and Financial Liabilities link:calculationLink link:presentationLink link:definitionLink 115 - Disclosure - Related Party Transactions link:calculationLink link:presentationLink link:definitionLink 116 - Disclosure - Due To Officer link:calculationLink link:presentationLink link:definitionLink 117 - Disclosure - Stock Options and Warrants link:calculationLink link:presentationLink link:definitionLink 118 - Disclosure - Equity Transactions link:calculationLink link:presentationLink link:definitionLink 119 - Disclosure - Convertible Debentures link:calculationLink link:presentationLink link:definitionLink 120 - Disclosure - Subsequent Events link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 6 ctix-20120331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 7 ctix-20120331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 8 ctix-20120331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Accounts Payable Current Accounts payable, including related party payables of $1,695,683 and $1,789,818, respectively Accounts Payable Related Parties Current Accounts payable, related party payables Accrued Liabilities Current Accrued expenses, including related party interest and rent accruals of $272,573 and $119,598, respectively Additional Paid In Capital Additional paid in capital Additional Paid In Capital [Member] Additional Paid-in Capital Adjustments Related To Tax Withholding For Share Based Compensation Forgiveness of liability in connection with settlement with stockholder Adjustments To Additional Paid In Capital Other Forgiveness of debt from a stockholder Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition Issuance of stock options Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Amendment Flag Amendment Flag Amortization Of Financing Costs Amortization of accrued settlement costs Assets Total assets Assets [Abstract] Assets Assets Current Total current assets Assets Current [Abstract] Current assets: Basis Of Accounting Financial Statements Cancellation of Previously Issued Common Stock Shares Cancellation Of Previously Issued Common Stock Shares Cancellation of shares issued (in shares) Cancellation of Previously Issued Common Stock Value Cancellation Of Previously Issued Common Stock Value Cancellation of shares issued Cancellation of Shares Cancellation Of Shares Cancellation stock Capital contributed by affiliate. Capital Contributed Capital contribution from a stockholder Capital Contribution Capital Contribution Settlement of accrued payroll and payroll taxes Cash CASH, END OF PERIOD CASH, BEGINNING OF PERIOD Cash Cash Period Increase Decrease NET INCREASE (DECREASE) IN CASH Class Of Stock [Domain] Class of Stock [Domain] Commitments And Contingencies Commitments and contingencies Commitments And Contingencies Disclosure [Text Block] Commitments and Contingencies Common Class A [Member] Class A common stock Common Class B [Member] Class B common stock Common Stock Issued To Acquire Businesses Common Stock Issued To Acquire Businesses Common stock issued for acquisition Common Stock [Member] Common Stock Common Stock Par Or Stated Value Per Share Common stock, par value Common Stock Shares Authorized Common stock, shares authorized Common Stock Shares Issued Common stock, shares issued Common Stock Shares Outstanding Common stock, shares outstanding Common Stock Value Common stock Common Stock, Votes per share Common Stock Votes Per Share Common stock, votes per share Contribution Of Nonmonetary Assets To Charitable Organization [Member] Contribution of Nonmonetary Assets to Charitable Organization Conversion Of Warrants To Common Stock Conversion Of Warrants To Common Stock Reclassification of warrants to equity Convertible Debt Current Convertible debentures , current Convertible Debt Noncurrent Convertible debentures, net of current Convertible Senior Debentures Disclosure Convertible Senior Debentures Disclosure [Text Block] Convertible Debentures Costs And Expenses Total operating expenses Costs And Expenses [Abstract] Operating Expenses: Current Fiscal Year End Date Current Fiscal Year End Date Debt Conversion Converted Instrument Amount 1 Debt converted to common stock Debt Disclosure [Text Block] Due To Officer Development Stage Enterprise Deficit Accumulated During Development Stage Deficit accumulated during development stage Development Stage Enterprise, Deficit Accumulated During Development Stage Development Stage Enterprise Deficit Accumulated During Development Stage [Member] Deficit Accumulated During the Development Stage Disclosure Of Compensation Related Costs Share Based Payments [Text Block] Stock Options and Warrants Document - Document and Entity Information [Abstract] Document Documentand Entity Information [Abstract] Document - Document and Entity Information [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Document Fiscal Year Focus Document Fiscal Year Focus Document Information [Line Items] Document Information [Line Items] Document Period End Date Document Period End Date Document Type Document Type Due To Related Parties Current Accrued expenses, related party interest and rent accruals Earnings Per Share Basic And Diluted Basic and Diluted Loss per Share Employee Related Liabilities Current Accrued salaries and payroll taxes Entities [Table] Entities [Table] Entity Central Index Key Entity Central Index Key Entity Common Stock Shares Outstanding Entity Common Stock, Shares Outstanding Entity [Domain] Entity [Domain] Entity Filer Category Entity Filer Category Entity Registrant Name Entity Registrant Name Equity Cancellation, Date Equity Cancellation Date Cancellation of shares issued, date Equity Component [Domain] Equity Component [Domain] Equity Issuance Dates Shares issuance, date Equity Issuance Dollar Amount Per Share Shares issued, price per share Equity Issued Since Inception By Issuance [Axis] Equity Issued Since Inception by Issuance [Axis] Fair Value Disclosures [Text Block] Fair Value of Financial Assets and Financial Liabilities Gain Loss On Investments Gain (loss) on financial instruments Gain (loss) on financial instruments General And Administrative Expense General and administrative Going Concern Disclosure [Text Block] Going Concern Disclosure [Text Block] Going Concern Goods And Services Exchanged For Equity Instrument [Member] Services Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments Net loss before provision for income taxes Income Statement [Abstract] Income Statement [Abstract] Income Tax Expense Benefit Provision for income taxes Increase Decrease In Accounts Payable Accounts payable Increase Decrease In Accrued Liabilities Accrued expenses Increase Decrease In Employee Related Liabilities Accrued salaries and payroll taxes Increase Decrease In Operating Capital [Abstract] Changes in operating assets and liabilities: Increase Decrease In Other Receivables Other receivable Increase Decrease In Prepaid Expense Prepaid expenses Interest Income Expense Nonoperating Net Interest expense-net Issuance [Domain] Issuance [Domain] Issuance During Period 1st [Member] Issuance During Period 1 st [Member] Issuance During Period 1st Issuance During Period 2nd [Member] Issuance During Period 2 nd [Member] Issuance During Period 2nd Issuance During Period 3rd [Member] Issuance During Period 3 rd [Member] Issuance During Period 3rd Issuance During Period 4th [Member] Issuance During Period 4 th [Member] Issuance During Period 4th Issuance, Transaction Date Issuance Transaction Date Share exchange, date Labor And Related Expense Officers' payroll and payroll tax Legal Entity [Axis] Legal Entity [Axis] Liabilities Total liabilities Liabilities And Stockholders Equity Total liabilities and stockholders' deficit Liabilities And Stockholders Equity [Abstract] Liabilities and Stockholders' Deficit Liabilities Current Total current liabilities Liabilities Current [Abstract] Current liabilities: Nature Of Operations Background Information Net Cash Provided By Used In Financing Activities Net cash provided by financing activities Net Cash Provided By Used In Financing Activities [Abstract] CASH FLOWS FROM FINANCING ACTIVITIES: Net Cash Provided By Used In Operating Activities Net cash used in operating activities Net Cash Provided By Used In Operating Activities [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Net Income Loss Net loss Net loss New Accounting Pronouncements [Text Block] New Accounting Pronouncements [Text Block] Recent Accounting Pronouncements Notes Payable Related Parties Classified Current Note payable to officer Operating Income Loss Loss from operations Other Accrued Liabilities Current Accrued settlement costs, current Other Accrued Liabilities Noncurrent Accrued settlement costs, less current portion Other Costs and Expenses Other Costs And Expenses Patent expense Other Noncash Income Expense Cancellation of stock for services Other Receivables Net Current Other Receivables ( Grant) Other Significant Noncash Transaction Value Of Consideration Given 1 Treasury stock as a result of settlement agreement Preferred Stock Par Or Stated Value Per Share Preferred stock, par value Preferred Stock Shares Authorized Preferred stock, shares authorized Preferred Stock Shares Issued Preferred stock, shares issued Preferred Stock Shares Outstanding Preferred stock, shares outstanding Preferred Stock Value Preferred stock; $0.0001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding Prepaid Expense Current Prepaid expenses Proceeds From Contributed Capital Capital contribution from a stockholder Proceeds From Convertible Debt Proceeds from convertible debentures Proceeds From Issuance Of Common Stock Sale of common stock Proceeds From Other Equity Proceeds from subscription Proceeds From Payments For Other Financing Activities Payment of settlement liabilities Proceeds From Related Party Debt Loan from officer Professional Fees Professional fees Reclassifications Reclassification Modification of stock options Reclassification Of Warrant Liabilities To Equity Reclassification Of Warrant Liabilities To Equity Reclassification of warrants into equity Related Party Transactions Disclosure [Text Block] Related Party Transactions Repayments Of Convertible Debt Redemption of convertible debentures Repurchase of Common Stock, Shares Repurchase Of Common Stock Shares Repurchase of common stock in connection with settlement (in shares) Repurchase of Common Stock, Value Repurchase Of Common Stock Value Repurchase of common stock in connection with settlement Research And Development Expense Research and development, gross Research and Development Expense, Net of Grants Research And Development Expense Net Of Grants Research and development, net of grants Revenue From Grants Grants Revenues Revenues: Scenario Unspecified [Domain] Scenario, Unspecified [Domain] Shares Issued Ending Balance (in shares) Statement Class Of Stock [Axis] Class of Stock [Axis] Statement Equity Components [Axis] Statement, Equity Components [Axis] Statement [Line Items] Statement [Line Items] Statement Of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Statement Of Financial Position [Abstract] Statement of Financial Position [Abstract] Statement Of Stockholders Equity [Abstract] Statement of Stockholders' Equity [Abstract] Statement Scenario [Axis] Statement, Scenario [Axis] Statement [Table] Statement [Table] Stockholders Equity Ending Balance Total stockholders' deficit Stockholders Equity [Abstract] Stockholders' deficit: Stockholders Equity Note Disclosure [Text Block] Equity Transactions Stock Issued During Period Shares Acquisitions Shares exchanged in a reverse acquisition of CellceutixPharma, December 6, 2007 (in shares) Stock Issued During Period Shares Conversion Of Convertible Securities Convertible Debentures converted to common stock (in shares) Stock Issued During Period Shares Exchange Of Owners Equity Stock Issued During Period Shares Exchange Of Owners Equity Share exchange with CellceutixPharma, Inc. December 6, 2007 (in shares) Number of shares of stock issued during the period pursuant to a merger. Stock Issued During Period Shares Merger Share exchange in reverse merger with CellceutixPharma, Inc. December 6, 2007 (in shares) Stock Issued During Period Shares New Issues Shares issued (in shares) Stock Issued During Period Value Acquisitions Shares exchanged in a reverse acquisition of CellceutixPharma, December 6, 2007 Stock Issued During Period Value Conversion Of Convertible Securities Convertible Debentures converted to common stock Stock Issued During Period Value Exchange Of Owners Equity Stock Issued During Period Value Exchange Of Owners Equity Share exchange with CellceutixPharma, Inc. December 6, 2007 Value of stock issued pursuant to a merger during the period. Stock Issued During Period Value Merger Share exchange in reverse merger with CellceutixPharma, Inc. December 6, 2007 Stock Issued During Period Value New Issues Shares issued Stock Option Plan Expense Common stock and stock options issued as payment for services compensation, services rendered and charitable contributions Subsequent Events [Text Block] Subsequent Events Supplemental Cash Flow Information [Abstract] SUPPLEMENTAL DISCLOSURE OF NON-CASH FLOW FINANCING ACTIVITIES: Supplemental Forgiveness Of Debt By Related Party Supplemental Forgiveness Of Debt By Related Party Forgiveness of debt Supplemental Reclassification Of Accrued Interest To Debt Principal Supplemental Reclassification Of Accrued Interest To Debt Principal Reclassification of accrued interest to note payable and convertible debenture Text Block [Abstract] Text Block [Abstract] Trading Symbol Trading Symbol Transaction Date 01 [Member] Transaction Date 01 [Member] Share exchange with CellceutixPharma, Inc. Transaction Date 02 [Member] Transaction Date 02 [Member] Share exchange in reverse merger with CellceutixPharma, Inc. Transaction Date 03 [Member] Transaction Date 03 [Member] Shares exchanged in a reverse acquisition of CellceutixPharma Treasury Stock [Member] Treasury Stock Treasury Stock Retired Cost Method Amount Cancellation of treasury stock Treasury Stock Shares Treasury stock, shares Treasury Stock Shares Retired Cancellation of treasury stock (in shares) Cancellation of treasury stock (in shares) Treasury Stock Value Treasury stock (2,762,084 and 4,142,084 shares at cost,) Weighted Average Number of Shares Outstanding where Basic and Diluted are the same and reported as a single line Weighted Average Number Basic Diluted Shares Outstanding Weighted average number of common shares used in basic and diluted per share calculations EX-101.PRE 9 ctix-20120331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 R9.htm IDEA: XBRL DOCUMENT

Financial Statements

9 Months Ended

Mar. 31, 2012

Financial Statements

2. Financial Statements

EXCEL 12 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\U,F-A,S4V.5\S8V5C7S1C9C%?.#9B95\U.64T M.&5E-#4V,#0B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D)A8VMG#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D=O M:6YG7T-O;F-E#I7;W)K#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D9A:7)?5F%L=65?;V9?1FEN86YC:6%L7T%S#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E)E;&%T961?4&%R='E? M5')A;G-A8W1I;VYS/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I% M>&-E;%=O#I7;W)K#I. M86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I7;W)K#I3='EL97-H965T($A2968],T0B5V]R M:W-H965T&-E;"!8 M4"!O3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%\U,F-A,S4V.5\S8V5C7S1C9C%?.#9B95\U.64T.&5E-#4V M,#0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-3)C83,U-CE?,V-E M8U\T8V8Q7S@V8F5?-3EE-#AE930U-C`T+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R2!);F9O2`Q,"P@,C`Q,CQB'0^,3`M43QS<&%N/CPO'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^0U1)6#QS<&%N/CPO'0^0T5,3$-%551)6"!#3U)0/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$"!+97D\+W1D/@T*("`@("`@("`\=&0@8VQA2!&:6QE3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^4VUA;&QE3QS<&%N/CPO3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%\U,F-A,S4V.5\S8V5C7S1C9C%?.#9B95\U.64T M.&5E-#4V,#0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-3)C83,U M-CE?,V-E8U\T8V8Q7S@V8F5?-3EE-#AE930U-C`T+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S6%B;&4@=&\@;V9F:6-E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\U,F-A,S4V.5\S8V5C7S1C M9C%?.#9B95\U.64T.&5E-#4V,#0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z M+R\O0SHO-3)C83,U-CE?,V-E8U\T8V8Q7S@V8F5?-3EE-#AE930U-C`T+U=O M'0O:'1M M;#L@8VAA6%B;&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L M-CDU+#8X,SQS<&%N/CPOF5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M<#XQ,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S2!S=&]C:RP@F5D/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$;G5M<#XS,#`L,#`P+#`P,#QS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\U,F-A,S4V.5\S8V5C M7S1C9C%?.#9B95\U.64T.&5E-#4V,#0-"D-O;G1E;G0M3&]C871I;VXZ(&9I M;&4Z+R\O0SHO-3)C83,U-CE?,V-E8U\T8V8Q7S@V8F5?-3EE-#AE930U-C`T M+U=O'0O M:'1M;#L@8VAA'0^)FYB'0^)FYB'0^)FYB'0^)FYB'0^)FYB'!E;G-E7)O M;&P@86YD('!A>7)O;&P@=&%X/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M;G5M<#XQ,3,L.3'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQA3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$F%T:6]N('P@27-S=6%N8V4@1'5R:6YG(%!E'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M&-H86YG92!W:71H($-E;&QC975T:7A0:&%R;6$L($EN8RX@1&5C96UB M97(@-BP@,C`P-R`H:6X@'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S%!H M87)M82P@26YC+B!$96-E;6)E'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&-H86YG92!I;B!R979E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S&-H86YG960@:6X@82!R979E M%!H87)M82P@1&5C96UB97(@ M-BP@,C`P-SPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S2!S=&]C:R`H:6X@'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S2!S=&]C:SPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S2!I;B!C;VYN96-T:6]N('=I=&@@'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$2!S=&]C:SPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$2!!'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$%!H87)M82P@1&5C96UB97(@-BP@,C`P-SPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S2!3=&]C:SPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'1087)T7S4R8V$S-38Y7S-C96-?-&-F,5\X-F)E7S4Y930X964T-38P M-`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\U,F-A,S4V.5\S8V5C M7S1C9C%?.#9B95\U.64T.&5E-#4V,#0O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA%!H M87)M82P@26YC+CQB%!H87)M82P@26YC+CQB&-H86YG960@:6X@82!R979EF%T M:6]N/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^1&5C(#,Q+`T*"0DR,#`X/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&-H M86YG92P@9&%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^1&5C M(#8L#0H)"3(P,#<\'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^2G5N(#(P+`T*"0DR,#`W/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^07!R(#(X+`T*"0DR,#`X M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M075G(#(Y+`T*"0DR,#$Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^2G5L(#8L#0H)"3(P,3`\'0^36%R(#$L#0H)"3(P,3$\'0^1F5B(#@L M#0H)"3(P,3$\2`R-BP-"@D),C`Q,3QS<&%N/CPO M3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%\U,F-A,S4V.5\S8V5C7S1C9C%?.#9B95\U.64T.&5E-#4V,#0-"D-O;G1E M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-3)C83,U-CE?,V-E8U\T8V8Q7S@V M8F5?-3EE-#AE930U-C`T+U=O'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S6UE M;G0@;V8@'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M2!F:6YA;F-I;F<@86-T:79I M=&EE'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S&5S/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\U,F-A,S4V.5\S8V5C7S1C9C%?.#9B M95\U.64T.&5E-#4V,#0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO M-3)C83,U-CE?,V-E8U\T8V8Q7S@V8F5?-3EE-#AE930U-C`T+U=O'0O:'1M;#L@8VAA M'0^/&1I=B!S='EL93TS M1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE M$$P.R8C>$$P M.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.T)A M8VMG6QE/3-$)TU! M4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE"!#;W)P M;W)A=&EO;BP@9F]R;65R;'D@:VYO=VX@87,@16-O;F]3:&%R92P@26YC+BP@ M*'1H90T*)B-X,C`Q0SM#;VUP86YY)B-X,C`Q1#L@;W(@=&AE("8C>#(P,4,[ M4F5G:7-T#(P,40[*2!W87,-"FEN8V]R<&]R871E9"!O;B!!=6=U M3L@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E2!O=VYE9"!$96QA=V%R92!C;W)P;W)A=&EO;B!P=7)S M=6%N="!T;R!A;B!!9W)E96UE;G0@86YD#0I0;&%N(&]F(%-H87)E($5X8VAA M;F=E("AT:&4@)B-X,C`Q0SM%>&-H86YG928C>#(P,40[*2X-"D-E;&QC975T M:7A0:&%R;6$L($EN8RX@=V%S(&EN8V]R<&]R871E9"!U;F1E"!E87)L>2!S=&%G92!P:&%R;6%C975T:6-A;"!C;VUP;W5N M9',@8GD-"G1H6QE/3-$)U1%6%0M04Q)1TXZ(&IU#L@ M1D].5#H@,3!P="!4:6UE XML 13 R8.htm IDEA: XBRL DOCUMENT

Background Information

9 Months Ended

Mar. 31, 2012

Background Information

1. Background Information

XML 14 R2.htm IDEA: XBRL DOCUMENT

Balance Sheets (USD $)	Mar. 31, 2012	Jun. 30, 2011
Current assets:
Cash	$ 93,660	$ 68,661
Prepaid expenses	6,592	40,290
Other Receivables ( Grant)		204,144
Total current assets	100,252	313,095
Total assets	100,252	313,095
Current liabilities:
Accounts payable, including related party payables of $1,695,683 and $1,789,818, respectively	1,997,364	2,139,527
Accrued expenses, including related party interest and rent accruals of $272,573 and $119,598, respectively	272,573	127,432
Accrued salaries and payroll taxes	2,604,188	2,030,621
Accrued settlement costs, current	261,046	300,859
Note payable to officer	2,022,264	2,002,264
Convertible debentures , current		167,099
Total current liabilities	7,157,435	6,767,802
Accrued settlement costs, less current portion	275,229	484,158
Convertible debentures, net of current		349,213
Total liabilities	7,432,664	7,601,173
Commitments and contingencies
Stockholders' deficit:
Preferred stock; $0.0001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding
Additional paid in capital	7,893,202	4,838,968
Deficit accumulated during development stage	(14,707,305)	(11,376,830)
Treasury stock (2,762,084 and 4,142,084 shares at cost,)	(527,733)	(759,388)
Total stockholders' deficit	(7,332,412)	(7,288,078)
Total liabilities and stockholders' deficit	100,252	313,095
Class A common stock
Stockholders' deficit:
Common stock	$ 9,424	$ 9,172

XML 15 R6.htm IDEA: XBRL DOCUMENT

Statement of Changes in Stockholders' Deficit (Parenthetical) (USD $)	0 Months Ended	12 Months Ended					9 Months Ended	12 Months Ended			9 Months Ended	12 Months Ended			9 Months Ended	12 Months Ended			9 Months Ended
	Jun. 30, 2007	Jun. 30, 2009 Services	Jun. 30, 2008 Services	Jun. 30, 2008 Share exchange with CellceutixPharma, Inc.	Jun. 30, 2008 Share exchange in reverse merger with CellceutixPharma, Inc.	Jun. 30, 2008 Shares exchanged in a reverse acquisition of CellceutixPharma	Mar. 31, 2012 Issuance During Period 1st Services	Jun. 30, 2011 Issuance During Period 1st Services	Jun. 30, 2010 Issuance During Period 1st Services	Jun. 30, 2009 Issuance During Period 1st Services	Mar. 31, 2012 Issuance During Period 2nd Services	Jun. 30, 2011 Issuance During Period 2nd Services	Jun. 30, 2010 Issuance During Period 2nd Services	Jun. 30, 2009 Issuance During Period 2nd Services	Mar. 31, 2012 Issuance During Period 3rd Services	Jun. 30, 2011 Issuance During Period 3rd Services	Jun. 30, 2010 Issuance During Period 3rd Services	Jun. 30, 2011 Issuance During Period 4th Services	Mar. 31, 2012 Issuance During Period 4th Contribution of Nonmonetary Assets to Charitable Organization
Cancellation of shares issued, date		Dec. 31, 2008
Share exchange, date				Dec. 06, 2007	Dec. 06, 2007	Dec. 06, 2007
Shares issued, price per share			$ 1.05				$ 0.38	$ 0.55	$ 0.43	$ 0.38	$ 0.41	$ 0.32	$ 0.30	$ 0.38	$ 0.45	$ 0.20	$ 0.45	$ 0.81	$ 0.52
Shares issuance, date	Jun. 20, 2007		Apr. 28, 2008				Aug. 29, 2011	Jul. 06, 2010	Jul. 06, 2009	Jun. 11, 2009	Nov. 08, 2011	Mar. 01, 2011	Feb. 05, 2010	Jun. 30, 2009	Nov. 01, 2012	Feb. 08, 2011	Jun. 01, 2010	May 26, 2011	Jul. 03, 2012

XML 16 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.1.0.1 * */ var moreDialog = null; var Show = { Default:'raw', more:function( obj ){ var bClosed = false; if( moreDialog != null ) { try { bClosed = moreDialog.closed; } catch(e) { //Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control // that somtimes causes it to throw when checking the closed property on a child window that has been //closed. So if the exception occurs we assume the window is closed and move on from there. bClosed = true; } if( !bClosed ){ moreDialog.close(); } } obj = obj.parentNode.getElementsByTagName( 'pre' )[0]; var hasHtmlTag = false; var objHtml = ''; var raw = ''; //Check for raw HTML var nodes = obj.getElementsByTagName( '*' ); if( nodes.length ){ objHtml = obj.innerHTML; }else{ if( obj.innerText ){ raw = obj.innerText; }else{ raw = obj.textContent; } var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g ); if( matches && matches.length ){ objHtml = raw; //If there is an html node it will be 1st or 2nd, // but we can check a little further. var n = Math.min( 5, matches.length ); for( var i = 0; i < n; i++ ){ var el = matches[ i ].toString().toLowerCase(); if( el.indexOf( '= 0 ){ hasHtmlTag = true; break; } } } } if( objHtml.length ){ var html = ''; if( hasHtmlTag ){ html = objHtml; }else{ html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ objHtml + "\n"+''+ "\n"+''; } moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write( html ); moreDialog.document.close(); if( !hasHtmlTag ){ moreDialog.document.body.style.margin = '0.5em'; } } else { //default view logic var lines = raw.split( "\n" ); var longest = 0; if( lines.length > 0 ){ for( var p = 0; p < lines.length; p++ ){ longest = Math.max( longest, lines[p].length ); } } //Decide on the default view this.Default = longest < 120 ? 'raw' : 'formatted'; //Build formatted view var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ; var formatted = ''; if( text.length > 0 ){ if( text.length == 1 ){ text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ; formatted = "

"+ text.join( "

\n" ) +"

"; }else{ for( var p = 0; p < text.length; p++ ){ formatted += "

" + text[p] + "

\n"; } } }else{ formatted = '

' + raw + '

'; } html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+'

'+ "\n"+' formatted: '+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +''+ "\n"+'

'+ "\n"+' '+ "\n"+'

'+ "\n"+'

'+raw+'

'+ "\n"+'

'+ "\n"+''+ "\n"+''; moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write(html); moreDialog.document.close(); this.toggle( moreDialog ); } moreDialog.document.title = 'Report Preview Details'; }, toggle:function( win, domLink ){ var domId = this.Default; var doc = win.document; var domEl = doc.getElementById( domId ); domEl.style.display = 'block'; this.Default = domId == 'raw' ? 'formatted' : 'raw'; if( domLink ){ domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed'; } var domElOpposite = doc.getElementById( this.Default ); domElOpposite.style.display = 'none'; }, LastAR : null, showAR : function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }, toggleNext : function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }, hideAR : function(){ Show.LastAR.style.display = 'none'; } } XML 17 R7.htm IDEA: XBRL DOCUMENT

Statements of Cash Flows (USD $)	9 Months Ended		57 Months Ended
Statements of Cash Flows (USD $)	Mar. 31, 2012	Mar. 31, 2011	Mar. 31, 2012
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (3,330,475)	$ (4,668,254)	$ (14,698,226)
Adjustments to reconcile net loss to net cash used in operating activities:
Common stock and stock options issued as payment for services compensation, services rendered and charitable contributions	1,527,323	2,585,387	5,512,508
Cancellation of stock for services		(11,250)	(28,750)
Amortization of accrued settlement costs	51,259	8,543	76,887
Gain (loss) on financial instruments	439,892		439,892
Changes in operating assets and liabilities:
Other receivable	204,144
Prepaid expenses	(1,010)	12,778	8,160
Accounts payable	(142,163)	693,624	1,997,414
Accrued expenses	149,562	145,140	489,984
Accrued salaries and payroll taxes	573,566	669,833	3,537,153
Net cash used in operating activities	(527,902)	(564,199)	(2,664,978)
CASH FLOWS FROM FINANCING ACTIVITIES:
Capital contribution from a stockholder			50
Payment of settlement liabilities	(300,000)	(100,000)	(400,000)
Loan from officer	20,000	750,370	1,925,587
Sale of common stock			100
Proceeds from convertible debentures			400,000
Redemption of convertible debentures	(167,099)		(167,099)
Proceeds from subscription	1,000,000		1,000,000
Net cash provided by financing activities	552,901	650,370	2,758,638
NET INCREASE (DECREASE) IN CASH	24,999	(86,171)	93,660
CASH, BEGINNING OF PERIOD	68,661	3,994
CASH, END OF PERIOD	93,660	90,165	93,660
SUPPLEMENTAL DISCLOSURE OF NON-CASH FLOW FINANCING ACTIVITIES:
Common stock issued for acquisition			9,079
Forgiveness of debt			50
Settlement of accrued payroll and payroll taxes		932,966	932,966
Treasury stock as a result of settlement agreement		859,388	859,388
Reclassification of accrued interest to note payable and convertible debenture		137,964	197,964
Debt converted to common stock	353,635		353,635
Reclassification of warrants to equity	857,500		857,500
Common Stock
SUPPLEMENTAL DISCLOSURE OF NON-CASH FLOW FINANCING ACTIVITIES:
Cancellation stock		33,750	138,750
Treasury Stock
SUPPLEMENTAL DISCLOSURE OF NON-CASH FLOW FINANCING ACTIVITIES:
Cancellation stock	$ (231,655)		$ (231,655)

XML 18 R3.htm IDEA: XBRL DOCUMENT

Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2012	Jun. 30, 2011
Accounts payable, related party payables	$ 1,695,683	$ 1,789,818
Accrued expenses, related party interest and rent accruals	$ 272,573	$ 119,598
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Treasury stock, shares	2,762,084	4,142,084
Class A common stock
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	94,238,151	91,720,646
Common stock, shares outstanding	91,476.067	87,578,562.000
Class B common stock
Common stock, votes per share	10	10
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	0	0
Common stock, shares outstanding	0	0

XML 19 R17.htm IDEA: XBRL DOCUMENT

Equity Transactions

9 Months Ended

Mar. 31, 2012

Equity Transactions

10. Equity Transactions

On November 8, 2011, the Company issued a total of 125,000 shares of Class A common stock to two consultants and a member of its scientific advisory board valued at $51,250.

On January 11, 2012, the Company issued a total of 200,000 shares of Class A common stock to a consultant valued at $90,000.

On March 7, 2012 the Company issued a total of 265,228 shares of Class A common stock as charitable contributions valued at $137,920.

- Definition

The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable). Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187143-122770

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 3, 4, 5, 6, 7, 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 5

-Paragraph 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Article 4

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 4

-Section 08

-Paragraph d

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 17: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 18: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 19: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Chapter 1

-Section B

-Paragraph 7, 11A

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 20: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 21: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 22: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 23: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

XML 20 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information	9 Months Ended
Document and Entity Information	Mar. 31, 2012	May 10, 2012
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2012
Document Fiscal Year Focus	2012
Document Fiscal Period Focus	Q3
Trading Symbol	CTIX
Entity Registrant Name	CELLCEUTIX CORP
Entity Central Index Key	0001355250
Current Fiscal Year End Date	--06-30
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		91,476,067

XML 21 R18.htm IDEA: XBRL DOCUMENT

Convertible Debentures

9 Months Ended

Mar. 31, 2012

Convertible Debentures

11. Convertible Debentures

The Company paid off the remaining Convertible Debenture balance in the amount of $167,100 plus interest of $14,826 on January 3, 2012.

XML 22 R4.htm IDEA: XBRL DOCUMENT

Statements of Operations (USD $)	3 Months Ended		9 Months Ended		57 Months Ended
Statements of Operations (USD $)	Mar. 31, 2012	Mar. 31, 2011	Mar. 31, 2012	Mar. 31, 2011	Mar. 31, 2012
Revenues:
Operating Expenses:
Research and development, gross	269,043	933,382	478,909	1,679,420	4,738,972
Grants				(529,294)	(529,294)
Research and development, net of grants	269,043	933,382	478,909	1,150,126	4,209,678
General and administrative	159,710	23,373	178,779	75,683	507,763
Officers' payroll and payroll tax	113,975	658,028	1,412,879	2,275,069	6,593,527
Patent expense	14,077	2,522	95,797	31,911	165,480
Professional fees	159,350	611,158	516,671	979,907	2,248,724
Total operating expenses	716,155	2,228,463	2,683,035	4,512,696	13,725,172
Loss from operations	(716,155)	(2,228,463)	(2,683,035)	(4,512,696)	(13,725,172)
Interest expense-net	(62,462)	(68,997)	(207,548)	(155,558)	(533,162)
Gain (loss) on financial instruments	470,000		(439,892)		(439,892)
Net loss before provision for income taxes	(308,617)	(2,297,460)	(3,330,475)	(4,668,254)	(14,698,226)
Provision for income taxes
Net loss	$ (308,617)	$ (2,297,460)	$ (3,330,475)	$ (4,668,254)	$ (14,698,226)
Basic and Diluted Loss per Share	$ 0.00	$ (0.03)	$ (0.04)	$ (0.05)
Weighted average number of common shares used in basic and diluted per share calculations	91,256,613	89,714,469	89,649,308	91,207,738

XML 23 R12.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

9 Months Ended

Mar. 31, 2012

Commitments and Contingencies

5. Commitments and Contingencies

Settlement Agreement

Pharmaceutical Compounds

Employment Agreements

The Company’s accrued officers’ salaries and payroll taxes as of March 31, 2012 and June 30, 2011 are as follows:

	March 31, 2012		June 30, 2011

Krishna Menon	$	1,346,250	$	1,075,000
Leo Ehrlich	$	1,108,750	$	837,500
Accrued Payroll Taxes	$	149,188	$	118,121

	$	2,604,188	$	2,030,621

Litigation

In the ordinary conduct of business, the Company is subject to lawsuits, arbitrations and administrative proceedings from time to time. The Company expenses legal costs as incurred.

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14435-108349

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Interpretation (FIN)

-Number 14

-Paragraph 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 5

-Paragraph 9, 10, 11, 12

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

+ Details

XML 24 R11.htm IDEA: XBRL DOCUMENT

Recent Accounting Pronouncements

9 Months Ended

Mar. 31, 2012

Recent Accounting Pronouncements

4. Recent Accounting Pronouncements:

XML 25 R19.htm IDEA: XBRL DOCUMENT

Subsequent Events

9 Months Ended

Mar. 31, 2012

Subsequent Events

12. Subsequent Events

On May 7, 2012 the Company announced that Syracuse University’s basketball coach Jim Boeheim joined Cellceutix as an advisor to the Company.

XML 26 R15.htm IDEA: XBRL DOCUMENT

Due To Officer

9 Months Ended

Mar. 31, 2012

Due To Officer

8. Due To Officer

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References+ Details

XML 27 R13.htm IDEA: XBRL DOCUMENT

Fair Value of Financial Assets and Financial Liabilities

9 Months Ended

Mar. 31, 2012

Fair Value of Financial Assets and Financial Liabilities

6. Fair Value of Financial Assets and Financial Liabilities

•	Level 1: consists of financial instruments whose value is based on quoted market prices for identical financial instruments in an active market

•	Level 2: consists of financial instruments that are valued using models or other valuation methodologies. These models use inputs that are observable either directly or indirectly; Level 2 inputs include (i) quoted prices for similar assets or liabilities in active markets, (ii) quoted prices for identical or similar assets or liabilities in markets that are not active, (iii) pricing models whose inputs are observable for substantially the full term of the financial instrument and (iv) pricing models whose inputs are derived principally from or corroborated by observable market data through correlation or other means for substantially the full term of the financial instrument.

•	Level 3: consists of financial instruments whose values are determined using pricing models that utilize significant inputs that are primarily unobservable, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation

The Company did not have any level 3 instruments at March 31, 2012 but had convertible debentures as of June 30, 2011. The convertible debentures were paid in full in January 2012.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6925170&loc=d3e19296-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 159

-Paragraph 17-22, 27, 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13433-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 15C, 15D

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13504-108611

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 15A

-Subparagraph a-d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13537-108611

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 133

-Paragraph 44A, 44B

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6925170&loc=d3e19207-110258

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 3, 10, 14, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 15B

-Subparagraph a, b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 157

-Paragraph 32, 33, 34

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

XML 28 R14.htm IDEA: XBRL DOCUMENT

Related Party Transactions

9 Months Ended

Mar. 31, 2012

Related Party Transactions

7. Related Party Transactions

Office Lease

Clinical Studies

- Definition

The entire disclosure for related party transactions, including the nature of the relationship(s), a description of the transactions, the amount of the transactions, the effects of any change in the method of establishing the terms of the transaction from the previous period, stated interest rate, expiration date, terms and manner of settlement per the agreement with the related party, and amounts due to or from related parties. If the entity and one or more other entities are under common ownership or management control and this control affects the operating results or financial position, disclosure includes the nature of the control relationship even if there are no transactions between the entities. Disclosure may also include the aggregate amount of current and deferred tax expense for each statement of earnings presented where the entity is a member of a group that files a consolidated tax return, the amount of any tax related balances due to or from affiliates as of the date of each statement of financial position presented, the principal provisions of the method by which the consolidated amount of current and deferred tax expense is allocated to the members of the group and the nature and effect of any changes in that method. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 3A

-Section 04

-Paragraph b

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 57

-Paragraph 1-4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 4

-Section 08

-Paragraph k

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

+ Details

XML 29 R16.htm IDEA: XBRL DOCUMENT

Stock Options and Warrants

9 Months Ended

Mar. 31, 2012

Stock Options and Warrants

9. Stock Options and Warrants:

On December 29, 2010, the Company entered into employment agreements with its two executive officers, Leo Ehrlich, the Company’s Chief Executive Officer, and Krishna Menon, Chief Scientific Officer. Both agreements provide for a three year term with each executive receiving an annual base salary for $350,000 per year commencing January 1, 2011, with an annual increase of 10% for each year commencing January 2012. In addition, the Company’s Board awarded stock options exercisable at $0.11 per share pursuant to the Company’s 2010 Equity Incentive Plan to each executive officer as follows: Option Group A, a total of 18 million options with 6 million options vesting on December 29, 2010, 6 million options vesting on June 30, 2011 and 6 million options vesting on January 3, 2012. The Board, at its discretion, may increase the base salary based upon relevant circumstances. The Company recorded $0.0 and $1,093,416 in stock based compensation for the three and nine months ended March 31, 2012 and a cumulative total of $3,292,248 in stock based compensation as of March 31, 2012.

In July 2011 we issued options to purchase 50,000 shares of our common stock to a consultant for services rendered to the Company valued at $28,000.

	Nine Months Ended March 31, 2012	Nine Months Ended March 31, 2011
Expected term (in years)	5 – 10	5 – 10
Expected stock price volatility	142.51% – 148.15%	121.23% – 152.05%
Risk-free interest rate	1.97% – 3.0%	0.88% – 3.75%
Expected dividend yield	0%	0%

Stock Options

The following table summarizes all stock option activity:

	Number of Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (Years)		Aggregate Intrinsic Value
Outstanding at June 30, 2010		3,355,430		$	0.25		1.36		—
Granted		38,442,500			0.11		9.24		—
Exercised		—			—		—		—
Forfeited/expired		(2,755,430	)		0.25		—		—
Outstanding at June 30, 2011		39,042,500		$	0.12		9.15	$	24,003,475
Granted		140,000			0.58		7.00	$	4,300
Exercised		—			—		—		—
Forfeited/expired		—			—		—		—
Outstanding at March 31, 2012		39,182,500		$	0.12		8.64	$	15,819,150
Exercisable at March 31, 2012		39,117,623		$	0.11		8.63	$	15,816,685

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Statement of Position (SOP)

-Number 93-6

-Paragraph 53

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph 64, 65, A240

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 40

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

ZIP 30 0001144204-12-030606-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-12-030606-xbrl.zip M4$L#!!0````(`.M]LD`4N=E1>VL``)OI`P`1`!P`8W1I>"TR,#$R,#,S,2YX M;6Q55`D``TFGMD])I[9/=7@+``$$)0X```0Y`0``Y%U;$G7][:%UHGZ$]&PH_/M$7%Q??OW\_%X,G M)]0#]<#S?C"ZT'1]]K)?$CHO-@TR%" M^N-08'U@6D,3]0VS/^RG[FJ'PHGAB=H`:+W4L(&P;C`=60^(7E)R28W_2X\. MQF^A^_0<:W_I_Q4&PTBX`V7FX`P0]\^UIN=I=W)HI-V)2(0O8G`^?=+K8^AI M,.M^]+&1PBU_/@_"IPMX+KEPI]/62$9>RJO>AO'PZG_)>9V/ES]DQG\G:C2R M;?M"79T-=:.`8L0W$9.,F#\[#$/1Q6]?O]SWG\7(T9<1](%!;SKOX@HSK\CN99SDQ_X_F24/V&#.+R(W\;B`@;I,$J$;G]^W_:;LC?`^GMR MG/'\IJ$3/:H;IA=R:(,K\DE1[CWJ2LY-DI#!TKQ-66I>)!")W<1;W?$MRY'G&%;UQ%&AOX/`U9+[_ZATS-Z"@%#1@]T[\1WDWLB M]<2&-A!]=^1XP,_KFZN&Y@X^-MQ!#Q,&MZ..1;G1Y;K%:%>G]`KI+<,R=&)T MV[S%6UV[S7JXQ^!=!FM\LA'EIF'RGRYVPY#@G8K:9=N)GO=$A21?,JBFFJ3W M\WTG#0-@/(@GT`DQ9-PC?%TU\<;R)J!I"2 MQB>&.2=D`7"5Z"RH^G.--SYQQ#@E*4GG$=/W`D/G,3!-R>L,:<,@&;:S+2RK-J* M8TG7@U5P8^FM1TU_T`:(8`X@+(#QQ0(&5_+2=\'^QB!,[X.,T=PTS\C_!MZ! M`%B#E%UK3N+G('3_#9''H0AV,`JNG-+)UZRQ7Z#KB M17C!6$K=?>P\"7!01#@.W4ATQ-#MNS'(\60T4<+;F80@D.^Z@^SH6?B3J*>_@V)C,QAF$JT0O M2?U$/`1_"-."5YV`]<3OY(#?!'Z_GE@MB16"$'NK#[[`L*27!P-79I8<[QM( MP+7?=L9N['@U`TK!L^.63;"1UM'YI*_UR,%%4"OX.?`&(HRZOT\@L*P;T!R? M;QN$[7KV.HHF-7,HS*TJ-B%Z$[@2HL8B'#VRXNC57^S`!=(ATL44I01O/U$# MQ7H;@N$'':L8\TV$BI%%0NV-1=A;%4/Z3DY1$,)S^?IUDK@.TUH=4S.^8HBS M(-;'IDES]N&-34 MDX%%"08/XS3S]H"S,4M03\@V6#_;YB2-.)_P++CN:.P%;V(V(_7/5!&9/#4H MLJP%T*T@#DYTEZYN&I]L8IK&IB1W8DBD<9>[;IW`\YRP.9( M*;N*XI27]X^W&73HIFY56*W%+N\FS,M[O+*^+3WJ%Y6C*$?( MQY-0%(97)=M_NMA(_UK6'I!]GJ-C!D=KG.:#PW%9Y]K#]K(SM8R@,CV]C+4P MV55`"9D6#IZKRL$ZZNL-S"Y27R?38=167YS^%["0\M<+"\PW(JP8"8F MT?T49'5QT@K,,N,D-`N3E*BRO43U4)Q6J:N0S%JNAM@A3T2O=.Z$)!R;#NW#A@Z^1@]MME>T0SK-+WTQ&WB<'V6,B% M\]R>\?R8>[!HX2G*>O5Z[<'F3E'E>[`(+Z;(.G2*#K#I=H7.]=2HRY4"YHZ8 M51GU;1B+U@B)59_"W&?WK&B@95IU"30QZQ(H!BG>RPLM&FK)L<34KBLE+P\N MHTHWTXQRC=BB8D:>M-0IM[F)K#VVE/:O?WHWHIT.^JH=;%E32FP[G7`MOP3* MJ(7Y7=3WD*2^A]3'_.9.4?7F=U'?0U1]3SI!4,LIJKP$"B]\6[7U>E`)U`%9 M:Z,R#X7//!2JMC!L8K-J/)2M&(M6]XF',H59H8>R`K14#X7//!0)U"2(8W1$ MJ*5Z*'SFH2@+SBBQV#X>2J']+M![;?MN&RVJWP61]2_;S]JM.:ONOX@P=A\] MT1&/<4U!RM2)R0W;3N\CY1%><#./LH%)`>7,)NEZ^]*;>93.+0X*AIL\D^^K MJIE'Z>`@Z$%8'EZJIIE'V7A@91%$##OESN0U\U`JY4[TA?LB3[M$-Z)L5?'> MK>>>/(YE4$3IDD+,I;[TEB6ERZ-L6<(MVTK'J,=L6;(%\,$G67'I+4M6$117 M&''DEB5E2R-;ITWJT;*D=',N6Y8@PDTK'4'7NV5)N=)^0,N2)0?OW=TN2M?` M-@@]M3$B:YW3=5TNBNC*4C8\\%"I@>TL%RMKRU(Z\]2*M9F=LI[':LM2.E8+ M6&E1Q*RMH6*Y;5E*5\-(`B66;:9]HB.T92D=:([W?J2V+.6:D6.U9:G`F2VA M+4OI8J?:LF#+,O@>&V.EM&79"+70\O4:M&4IFZ^J+8L)[TDW*2NQ+4NI.D.V M9:&(UJ8M2^G67;5E,>K4EJ5LR.!X@]=M,\S7ICXJ:0! M#34JF:+J:Q(6E2U,54WB.I5MY$V17?D4+2I;3%7\8QW0W.?PZ*C\L@T\;\MB MFK*>@6/#3'\*H<2RC6T8B]SBQ_.V+#.8E;1E68%85EL6/&_+(O&MN+%5MV51'%W.3E6.M MG'1DS5TRY`,[L]R(^-KO!R/Q)8CVR/DC5'Y7EL5!4H,LM[K(D)WC7B:69%F7-AW%I3_FO8=07N^AG<`5K[*JB9WGK7KVT5_?PJ`OQ""Z M"H.1*NG9-T>`..4'M>+?[9NSLG9WE:%KJ%\/4=8GA^[C!+R1O2N0JD(J]V/9 M&I"K]*_'FMJV?9.UA#5$RN7G,3!C%L^'NPQA/=AOSINJ0;\*0B4(5ZX/^AZ6 M>!.BKI<]:R8JPR^37'2#3.^`*CLE=^)%^/LIZ-VP;BI8HBV[V\1&6^_8V-`I M;EFZU6VV=40ZS#"M=H?;S1Z3S[Y8=H,C=6I@6A!:)8=VI%FV6B(]I!T9+=,8A!&39#Z0NAN>%24\%%&DZF.O1!W7L/RF)*;@>=&,DLU0 MG<6T<)9F-M?U)R#H4XD/_*@EAD$HDG$/SJN(OKH^!+P0:,@C&B`OH!ZR3TD\ MDZ\"`N-!O9<#40WQ3=O".)77J'!.5I@A:^]$1R3_7OO98P3UTZ*R:YV%TE^- MVH9A&^+5.OOZH4:J=MZVT]O-NR`I)MRJ:G&PW,6Q(<"Z$Y%PPOXS"'_J<%;U MLKLC0+"%E!-@:LH6;H2P++K)4D]F8SKD)O"#F:\`,U6I/=R5KTC%S`29."V] MV\'D'.RY=Y]\=^CV'5\=WP+/Z2%T_,CI2RVI;\[(+37D\W M`:;%6BJN.`1C3J[I=BPO?_,IO%Z;;6;J3X43S)UW_FT+ZWKV8JOM6TRI&U: MB59S:,]16M-5G%%U]1-2V:'!XNGDV%KB=W"ITN7^]<.J^C/8-J=HFT.5QI&; M#I*^]F?0SW4,-Z1RQ39.M\]:H7I]VF^VKR/UTWP/LH:\M)9V9K9BV)C"KK?@X7<8MX8NA6SS*`O*9B*XF-&6:3.TI+2_4.GIWF.1^WC@? MP#9]NOY440TE%*OL%T>,;%*MZR$MY3E!1D/'`Q^B.1BYOAO%TN"^',&,[BBY M:H.)@F;_ M]XD;BM8D=$F,Q` M<-5!=C<,*;SWD_'8$S*`=;P[T9\>7.Y/Q7V:BIQE>1X"Z8U\"UU8`N,ZU@7( M>D-D

X*)6.R(*+RO.E: MV+?)Q!+2Q2F!]Y7Q[23+2![SPJK@($EQK,51/LSW'=W;"2:6,(G\FAPF(,]L M*\YB2YLPITG9=)EJ*>ED"TPD?$T,?*3"IJK0J\-[QZUKV@WJP6D`6FA9TZ'\ MV9%DF:!A")NV>6]+T_FJ7BE@+[A"XB!`B_*%K72J: M+"4:U#0MS.C_JTJ7BI:6+'1!F*=K!8]9Z5*50I&5Z*`_Z<8"GY(*7:I:&2QO M991?YE(1/*SVNFV:/BATM"J7?3&_L\B%)D4NB,%_5OV+7`Z?E1V7<[UK7"K2 M:;)/'+,822>'=REQ.;3PHZ+U;LH28(C'3+O"NH^J5+4L^UAQYZNH^JA(-JEL MM(V/6_11E6L!O#1M8N*CE'Q4)+#[5WP<7!1063*@I)J`RHRA+`G0+1-Q5)>: M@*I6GNPI:MH6J5=%0$5+4NX,,].J4SU`17R7Y0#F4J+VN-4`%0%7^ZKI+]IN MKP68MU1P0A^NS%L7M9S([1BH>[8U'-7_2PST\:YD>Z:NQE-4640 M53GR^U5!5+-#7A5VK$[K%KY!_JMPGYY!%)HOH!*?Q,UD]"A")293&3F@A=7: MJ5D5^??&![)D!&&#<(V66G?"#8K]RH[WB).WL%O^T%E&6J'S)TVQ0WP7\T M]!9I7T$X;IIZJ],R]#9JL:[9;E(3=WM(LNL?8',W4K0@^B%TY.*[?QL]!GNI MVPV$HHY%N='E.EC_KD[I%4RP81DZ,;IMWN*MKBTG..FA`[:D_7#]6T)OAI@% MC5T_=N.W._&D7$0_OG%&>_FW!9&*@-3NER_M[L]`L-:^O?N64)U'WH+X)C!@ MH)C@.7LI[<,E`0@>P@H0"9D90I8G]\KU0'E!P/$4A'N48!4VMR"T][!:@0CM M3HREEP@6KAV,QH[_EI[E#)WKEM[_@G8ZPL)3'\)`.&_IS2E:)?GA;5R4,.]( MISST`\_,TBG)6"4N41E=T/,PY=52B9/9U`VB$Y2E-4/5LB2W80!$E=?^0+S^ M71Q#EH%R^5#"F,HHKB5M0?GTHR@+62EVQOY-$JPZH!+^-O4F1EV&I'>/GIJ@XL"2^()J%X`/@M M;Z_:]LT:$@%"S$'QP5\ZM:^Z>LLR;`!ERF9\W19%*-'C/WKQAX'[HD7QFR<^ M-JYN;QXN-62,8^W!'0%O;L1W[2X8.?Y9\L.9=@^Z<]CX\2G^<'HB[Q[/[GWH M_O:@-[]O&+IA%)^>_#X!'0,^'3QSJ"R(]@8F1)*"SQ]@ MV.JK,V^$'T]/7N0V^$!S8LT!$F0[11CV`['DC>=_&D;>BW$L9`Y%R["RGV4E MY>B,(6L^B[-I/3U)#YZS\]=G%YR,^QA8`G&-YO@##330&6?VTA/BX/2DXSQ[ MKJ/=!.'`<_O/L389)\G)Z5F9A'OS<[>@R!]!RX)ZC,ZUOT0"..F#UM00^NN? MAFDWP4O",VO#\DM)-<(LM1Q.3Q9+45M>B?'W[&J4O'.T4?(ZN,^-X?ZH[P(+ M9#Y2-,D.J8BV,05G=-1& MIC@IEBRF^/3D!]M(M-614!]QMK_*1*'&DZG>-M,F.\/82JNMW)EVP.F$(6X\ M+["8;3M$F5E'A)_9>%6T+\!EDO^WZ9L_:SR\PX\,[.(#'UPE0'*/#(Q&;E(3 MW/0'21]-D[NM5I<]WDK,5:S2YI$5JX*UN8 MU\I*=%I!MA<,4>H[PY(=?-4_JE:83^^]B.-D[TQK/H5"_?4G]-&OQ&.86"2: MYR8XOA],_+[TK6/PLYW^L]*:T7SR3D^QIH",=#Y1I>I_0<]Q1(F%NTEG_ M4<3?A?#3;X%GP/5@$DJW?@0N1+M[>Z9]#<^U[@L$4/`/O%<;JP.Z@S`8CX$& MN-T-@:)H+&3@#`Y>ZE6@HQUY#8QA0M%P\33-2;9%M0%WG-1/P*_@R<`EM:C4K(TG8'=D`10],PU\ M1L#X9%W:9^$-M,>W-%7^X"((3T_FOTQE`EAB?_A/>^_:VS:2+`Q_-^#_0`09 M(`$DAS=)U&0W@'S)K,],XCRQ9^=YWR\!)=$V=R12AY3L>'_]4Y?N9E.B9,F6 M*-K2P>),;)/-KNJJZKJ7D>+60)]+`*X1.2!Y.[`5,FK8()*W63H9DJ801X$Q M#`<#U(_[-,03<"D<$/CUW(7()^)3"URZ_=Y*^^@>T#GT`5#2N?&I%#.'X71G M4(+(?^OP>X<'^"*61N#BBL[(_$*T`GID]S5Q5LJ"@\.D$Z!8%^FF-<\UX7IN MSS'6CNQ:JVG73,_5[^_`/I,9NN!R$E[D-0W M@N,.I,HK?WD]0>-/.U+D\;$\**898WIC_B"-]3T%R%6RR)XHJI@[I42!KR7` M9D0A";LYU>_&6$9%$"!Q9Y,95*(-^A7:CEUK-YM'1H&!SHF.V*L`&75;,>== MK3V?2-=V%4\1YC8N8+F5;R`]AGXO@#-!AQ%2!PC$_BY[[Y#ZS%9>+4!ZPV2C MFPBI!L@[P80;>"8$VJPQMX4B[X@(M=+;T95B[TS?B1+O47;PVD.2"C-XY1$EDM MB0O8IN4X^!^G:8O=`J.VW"/C'(S\R0"YRVS7\FK!XUC+[1.6;#GVT3GL(/@) M^@1HYW3-C^GN5%N<4MCPGNKCZR!Y^/,*;4;C%Y0-43!&Y2=0*DT&;8@^M0E* M)?CK_6V`+E#Z:QI*(37TQ^A4'8%T0\%ZZ]\%H-.!0B=-:H#"R7\'MV#$&.W( M5C\RI@]=_-=3Z`3,WM,.?&[YTS>NDWA(>N(WP!&H7N(V[L,?X8B2FG$*\OGW M)$QO(]_X$D1Q1)22G$>33,;Z[5BV0).(P?>?%8#3DN)T0`=_WDXH\_.M\NSWX%!@*#>90&*WS=0*=!.O(QG$\9!/CS"'4-_EG;1R(W\>^S M[U?G)YT_Y"EWX_$X'NJ/]@M49/ZE?$"N]:US>GK^];?Z\<75U<47V/)HS+NO M_W5V_MN_KG#U0?_-TNL)G,CEN@,?S%M8U$CC0=C_:.C4V0M01A=]#C$)2(FP MI@&_0F22?1_HA=@S,3[P'I!X2@3R92`-&4G#F3F+,VOC,'X8)YNBX*6Q.XN] M&50][T-5VSJ)$>^B.(C;/;!+,^UL6N:NV5$"V0 M:YE>K;426:U!*JT9"L]IU1HK$T;1CM84:4V5JM=D9NY M\Y?:S'O-R>*DA(EQ;`3* MK:FEXZ3&?3A&CWA*^;K!SZ`WP4P9Y=ZK&9IN75N0M'!R&P;7QIE:X((7X(A5 MSD*L\;.'!Y=9\J]X^L@XCF$[VO9D_HQ(75')+)1OJ`C/O)4XH>4\"RHN0N4Q)4#[]S[%VSDS1:8>`9A)+TS)18FYT>:1 M93$0E-."644X2$L$5.?X<"E10A3`G4?HF*#D*&QPA^]-X5.0@NZ5S:6$>S)_ M2$N00GPU55Z1_#6V?*64H$+*;1X>+'AARDL,1#6S_N&!_KS`O%/+BCD(L37$ M&Q)\/TSA&/DPAOX#1I#$L2+B=(K!?_N7'3[:= M%_D'T/`-13=I`SL4%SGGY+8XZ8>1SX7H_4F/0H5=,6UF.EW?2"?=_P2],=6H M#/S[%/@.'O*3;C@6O90Y7RS78PHE'Q8$8E<>CFF/83>T!OXCG]T0R`XD@^"& M,A.PV9*/D3Y*U>GO"'U>Q3_#OX%)3^)D%#-J`<\@1:(^!OYO"2.85X9)5P-% MPRRN.#440\`D'_#@XGM*!.B*?#P,!X_@6'Z&0UAA\&"H[$>*YLH`-">3\$E< M!YC%56U2]83M-]\LIN>8SJ-9?OY8V7Q MY@H+/C=.;.^XZ=;/6J>G=??XN%GW&L?PKT;K%&<,6[!8=0L+O)*K84\G`?*O M5`27N%9>JI`ZG22HHN`=0=HBUJ7F@^"FR&N72KM:\Y;1H>S>B(0""GHFG!-@0[X"RNSJ&@/ MC30$FR7(\MVZ@"_`70V$Q1!E(I9K'AD:0E-_&-`"8=S/(3%#1CZQ[ZW']8P2 M13*U'&L,2-XS2O*86PE#AP<$[/%3,'0\BZ'#@^8OQHH8VHW+?W6^PJ/E'.XL M^4^OX&ZW[%K;;!UU2,L+508@Y7X17>#Q9)4=\PD=CV+^(7?19AT-_%[0%Q8M MYZ_AX=6,Q[C/.#G*:,O0R`D,NNDG46W0R4DG$P:D2X4B[5\$96EI=1G1"6U% M+Z4F^3'/WIPJLF"SM6$:RFIE998VD024QJFC5>T@P88SL5Z#P@GK\*LYN$D9 M]X<'A&1.W\-4]G$2^U01-``1V@UNPHA*550.;TVF(,:`BJ,+L&P[HR0<9`Z! M7#;MD$F-A,*CHO)$.RS2^E6R8&Y;$KLJWTIA@]`)$$ M!A#R^#85XF7Z&YI\`5M/R1>M5"YW^]BB>(K24KMTEF/A?2#%GNYH_#G'IS&\ M6#-MNV8WW<>5_CE:;AFCKQ6V[2?/]KJ-S#,<$S`1?3$D4VEF#K8 MI[ON.FVOK8%L0U)UI0$EJP'\Q)[LU@_'H6GE M3=VZ6Q:<]4TO*^5T<9BKU6SJW>=?Y/2RTZZN,\$NQ9D@ MNJ3Y@\.#RS&HBLOF[;]4%4>ZHD=AI&I!(O^&X*Y1D8S?QX\IQ@72%-&1P0.I MD4#QP'P8,)LDI.3H+T2@4Z:I#)CYQK4?8NZ!0"Q^[IW_GBMFN#*;\OMCQ6&R M#$T$[4A]4?J3*%`'):M(C^(^3Z1HO^N^%^VZQ.$:JOC%%RK>X4'NO7>]]VS+ M7V.H:CV[R`K8L.1[@]6N6ZSVF$3^!#13K*!3N%;'S3[HB$PJ"C-R/35IT.1P M&89C_*G[8'Q&UPE*MB,#Q2`&2F[0S.K!YA<8<>[7/3PH*\T5'1L(UD. ML-]`;S#IZSW;"C8VPM&*24`58*C7PQ?))\Z&=":(A06$!5`W/-<#O@!_Q[9E M64^!/R-"`0D0(NC.$/#4\S42B!E6-EKQ`Z3:D]?^$SH@Q_BBO"OZ MSR3JJ2@$\U-AT%;@]7=%T7J_NKRS@W/]"X7NU8KL>GB0XQ3Q(:3(:_B])$J1 M@$2Y(5G]AJK*YU(-?('-WH2,?25A0CKJ/M5+WHGJ_#@E0P=0A699;XSG*W>( M\>J$O3P[8LU>:;WQ,((48!\#BF*AF$\GW33XWPE*96SWA+D*IH[(Y);=V#1-!TP?BRO[IQB M8/%S"X%Q/M<[UMF)^]GQ.LYIN[JV@%6.,9#]*SN.PP,^D#)L@L%3VI8\]ZM3 M>0:DK5!;3?)"4G]:/6KU-1Z'G-:`1F_$"2J7L(8>H3(LSZTYK8;65&F.BJ*: M3IZ0MQ^M,"1Z48@.M\MGTOL"#+T`5QWE^_/2_J14YAKX08`WW+M+4$+ M&SV+)$$1GD(5!&FB&X+>"F#TJ*C]?R?Q.'OFXNK$.)X,@,I!\>"<3_B+`+HA M;%"*]IA';E./EE'74I7:^$A[V,.#N>VS'^W92STQ\HAZO"'V+)XXU1$MHD7ZA@O0[8O0)+O>*N#R7V>^3 MF=-+PA'3N\R>9XL9EPSX6L[B]:"Z7P>8&2KY6&6X@W(;D!N(>T(!:R3L`,2% M8>4;84:^M9"3J>XR;<.7?SHQ9'R.Z8-W$!7/(O^!DW<06V8XJ6'.CQAP?O M9%[E>^644+PIVN0,;ESK>.AG>1+807Q1A!';@ M8$!>S\\"@(Y(/T#*]/^&_6'V!IJ8"3;\"1,<[-#W'X"*K[$[C^AFJ,0=V>(2 MJ[*;)@$Z"%*0MRBK\CZ3=^%[XRV7;!OPWKL0?A[?PY:P7]4=R#*[\8OQGD1@ M+U#+P2:HI6>^[R'?#'?Q8(()Q8F/'IU^%N4>80$%06G;V`^1)IX9"`W+.X7[ MC(C$N#P4_M-9(;/)'QF8N"&/6R`57P:R3:;T74 M"J5649V=KD,X#=`=WUF-]P10MF`V)0`4.Q6A'SS4F-,74K>J_M#[M\J+&*L& M$`?Z$`*%P5&>#3%9F4Y3E9%(O`%)2@ZX]Q.>P@BO@#3M!IJ&C4`*FL9L$,XK M$"_`12Y?F"HBX?9N:H,"]:KM6]:25G:5.LK39HXH%DJ9?DP^EQ%>*V"88G>V M?M:H3^M]2SU5!P^2)&=)3K(X<;B^T?Q5KI!%S5A5'KXQ"F]N'O!6HJ:O-R+K M'NL[L'QM03U'Y6_MQ?0J.KI%;NV:C>NB`KE'4)PIVD`19S$&T)9Z;$*=QA%:]QM M4A:5KUXR0J,H&2&WY^GQ#`OFU%8.//O-)[?EM6V_'.S+-3K\KQH0V&AXY!`[Y) ML+4NJE,J#>45YXAI+K5<42S/4!D\&']'8D#%&1!??,E6*$9G:E3EI'9.`:.9 MH,_I1T,X:/3'LD'CN5(G=,10&H'8"/MC1`=Y+KEHR!@\Y=^@"ODUN//[OO3C M@`V1W/@S&(5LZ4R689E-Z`0C^B$=!\/=<4&JTI)F48]_U74](S2>CB")R*?P MQQW72P.IP:.GP0![6^!]IB@RU[?"UWQQ7+Y#G2G0<4+6R9ELQ#U3AR?_DB^Q MT]E`WQUY!G/TF(URP3I]:'T=T.P-,3DQ7>2L>%6T M^&VJLTG.WR`/OI@ZYQ)`.-75?=K)[2DS_/`@"NX'*KSV:#`\S3FD:CB8BIVP M%$;"BUPSMV?H6#C#2*O(TS).?5%CJZ1-GT$_!\YNT/-QIH!Q?QL/!@]U8D20 M96!TA_T0Q"U?\4?IS?$Z$(:_X7%N%C,AYT5@%%J M-#]#]%P)4\:['JS4D)'-4A".BNNY9YMS",I96ND$7IUY@9PKN8U*MRCUW)BB M,41.6#".2LPE4Y!>ST.(#E!-.(BS(X2SH0LLUVG":_]2Y%K+D>&\QDS:UZ92 M7B#(=`#7D3PY3"_VK]/HH_AH): M1"AN"$B2(,F1\:>8)9Q.AB)YN4CT:(7$_7@DG8.R,PSJ%-$"PO@KX('2\)!^ M+_0SSPJVL@KC@HMBFFD/#S#!)8J-'LA?,#NQDQ<0%/:J25%G2^1@4)R`X8_% M9)FA_V!$>%9XB+?8;R1[$%Z"!:[%3-,L<7A'KA]]+B]-030]#-<,_?]0V9"D MAKRPRY$XX!1Y^DXD'&'5\##([K,BK9D&+B1PR@,QK2[35L@['4LVI>I4/Y-5 MV6+X4$9N2)_J?4'469(P=SPX#:XI7@F'KQE)AJJI82X+0!&A6F4Q]RS;@MA2 MK,^-E`C+LP@.R3CC!.2,U0Y"WWZ-9X$.5L@M87,@93X[R14=AUT*#3$-Z>`(:04*N@0+Q M.F<;G4RXXIIYV:I6%/ERQU.Y##,-,`K3ZDCCM7ZUA+(+%W-\'RBJYX7S7,)Q M>H0/AUMAD.V.RH>D[DN1?*YO*'J?\@.5Z/4*6E9@/0;/...B(O>D6-)G7*=% M8L@@5UHCM11+.6^"U&+VDTB+0]T2,J1HB0Z.-7$;*@U7)+.\LTV1FC$331SZ MZI*B`WWLGF)]J/@IK414C*XEA&3YE[+1I+B;IJYU#$>C'BV"U0K9S!,6J-E8 MEL/*N4S(I"=5+#S%V:X$&N_.%WD6DQ_'\IL\EE7-*XG(SP9X)GDYPH'RA7^&6CJR?C`>KQ3'XT^XF^C+1%+?^RC:3BL\I)"<>.V^W!`JBS M8UX5&%%I;J*@%$V6;7_43?F\R(I`(F;.(Y$-_(^6C(Z:D_ ME65DY3WG4=9P2#462N6S?4Y;\QRGYCCN,@ZGPMN'O0MBQ#&E>CAB11JG'AE? M@9RX=5#Q%@S/(=2(2^>)6S"R'1P>T!80TV(+2J=HS=V"6[.:37UL][.VP$AH M-IM@[FOIT*LA?" MG','3ZR!:Q7M\:GC8-9O_F1`2G1+=IH&&_OHP+,K-Q#<&,44!G?+OFFF:%:C3-:IT17! M[6%$=V$X$%ST-)G<'!Z\._]Z^G[N2.&\`H`SC/FR!VD3UOE*-_JP3DVT"<13 M^_/H$CVS,5M,^!6CHS62AB^\^WS:>4^)C=J`7=+`MOZ$0BOP,.Z4FRP7UOAA84@HZWU8_S&$^D,Q74P)#@;A#1E2 M:#A,.)S[VY=O0-'Q0&1'P$;4ZD8(PUQ(-4_P`,GQ(/XVY'SU:9#W.,:4/ MY@W?Q+X$@R"A2[;/ MJ:L#](>S"%/"562*8\%#*J=%7$_PV(QO=&N?GT^!_T+NW_7.U;9XD.K"<@:- M-K-NZ;X\'0H(*\KN M^!+TZ3280C]DI6.<_YVFH$6!)!@#A72&P-5(I\JNDS;;;3B"&QF91'WES?L: M5W3(79+S@8TDD*>^&!(B%@*>ED4!H1+;@2:21W&*7GC4"2?#F"(CU#L0D\`' MG/\=&TF8_FV@G$#"NR&6/]><,)P^GQ=9F/F(A3<8!Q6^#IP50$AF0S)Z M@@-'@)@3$FU9C@O?VJ,82[=#+D:5N\X7:.P,H>O35E:B<^$.(Q%&JN+T!?VE M;H'%0!>=LKQ1.&.8T1BEJ#>FH?"-93U'!@]R9>IKBRG^+)E&25!'^3X,`@J@ MJML<)3VW>Y%_$G=-OI!\&/9E_HDL,=VYP\YNZE6..H\KM?M\/66NAI+.YCB` M_W>>)CYH8Z=@WL44]5X;_!S-(A#5NNB26^`Q69`N1^( ML,!*O8VC/BD(L'H=Y-]HC(TB#@^N9:KPB_VK4/PJX;1BP(\6H*9:DPJ-?C M\&_X4QJ$T6W8!;I!A'(\E6Y(O$5S!&2HBQ/M"\RI',0]/T]0.`(JHT`NO^I2 M=[!)C[-B<#$XGB.C(_^)(C*(;DG9I#22+Z=?;"/;%>7]L$K^7\I6:3B41J7U ML&->$*W>L/.$%H%&FA*ZM-(^WG4Z)]_?9S):A`UJF2(]0L:^C9,'5!%2VE$> M-ZEN*OP7?D0$X.Z'<11/NB'&N23FB\#_1I6KNO80&'1Z.&,H\T/?T@P;IO,; M4LYE"[`>.=F(91B0W#'Z#3D>LC=0845Q&H M"'45&/WWV6^?O^?.01C:18*/U1,E'P4_DZ8*;)G$0OG,##/1\BTC.R;0P$^Y M6KSGIR.?TKJ(IF5'QV^=[]\,O%;N_)M`+'\79^NJ7G((/C!8GL"03S/:26\HLN_;S,G;KU#77I@Q15)%I(F.QZT2X&708C6:*R+#WP M8VJEA,X$O';'G$-*VO30'X0WE&18,%=OMG!TMHQFNL12^/W37+T=]@ZO7$&5 M;;[YA*.AVKD*R[G[SP-*8=!.U/_.5FE5BTB;V&+/LKV6!F/QUO/@J=;]5:[_ M-;'\;WH(6<'.E^B52/U%OOD/Y/BJ&J$2H!8LV'0>Z92H@Y&'NI/UFKZ*LY8; MW_RP?QZ=<,(NU7L<8\,HC/4!41"':S6&Z?>`,XH#$?KGNKOOW-23Y%:)5:(K MUPZW@!E@,ZZKD4M)>"D:(7#E_Q2\=QQ$P76X=@GY,PU_C<+!/]^,DTGP1!YS MWQ@?\IO_[(<)55IF8T[6WG33`'_T@]]T79$*O=HG5RKHF>]*Z`DC6:P!\GJ58> MB:&;>(*SD:EE-*4V!KW;*$1_I/%.%#N20>%CU"XD2:!^0:>'\V1%OA[\ZCW[ MET041J2#9$"@.Z4?R/2-;C"([W^=QC/7$`A<_W5^>O4O1*/YRT=#3)L_N?CC MC\ZWR[-?V8T_2H,5L$UF#U@F:#+3%8<_C[`?(/^L[2.1F_CWV?>K\Y/.'_+0 MQ_%(?ZYP7+TB#`&!>60WPDCOJ&.;MCT[JW[A:O3Z'XA;P_I5EA(2FJ^S^1:A M&G&##:TQXL4-OD*-,D0NLZQF32@OCO(-*!6`?(-9-8^^(AIC$1MU@7A_!H8/ MXV3-:"SJ1+0:UA:\O-GM/N^8[:6.6;DJ17?-"85"R5"FVARVOA23H[S`"JEX M$-^$HG_.FC(?8MEY#6 M//:H$U3'Y,8=E])P&&(/.E$="[\9:#W`PRE*`RZFYG:\D&B>*AKQ*;I=9E6Q MG.;DQ3P#_A9]`SZ"BVMH9%824%$EEH84`F72)<=P2,,CJ'!F0NX_")(SP;`@PS;4"##99T\U^J(!J5K[ MCKG'^X%TC5U0+5$2IJGF8--(0$ROU^)<3!.J.D8[!DW1S,:Q*M3+,E&?'?GT M.=VU+>P><1G]D(Y3Q";A%TPG3EZX3$\/ M/CSH3KCN2"_ZZP==>)QFEO$1Y;>?-)]MMZV&0^?N?&G&K,('ADLPW*D(+)S'H M7)GW])L(K:S;6]ALG]C6YT:G?GQJ>@#G2;O>/O4`XH;7:'JGIR?']DOS%K;7 MWI=-5,1DO65!H(G:<U..,[>ITBZD)6GC9X]CSG<_"PBVOCE$SO.&LIH?5W M$`73K$'0JSI>N3Z:,V3IC_CS&^'"H[_Q\$91U'A#2\)'LO[#6=E7-\8D.%5Y MG3L^^,3YY47ZYGV-VQQ3"CM<1I07?_T@6KBDHD;/M>VLCJS/S4<.#[[&4?W_ MT/,AC6#4EM^1BZJR!?;O]'I&IB5X%O\TU9[J3]FJ9^%R\/<,Q3R.()J(8B2] MRB]7.H?I6ES5A3N_\\$"E7X9V6A:ZQ2$W]%:WKN-*8(^DD,+IBOTII?(@<[O MY-L:HC4DM%!TGU./K8!=9F1OU0B47'L"[#0WU4DLH?0'N+@>U`:O1)D7S-$RX&:=(9%<]B88($520R0\31X$!8* MGRDP=IV&$_`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`HZD6S;CIXHT4WK=%IB(:3X+B/7?J?J']%\PRRYL/N'/U:O8U M?6HGAXGRSMO'F)C2`V8G,%E:OZ#'/&8[2\A+E$AJ`AG0K%\0P7`TB+F3CQ(T MHBB-W%CW6.L@^KM@$RA4U+'MGC8);%%/R'R#&*GI"P_5[TF8WD:^\26(4(.= M9Q<<&$'6+S,\3#%T_@4I(`6UW4\&,3WZ:]& MQA1`J'R%4J-/HU/3-5O+,X;A8$"Q7"E[$)5-^>M,)MUQQX]<6RM)]K7L!6/V M^<.#?#0/Y=:BY]6A.&(^W](.^BOI6B8;#)D&TSZ2@,]SB,,9%64@\I'J#$%T M'%2G?EIP[P=WU`BK%R:]R1#=C?,4,#T"QZT342$PC[@'&,Z2;3LUUVKBEP6I M\)=Z6@QGCKJ04^>G+1B^N,`@8QOY+LA.]:U3L]LT>-#(?Y1;PJBO%D5?=[3F M_G\F@P>FSGLU=K1(*6E,:R3Q))EJGEJ@;Q1H%'GVYTP383G:'EO$.X'[JWQV MB/27"+5?\L4"XY9%!'$#GQ^Z+#B%*DN2R2M.L.@--[K+F16<>J8,%D,:+&RI MD']Y0GD30!Y#*>ZC6&NOS>*75J&$BJHO(2N^1MJ22TIOF+V^P@TCBC_[Y MAO];C(C'$QFG5K9_$=-D_SH[_^U?@(1N/.@7?FNI+PD<'U]<75U\$QAV&Y M*+!<^PA3&_*(<+TCJ_%+R3NQK2/;F=Y)PSXR"W:R8>[X'J9_UZ_1YE&CPC$4 M5S)"CMJM*70X1V;)IV(>>=[,)EK/.9&G<`K%(#!N^1`&@W[)&"@;XX_@=FY] M1:DQJ[5=E[FLLR7N[A(,RN=]XHI'T^4L+H.&F"5!P/Y]5L+2;_;YW3T_.OORFU$Q3.]:FL!;R%.`)PHW^^L>D[7RG_38M/7!-- M)L8'X4?72'(#$&P;_+\";%3$ZG(&=.\P/@/,*.5FG8R_^:RBK6 M"\T:E<0"039H?[$16ARLEJE MS:LX-0>PXCK+FF9/WLD&,/#V.8!CM=OG%I2L.V^#DB>R*_;51_P MWU*QKA3';@B;>XCV$%68AY>_:!\S2#['R74`B_4_!#]'85+(W*6;:`I7,PZP MYZ^='>+AP3N[UGJ"N3`/#QNSC:N(NY4-CI?A'2@+?4_6VO=HW!8:-Z]A+?#& M%*GQVS.3VC6SZX"D=52I,UF=+=V:LU8(]DZ*O0&\A^AE0[1W4KQ>$V>/QCT: M]VA\96@L)[%DWL:F?!KY.LE=.G*G7;.\59TF+XYO%MD83W7$XVS#A M>4?-54+G+PY]FR`YJU'S+QL:9=0OJ]%F^N<)NBV2K56O:SIX_5A;)JR06 MO3B<;5XD[TGN*2*Y66MZ&P\[[^B`&+T!RTU$K8BQ#8I5LUJ-FNLV1&NVFNM9 M>#'B'_5&*-C``R<6:?W>9,D0]OC)VG'V>3IX84>*POXLW)THUU[1H@"D!3_F MFKXL;`V7=;?@#HVTA.DVU1+SA^M8\\N8WL%-? MHAWP9/@023O2^MS23@\/1-_PV;]]S'7,U-O(,P&E//=(-MI4WX3/36/$.:K4 ML564FO"S"UOFG69"5XA(H+X+8/8N=J^3_9YYRD;6F8S;PFFGHUHXD2-CZ;Z2 M)]CAW.@4])<4],RMN<,(^Y=A9TF]P1M*-_5=FCU1^.G")G"PGZ)/, M$0]1=NP2@JUF-.LZ@:=2FYWZID4D*0^EM/!GT69J/0/(C(X(@/#R0 MPR?AMO@VU;M.S#0Q.JHO.;S?\R?<74U<*J)C].#!B(`C5>?I1,SYX(;_8Q#J MU/BPAQV1Y7$SDD!:7.=Q0(,,!@_B,0V*VC14U,LRVT$ZZ?Z'9KM1BRX_O1T$ M:9H)FGO->'IS\)%G'V/AM0L]).+/Y!$8_@'L5]!I8F4:? ML'2;$KO]6\='A#[@X9$.P%=L3OVPTB?9F+H>D>N MXR`?-I'TS-9J!1!U<7SM(+R12D\:C,=4YHY#,PII&&]3F@<'O'5+E`KB"8@: MQ16UD\[ZQN=I\?,DP1=J*#L,)3JR08F$\_M`=#ED8AC%XX#&K(J-\8Q&WC#I MSV.F!I8I^'GJQ*8ZK2GFU%JVY<14QA,Z-:J&GX`F'E!X>-`-<$W5@E'JH?$D MT<0+-NP#P_C>##`6:S-LE\TH^1M$AJPPH'.J^S>$ZGR,B)1D_/Z+E1 M@:!]:QV)(U<:Z^'!C(9C3"LX[A*#])XY-2X_@FYZ0-UY=$8MBX-`+/>'-JAZ M8\/WID?2+3EZS[+??&JTG$:SF6%G%8#RJ!!__^8GXX M,SVWV096K[OMME5W.Y_->L=LM^JMT]-CV_.<4]-MKWWRWMJZS[36/F1O\;^^ MR_D4=$*&?D3$*+2IN=;/2_6%*71SNV[C#R3J)>!]50[!T^1(MC&?VV!;S:#7 MM38P<$#/P?Y7.&")I*WP*L&%-TACZN++$XYH8>J1?L'J!,AW.3J)'!SR313O MOZ./2NNEGAN&]7OG^ZE^3;[':SP3\RWJ;VNV\H,\NL&-CVVJ(^Z8S8>-+88" MOL)PT1IJ]SZ;S*3T\@BBKI^&/+H<]`9MTA$I+`L&\5*;7?B#&(B4\K2D9LT3 M-]=;QZNUX-_P(?RZ,)'9L\=#K*?G#^=]D4?&HXZ`S[&8O[>@2W;>%IZ-#R[\ M0,[+FKE5&0.=:"9,O<39T?I>JIO/^OS,A)X,?V]M1&X-=)F:1?_E MGT%EI%_P"8C3`%-$S%\NFFVAL(^3E33TYW:^&X)"2.SQ`(F+U>90$]9[$I9P'%X$H2U,Y MUD%?D29,!2/RT>"LPZ^G:*<,0YHX)5TJG]F*54.N8UPRFW*-3H\!F)-HM9#F M?9/-5:*M@EP;#(S[./D;N1E'RK&Y0&`,`8.\$EP(:,8HNUUX@6;G;4RY[%0( M)>ODG@1CFDKFT^3K<3`8!-2A"@TFV,(8PU1RMI,:+:D:Q'=A!=[WLO*P>&@` MSA99ISQDHW"A0#26DH>'!T\4B+`Z^@I`T+5KH`BC\,LM3[]=8LVW+;=5L_%* MQ5B<8]>\9DM,0<&I4*95LRPR%G$L*R&,!A_B,/5X1,2E!D0)'L@H:J%4G;UA M9R?=YR@I=P5H4SO>XFBD1JUA-61(L>69]&.(70Y[\80,4#F[$*]D5$%F=[;0 M=%S!Q,G;1K_Q[=.)^IW//):GFMEC:4_1$0\O!^#<8TQ%T,=#Q^^!-,Z?/H,X^8 MBFXZW'>RBD:QC48Q?-^T,MB7!R>/A@X'C,F]<'&M'B<70^4`AS-O6'9#._)% MV\\#>N8GZ%A*OP6)=)V$/2"5TW`P&5.\?(VP_@"1^X-]MCK8]M-(W6J^^50W MCTPW@_L1:!AT./*?OY[$T1W<@(0?.<[^*N:9PMQ=MFJG[,`Q>XU6PS3_\6$Y M$#1P97M*T9"2VY@2=@1J>&3V16X<^7/AGSWI)PHUJP6@MYMNVS$]`?SJ`,T< M_ABC+Y=!!,K2:="%NQ!N@0WZO)K'QQVO=>8"K`"P^]EMU8_;SG']Y-3ZW/"\ M$^NL<[9VG]=F;8TY`_C6_2_MN`X/LJ/:FF4CP9\R<;:P%3&OM47*JS>E8G)( M7T.>D>&.9HJU?P&]BIP\T618,\30.U+,_"'J7>P7X6#`$08B,E<3QXN$7U)Z M0U3?>W*8]">![N+'R>#X5@I62,):YOQ,!9S$+D,JV:[9!X"I+.*#^/,DPD&G M%$_6/M[3P*9(\USW63[>*X=H3\]SQR@@?(-SYX@MDWNG!CX9Y=*Z%K@KF MZ,H1U`3,,!M''2?A34BY8H5GI@\J[,IE9':!?-<8^O!L.`:%FPR9@DP>,4B\ M:/MC_8C9:X@[9@QKIXN#QWE(-0V]-@%H+87#N-+U?K8W)`PR`8%V4O(R?@V["T353BT]F@W+GHOTQ9!\>/(YM8QZR MK2/J[/XHLHVN/Z`XK!P#SJDQC%>1RYB7Y<@8SR4/ M9OO-S'XTT]"+$2@8<&VX\7#QRDP-V[@W]AL8EQ.?83XX\_3GB@HT9+B&C;MFNMMJ76R(X('Y@D0+JA&$:I*7?] MO$Q]:V&.8X,'GTH:^:C<05-`@#Y3:S7:4T`@J9SZMX/0-[[&21\GN(X+=VP! M;IQV:Y8':$+GLCMNUES/-O3]'AEG/KIDQ+I?@213EE7,!9P)(3XIR'163QZ!N,0KDXUN,%AIUFG;<6J4I\&2K&P^JXX* MI,M$NJ;B:S[_+&FB6,)+:87A'$K6SE0>J]FB2,1H,$GS(M-R:Y[=+)[K.M<) M]02;0S-6`/P.N\$`EF])',$_>T$^M6%-)HK7;)Q8EG=6=T\_8VS^N%'W3IKP MHVD?GSEG=KO1-JL;EG_-;I?*/GSC]_OQ2F MAO85D?%*>6MPG>&!3U+6JOH!YI]U*7\4I$XLY?3X%_%H[!G>+8Y@UGYI0E_R>?Z M!D0GK4NQMU@/IM/[?5'%1-^#MV\F89_E-X&&R;A9'0\'U%`]!]K%$>IP/^#% M*2;;LC^4XGHBF3+=#3V5AD-3N*N(?Q5*.2L[&(1#P-18%#,Q_BG[@C-@C9BB MF:@<)L$M5I-0PC+\S`&\D%SE0]``LV-']4I/8!49KVJTM[!C=+M;Y"P*CX/( MW\6B)LP8&[JO!DYOC$(BH#YAQV>78:[\X> MWI2ZNXS6JBFYO\44GH)'DFAS+OB6;=F-9LNMMS\WO;I[UG#JG8[5JG_V6C:L M8+?,TV9U]5MG@_HMX9\@;(I,T9I/P M;OT^RH+>9$@^"(`2;S_@ME2:M\VV5[/M)GE)*=6(H/%'(5ZK_0!KD81;ME4S M&V`G>PZZ59;?)IO+N7T6$C8GY6@TO`W*-S2^8U(HV.`-RK->32[*- M;HZ,RY#=&()TIOS>"#4_'+!*YF<9',KU!K>&PL8D%<5MK':ERO=40Q_<.%\R M-(C]*!6E)I',*R.5S'\0WD34H:;*E+(LJ+$LW5/PT`O7$W2,'![HB4K:OJ5V M.4V>41#`:@,?CE=`Q-RJM@SG13!(/2_U!_3+`ECQYAJ(VC2JEJ*[^GJ"^U4> MONZ#!AM9,EJY'F`!'S\\F-ZF;BH10C!>A85M`9:5HJ!):+>R,#`[3!(W72J9 MPT3$Z\F`8E%D#"O<*4S>Q/X@I8@6%H3$6./W0$Y;K-G!>KX@&;+R@(L,!B^N M(\`Z+H,`F#,>@JG:C^_1'1<1<8C"T#`"<2`8$1EIZ/?9)=#%JC^J0^T-J-3/ M&,:)&LC.O$&_P4X/F*%6`.NYJ,1DQ4TQ'+[:@QL'Q"SO`H4&JFXQR8!KKFQ$ M@Z(?LU$_I+I^+"Q%+>\!7OL[T%)5B>+A<;%^1A^TP7Z(!`N&?HU^YO8A@X<, M@C[F4\!-40C#9Q_^R@8\QW4-\D=H>;(97Z.)A)PTP!U&D2@"0][W[P`VRNY# MBN1JT5F+PN]C%"$01M!"_?4FB>^Q4H"<\L'-0TV[YD7FK!)A'&SAD`#AGK1F MP:,L/_K!P"=A'P$Y`;(Q3S*71$GOR63A<4*Z\F@`HK$0:2=252^^GXC(.':: MR7LM'Y@K'L1I8LP>?5!<'OLP8MF=W0Z[86-=YLQ#.4EI^X>6^VZAREGYG'CM'EL>YT3Y^R':X'U\0/^GVEZ M]E1VX2I@Y;#!>>:8=)D)2(&VK\'XXOHWKH^NVJF[;SZY+:]MMA7\RP&23Z>E MO,MS\N%PJY=O9/91<`-$&/WER;#_<%VGT39_PCY=N_G#Q5SGQD_7=1L>@(FI MS\V?\!_/=#9%+S9N#&C$;+;??++,+/%V*;B70A7G;6X'5[,)J^=?/S\=4:Y" M%/[?H\B:@GS[A-5PFFVO-,)R?C0%OIQ6N[T1VMH0MLK!CQ#4A"!O&7I:A""6 MV^?"+CZE(,]&T/$L6%O6FT\<,O;JME;>4+#[;9U_:QMBV)%BN`6WMN6\%#&\ M+*[6)X8=*88)47;C!8GAUC;$L"/%,.*K8=E.\X6(X59I^)&BB1'DMBLIAF?0 M\3Q872&&21)74@Q[VQ##KA+##4302Q'#R^)J?6+856*8$/62M&%O&V+856(8 M:_[:;>^E:,/EX4>*)D!0>REZVH88GD''\V!MD1BV20Q;E13#[7FBQ;1<>U/4 MT%!BV`,$;41CV8087A97ZQ/##26&"5$-V_9>BAANSQ/#&R8L(88]-+-:7MM] M(7*X71J"I&QB#+6?J05M2A#/X.-9P'JF$,0F/..L((BO$LK??B#,?`_&.$,3 M(PM?@O%MW.]P`.C7=\P.3,,Q8)Y:\EMW<(/CNCQ:"[\)MZ#B.Z;8T MRLI!HG>,0XM^,!!XX6OR&8`Z=J/U9-UGJ7Z!E(#DN)K:,Q>.M9RETZ1OMLVF M8VXL7]'*8I*.B&E<%5>5-A246%$5ZO1?CQX4V(P MXA%DE8,>*><0/\UMQH17P<;S0&T2Y[3K9K-N;3$FO`#@;61(6BHF;(/]4*T$ MR36@:GTB6(6$$4_5RX]<"EUG8E@QUQ"!!<88M^2X"Z,)^G@@3&D-7'GOFA/!KM\T=M4HM?B&J$G MP/L41*UJE#\)4X^WM%\!221WS:P^Z"GPOB@CMR3OH:72V+=N\6Z#UTN\#YL* MT<3K+M5M/9G?U^J"*L6=B)3&[L2E_5'E4D0Y-"!O0B*"QA-DV;30Y[M3?QWO MSW7AX7E`VG3=>_#).A[U@OVND:KATYMTK-I9(;AKHU_<=1Q7U]Y>GF-U>8P] M\9;1<.9@F-1S[+;U&AVK$I-;=ZS:JOSGHI(EFWX"VUEB"*V4#5^(8*E''^AK87SUX&?3A`0NO9C:5E%SQ%/K M)2EWVZBEME74'-'E.*UGYF>6BZUR\",%$R.HHD)X#;74&JRN)85P<[5:ZHI[ M.TKRL-LJB[0RKH^UN-=*<1K;*@=U95_;\X"T-NI#!`U']2@#;:[>:#N>K4?( ME_,A?N>ALE?QE?_SKW!\BQ-A0/!\CI-BDMD<%I[(&QH>&GB^;6".9K.0.U:% M]66(HA(1[.*593;-YM;$3V'F?'4YLX&EZT[+;'MSDOYS4(TF2>\6D(3%/,\+ M294(H8-E#2![,@CG@U%:2*X\^%U/:7'/#L1N1MFU*A).<%3YN>N^^=2HHL7Y M'%2MS>)T5,4QX:FB>=J/X*H\B]-1NC&BRVZY[8V0UH:P50Y^I*PB!%4@37`Y M=#P/UJ:T.-<33MC`^6\C4]M1,=T&$(-52;_?%1U_\[!5#GZDRHP(:B]SK6]##*\A^J+#VI0MQ9VM-E%< M`/`VHB^.:BG>:+WYM)&RADU(X=*C+XZ*?Q.>7I(NO(WHBZ,"X(@NRVFW-U*+ MM2%LE8,?*9@006Y5A?`:HB\ZK&TIA.VM-A1?`/#<[JR;I`85`F]BGM5+$<++ MHFI]0EB%P`E/]@L2PG/[V&Z8K$0S'4!7NV4];V9!N<@J!STR;D7XV68/VU6P M\3Q0Y4P'LU&W5W%'K+@15R^;=4DMGSRU/+D1T;["B*>.&. MHB@[ZK)PMYH"9%,=11D)GD3"DR3()F++)5/`4P/- M>QRD+8B`33901#P(;1JHO]UN/Z^E\!8RGTK*$#`)$_A&GRVVWD,`/_)G-R$7[.R7U.[NI=AN-L\T(1 MBYX`EI*P.QFO9B*52V$NL].(#>GI/Z72B0Z8(&;4@OZ*H^LM+, MIG*@QV:^+\!N*@49:#74UVPX;=)B*`YY/:DON&-VXMNVY3>UNFMYS'J)O27P=I"EI>Y^#ZD$$(K9I659# MHZCI+>C("&%-3T.KN,DX.>N_)]!^B6,X@2)%"`' MXVH,R,JOPC3,J2KGT5T@-.6JX2$92#)P_Z'WXT3P)'(O*KH^8*.U80K6[]GBS>> M!^Y"@EUAOC2)+Z?NL(*-%TE]$%X"[N,@"J[#=5/I&G0*RYU1*GZ#O2;^`,ZN MTQ^&49B.$=:[H**TU\`T,*>EGQ$//(U"!_!!C-W/LK"&]NX5>=.T#53?!U,NP&"3TN MGF7'[L5DG([]"),\GX^)QX,=RT(.NKW7;EFNVVP+PVYU>#1DD(NVZKHTC7VT M9;)?X99S29T+KE>X92ZN?\.!\96#TLTTA97@>+8-9VESWSRFI:>/+_8A/O-#R.\$2^BI]DFI4!%,8>IKA"%&U^;>5H*6&">6HVV MH\>H7J)Y6@X)H'GJF%[3:KU@Z[0<5#4*4%6"<5H*<#AYJ=DV7:<*QNEJ$#_1 M.+6$<6J[^KC-+1BGI9PO!@`LIZTW8=N\<5H.6Z)Q.GTYEV";EJ0K;=0V+>6` M&G0=M_0LHRT9IX^#NT[CU"+C%&Q3LW*VZ1Q$K,DVM<@V;5MVH]E41;=;M4U+ MH7/NB-5J;<\X+05,-],4GF"<"F#HRRL`0R_#Z["R#$?3SV$??W,=!HF1]FZ# M8?#/-[?C\>C7#Q_N[^^/TJ!W=!/??3@Y_QT8$3/7&@T;S8+L-;GPA]S*_QA1 MQ#?[#M!D,J:R!-Q4W;2H&V/V6_5@`%C('G-HYJ[\G?R4MCC@D!&R*G9R?HA* M8<=:#CO6!K&S,*"^:60A/H(;Y(%/__C930;]\-?@YV@0]L+QEP"%GM$/X:]H MB_[S399R`"C`=RY[0>0#`CH_P_3-)W5?QG$?Q8A(X5,IR_W/<2)B^1'G+ M1TPR5!.<\/A-<(96R"@)T^`4M%)8OM/K3883TM,Y)67ZC9T\]:(S459[VSIZG_2K/T]JE\ZR4 M!ZL:Z%G04ZR2Y/[2W1QBU-DR?LNR3WUO=[ZFT^26MR_Y-'-M8W?S#/>&W4L] MP04C*BIYGBNJD:JF4RM<=<>W.^41>@%D]\+B%Q4EPGTTY=6PPHOQQK](5MC5 MV$#%R7]79+^3]/=D5RVRVST%9!-$N%=`7@TK[)("4CXK[!602I+_]+#ZUTKP M=K170"I&=KNG@&R""/<*R*MAA5U20,IGA;T"4DGR;^X(P5OI8V>\)[N2R6[W M%)!-$.%>`7DUK+!+"DCYK+!70*I"_I5*-JT0>LQ]LFEI-;7MY4[=+/_4]\FF MK^(T]U'F5W^SO@"RVST;:Q]EWK/"/LJ\CS+OR7\?9=Z3W=;);O<4D'V4><\* M^RCS/LJ\)_]]E'E/=ELGN]U30/91YCTK[*/,^RCSCI-_I:+,U4&/V=XWY5XO MY7O+=:MJEWFT^P2"32<05/?47XRNN]P6DDN2_CTCNR6Y+9+=["L@^(KEG MA7U$QH"&DX&?IA?7Q%;;&(A.:;EOHY9 MB]L=DG,"IY*$W0EN[^+Z:QP!C05P]`^=-`W&Z55\<@LOC?WN(+A(;OPH_*^/ MC^XT!18ZK?;T6`']8\\5V^:**?_5GBM>N/]JSPFK<<*NA#%VK;_1"R"[W8NE M[?L;[5EA`2OL4BQMW]]H3_[[;.(]V6V3['9/`=EG$^]980$K[)("LL\FWI/_ M/IMX3W;;)+O=4T#VV<1[5EC`"KND@.RSB7>7_"N535P-]+@\9&@JF_@%9$'- MSR8N)P-J^1E()9U>M8B[`NBQ6FYKGRO_U%*0%A8QV.8VI=/<`]R+IQ=X?)62 M3Y7`CX6%3JU]`[K2&M`M=^C\V(;JMXH/_25(M`JDG5?N`%^B3-LH=LSV>]I!V"$>[#T_JH5/F[39^)VW+MQFLXD^/7<";[JW\# M5_\VCW)?V5GY(WH);H"ME6MN]6#VRG"ECJ6XL/)5!XG**ZS<7JAFV[2T*['W M72B!V38M[;.9][2T+EK:)Z;M:>D9M+1UEV"9,)M[#T9)'@RS[*/<>S`J?T1[ M0[E:Q[(W;EZ[$K$56MH;-WM:6AUIZ!BU52"'=/,R>NB(KSS$O@4:] M\LYK;T!LUH`H_2CW!D3ECVAO0%3I6*IT46\ZE2I6.I4I2 M9=,PSY3![\OJ'CN3K'R[K#/9E]55Z4SVM^]FD])*/\J]V57Y(]J7U57U8/:: M:Z6.93^O<(-!D$K,H]HV6>V34%]C;&T[M+2/^>]I:5VTM(_Y[VGI&;14(:?? MYF&N2G/7?%7AIL^Y857+N8OGW*A;*SEW)U'(`*>@:@:I@F9(UF7PB7_]CP_R M9UX"WYIZ/TQCU[9:/_Z\/)U91/SM5_C;:BO]@(W_F-I9/[P#'&7PXWM?068D M_CC.9.DR7V?<%+]/RYX&43P,HWD+%^$F6W/VY7]\T/9>"/H(EIG!'OYR#MI8 M/L(__A]02P,$%`````@`ZWVR0&35HA5C"0``]'@``!4`'`!C=&EX+3(P,3(P M,S,Q7V-A;"YX;6Q55`D``TFGMD])I[9/=7@+``$$)0X```0Y`0``[5U9;^,X M$GX?8/Z#UO.R"XQ\Y)I.T)E!SH:!=!PXZ4%C7QJT5(Z)D44/*3G._OHM2K)E M6::.V&I*Z7GICNTB^7W%$ED')7W\8S%UC#EP09E[WNJUNRT#7(O9U'T^;WUY M-"\>K_K]UA^___S3QW^9IG%S_>EB:`Q&2?MWG'[:.V7(?-=^\PX/CDX!GM\9,(!LVSV/CSUCLZ.#L^. MNO]=EV:S5TZ?)Y[Q;^L_*(R2V**74,>O1M^UVL:%XQA#*2J,(0C@<[#;44]. MI`<#=>Z*\]8:]<6(.VW&GSO8]V%G*=CZ^2[0F M,"4F=85'7"O14':VK6GO]/2T$_P:2@MZ)H)>[I@5J*8`0$,I(3^92S%3?F6B MA@][[86P6[_+`3]RYL`0QD:`X^U[XX9GP;H6X;L_\NPGZ"!ANI8X&./@8%YD;EV MI&RG4+>=7<$/L>6W1P_-3HXQ&-]2%Z>,$N>!"2J'N'*($'1,P7X#AX(=?T\6 M#X3#6Z:C1._>!#QJ$6?_O/":9E.X<#S@+AK`''8CDNYN/X@M:JZ-\CA!I4R8 M8^.B>?.WCQ9\X=H#5!*_8M,9_@2NP+%#,+L1*C>4=K)[L,7RXU5GG5=$3&X= M]B+ZKDTY6-YNU-+=[0?Q/?-`/+'55;P:4MP3S^J^;SB>$H5PR="NY>4V$Y3*!*GV#A73K,^FNO M[/+&JMP:X276[`-'S#YB"7ZJAG"A`:MFCJFN<0,#(+7"?O]8D35Q`K6!RKGNXRXU:M@VL8 M>57S58U1.;?5F+BGHU."'DFP^T7ZOV+"$X$;:DS$*$A.^<)\)F36D>F[#CB>6'X3)/3,;B_*4?T2??TM M\L\$KDP$#?7*YS*B6X[DD!$XYZTW-P'^XZ2$750CR!RH2ODM:`7`CRA M@AK^J`]7CB83,CI0RCA>`2[X20NF>+&7;E&V"A7"-AK\CK0W^"^ MR%X!(F^K\&J0WTX'FS48"MSK$IH18D";]O+R86]OIIE+MK'4Q#H"GRO:>=TZA&/'+7UOQVVM@,P0(ZEX8C[B%G=\MHH`/_ M`X<9H?;-0L;F.0[N=ED=J`NOK5FKZ5I`<\&3T`FWEAWBGZEH)EGMCB0ZPI^& M891),9Q9MA]S-DUYK\O!F,IQ-!A'R,&9C*-NMV6\@#Q5$'S&3S..\3)R.6\= MM`Q?(#@VDP.OJDQ:V6T8T3K)T#>-N?7>$3?%E123/7A'9+.6O9CQ87,8;_$N MU_ENVW!7/'L-,N,2/&TD^8]U6)33C-?L]4E:%3#'KD_?&ND#N)V;_VWMCGQ5"GG>''OOH%R36MCR9.&VI&F#[IJR=V+X&!1%)"IDL8I,1WYC$^$ MNG=,B(';1ZL5X:$H!>#MLEI0@PN<.*B\"WM*72H\'LQVI$H5_IQ6.IB$!BNU M>HM+37@4S:?NI_(`L1GZ@9+1=]%*\=I0#[)7D)O\C-X$V;G MS^KW1*!/PX@[FN9+M((Q564:5=)ZD(?J#3%%@#!"9.',N,_WH*91H*F6Z@X9 M,8[V$CD(V1>L0EA+E0>\V,15=9R$C)::P')Z<[%NDRR'.'W027[S+;HE(7,' MS!#44XE@8Q`B\+9N0;E?I\1T8)4W]Z'+.D&=7<,<'#:3*VOV993=9B^SGCD$ M7A>#\2=.TGM0N;9Z]#T'UP>YJ6UEH);3B#8'I-`;1:D6!QE#E32F1M:JLO@7 M=G`;F38KPESE(#0R8Y9KZHK=LI$)LB*SF]YJ&YD0TQ"U)9*,V]R\W=)+/Z8B MBT58C2RW:M:L(J_4R!+NUM@O:4;?4=>-+`L75.&6+(VB'FS6FV]&(+[..O;7 M&WDRJ2#++/_FM`&3^J8(-SG-F4%[HPYJ[4$9J8A:<6ZKJ#GH+#B5>Q!)L^#6 MK+:7?DR(CCNQIHQ[]'\!U55A5#X]0JCO&\MJHNL^K0?`JTJZ'!R(@&L(_U=5 M*M4-_JE9EJA#)537=S>.1*DK4CGM:L-FX]!+&4*;3>O!27V6J3"WC"[JP7'S M0'5A9JF&]>"3/`U?F,U&,TTUQF"EY6Q.<<.\?/TB`%?4VU6@O`7B5:.!WY\GDN9$8] M=%*5E=NL1C7@L7Y@L!B)1`O=#/I"^/(!L,&S=J;,#.LKWH9KK^3*^"%TVJB9X*_2S2KK3Y(M=]5@MM=\`. M@@S,@T/<[,U#(:RW3ID;_B9.M9=P6AI9*-J+.K8N-+$Z&G3&O[P3OE'?SG1/ MFEK_VI-*"NU/32UP[4E'Z9VMD;=$[D\A"N>RD?=*[G5U23H/L3X:=$!J-WUD M.E.Q/GYK0(UQ_P:2B&)B933HE%7Y?-&&I[+U>%23"NR[:4#EJ3>JWKP?560D MO78L/C=2'=E5S$:>JMY-(7G'U9*GK-^U;12I$"D.8_]@>MFL-"E.;?]@6DE5 MM1MYPKL"K:2JXXU\!L*^%9-58F_8$Q-*O1"H;A#3K_BI&\*\U_34#6^AM^S4 M#73)5^/4#7[V"V[JAK;,BVGJAEWUDIG:X=SQ13!UXU/\%2YU0U[RO2MU@Z]^ M@XH2Z+)>5Q@``#[#`0`5`!P`8W1I M>"TR,#$R,#,S,5]D968N>&UL550)``-)I[9/2:>V3W5X"P`!!"4.```$.0$` M`.U=W7+CN+&^3U7>0<>Y2:HBV[)GYNRZ9I*2_Z94F;%[Y]QL420D,Z%( M+4C)5IX^#9`221$@`8H40"URD4RL!M`?`'8W&MV-SW]_GWN]%<*A&_A?3@:G MYR<]Y-N!X_JS+R<_/?>'SS>CTZZ/>J/\= M1=A][_UB(P]A*T*]%^L]\(/YNG>+IJ[O1M!K[YOK_WMBA>BO/?+?3@_^],OU MT[?>Q>F@UWN-HL75V=G;V]LIT[U,[F)_U^OW-N/^,.;SJ?3H=?#S] MD/GE*5CZSE7OXZ>+C\B9?NBC"\OI?Y@.!OW)%%WTG4\_3#\-[/-/]M3.M+K! MR*+,.<#U5>_B?'#1/__8'_SP,OAP]>'RZL/Y_V>I@\4:N[/7J/=G^R]`#)30 M8I";C;_V1KY]VAMZ7N^)D(:])Q0BO$+.:=*3E\Q##Z;<#[^<9*"_3[!W&N#9 M&?1]>;8A//GC'WHQ\=5[Z.8:O%UNR`=GOWS_]FR_HKG5=_TPLGP[UY!TQFHZ M^/'''\_HKUEJX,.)MN19MCZ>Q3_&U*%[%=(QOP4VG4@!.#TN!?E__0U9G_RI M#^MQ.3A]#YV3OY$!/^/`0T]HVJ,<7T7K!?IR$KKSA8=.DK^]8C3]SE'?K3Y7\MW[OS(C=8C?QK@.>7^I$?Z_^EIE(,!N]JST1)Z MI-LQ2O;V&:$]$^KV;%_FGZ#EK\\1;%(RQGAZ[_JPP*[E/08A_;IN/"L,W:F+ MG!H8!#L^)(I'"Z,ZRR'1>_2*(M>VO.9Q@00(YFCH10C[L`%6:#\@Q>Z:X=AV M^YE1GE]A4EX#SP$1>_?;$G;PT'?&,$GX)I@OX"?DAS!VS,Q^@.2&4@ZV@;TH M/UY[N_/&"E_OO>`M'/F.BY$=[0>MV%TS'#\$$0I?@NU7O!TR?+"B)4;CZ7A! MC`WXL,,:"*2Z;QO1M16ZX7@ZM&VP8B*PN1H%5.R];3Q?`QCE)@`3!/NW;FA[ M00A3^H+>HVLOL/_=*+JJL5K?C>@MG=E'##PO@1?Z4SN`A09L&S6(K;D;T7^" M)(/I)\S`B<%%8=L++CETVS-Q;[GXGY:W1.G@+2U\^4AMXWQ"'OR3F$[1^@5; M?FC95#BVO=PRX[8]![=H$K6-ES=&Z]BV8X).!Z,$+!*J_9+YOPG"**1FS#4Y MO3]:ZQ9%W+Z\M#U7SQ&,DC/G"&W;.T-\U/:EO[]".'(G'GI&OAM@V+3P=R*0 MVI?^4D.WOA.6DQ#]MH1_WJW:^Q[XHR3X+&R+0N1X7S9^'>)V^4B16YYWTDLZ MSN+8MG+]Z,QQYV<)S1EIT"(_,!0Y)05^WT%3:^E%T1]RI`6;.%T49(OMT%JS.'.2>$1\T^0=U1O?/ M!XG']$_PIU^',+1#AK_WK-FF.\^:(._+2?'WL];YN5EBXMRX!U%M>?^'+'SG M.[<@YABL<4G;YW*S9O'8CPB[@7,/?PL9;/)I#\TGF2,Q+E/*P_&8V?;PI:$1 MJ+8R1IGDA^,V7D?^YF33'8Z_%^BVA"WZ<_O<4($&Y^X7:^*QV,G_?B!^UC

T(S-X3=Y4R2M<_=-S2S MO'CLX;O+$L"[%.WS]((MLHN?U_-)X#$XRO^^Y2>UW(8XSQF8?9MN$@M0[/"2 MM)GB8"Z@C#9#!BQ9UPLP'-._G`S.ST_/X3]`38W:*W)"1]90@X@@7APFIM'G;.`_O,2%Y7;2;D M]'Q`IJ/3R':LZA3:1>>A<0R@%.+ET4`L6,TIR`]'!C)WA$EA?NP\S!W=D4+[ MU'EH;$,B1?B_1X*P8*ZG$'_H/$2^OR-%^6/G43+M\2W`P?F1`"P_N*5X%1DX M3#?I+FKFD7T#LW`Z2#>IJC4L.-)W`7%.-/F5VQQ<9?%\/LO[AUOV&0L&8M8^ MD4VM<$*G>1GV9Y:UB(]ER(O"S5]VSV?)GW]-(D["1VM--DXBUG8.:Q7$]4^2 M>_$-!RWGFVM-7(]N_$K6.?1*N'<<-]Z/CY;KC/P;:^%&UNX9N8I:">=AB*)= M]\+.C^KX&DZ(265S-T&>2!V?%7LU1Z.<2Z%)W:55P36)6.4P27]2PA.1[N,I MM2V87M820B7\\H/P>(R7M%"%(-&JP^\Y$Y'!^`ZA.G[INM,@P%)N,V1J>-T& MZ9!PMG(QQB'6@.^'P+=E6,_0J^#^%JV0%RS()P:&Y`R!Z8LPF+@A(EEXMAN! M<;.<+VD(W>T2P^>WVX(#LX&.555WH%Z8A"RZ+1K_(#"%W=A94[$%.(>D7BB$-B:.84XSZQ6)( M8RPS]U*@^H5C2`/=N3W:8KO4+Q*C^@(D]^$QG/9IW(4JR:(V1D'%:LDZ?[)K M6.:LT#F2M@GL`L=GG2-MFYB"DCL6G>-O&][Y>D?A-K/.)3?$.L?I-@&^C%KG M"-Z&=SGGDD/G`%]QEWK.X.*$Q^D-,`,`'1E<"\T-G7)7?Z85[)I]M4WV.`_.D^'XV<.M"/92FYV3B_)[K9Q?NL[P/8TQ%28.%>^/"-/$_E(`Y2T5(XKK$@R7 MT2L([/^D\I6/I-!""P2C,%R*0O.>N<^C;9^[J< M5DD*VQ*]!#)ZLJ3![RU)2X*;O33;<26-Y<_KD@I!L+%Z7()JH:*1+CA*E4-) M`UWXKU815:U,$D1M[@N>9Y,$T5A0?KQ1.(S M'UF$'0RG;3(\&"PWK1"QENAXKJP/%7+]="'@6PUMV<.]" MI+,82M'#8A?"F^L@+AXCNQ#,7!_IYJ#9A8#E^BC956PUCE@NAUKA`>U"E++8 M6@I=9'0A/ED:;HDVN&T5,WXCR>&,3LGC0D$5U MH3$C'WY&0R]"V+XFC'+\C,!^=ZE4])`?J9ACX3I;Y M&G;!U.4)/1ZU&L[CZ8UY2AAZ`&48KXP_>T!\&`)-E93RM"8!AOV2^-+*/U@. ML8GMB*<'UC#][#A3F*=14H1RL^4J>651-A(O1E-^*RRU$D(U<17!%(4AM;3O M$=>N+)"IX/4)A0@.*:_$L$K3)LH_[?(VC:QZZ1#P78RG7\F[<\R-(-Q6S7RO MD+]$1-$R$?#I%');P:2)FM$C:H;S+?V,W-DKJ.#A"D3T##TLB>^(GJ:2HU15 MY%?=7A3&F%2T#[./<_Q1/(=]"+E>,("N;/=C`6L[GY3'!>H2AJ0N/H>N2KY,C^\D1]'Y`GXBL[)*!+*2 M^C7L`EBE13[*VZCP"0^=?RT3Q90X,5X"D.<_N]$KF7SX&NZ#K7Q`#IE[F'BJ M$KD8Z_>H>`9>`LX"T7U7C;>BO:[HV(M!H_K&5!S`0L(7&+H1>D9XY=HD@MH- MG"=D![-8#NPQ-TV,WDQ=$,LGPHD./YX^8K1R@V7HK>,0XT)8+NN*0K:+P_+- M>A6L3@\-<4U7GYC:V)TPHO!X5(KKV`@4<$VF2VZG'`L!9Y09.%U7!3W M);B!W0?3"@;#&,\LW_T/7?D*9/OTVTD9$N'F2N)T@\"A-:YCM1_> MO=NOEC]##AB0">-^&.$E^09+A5>-CI1$;"837KKY=H@:D:S;/JEDB\VK0 M4X$&K?%TX3MR/*4-6N/I$DORE#9HC:`F8+SG+MV^(X\42@R`/T7@J=#HK;]`F3]R35RF] MDAA!&_E@R`<_^>$"V;12=*DZXM,KX;ZZ`I[RFG=;'^>.&1F*5(MCMC&QKQ+\ M;C:LR&SG:(\S8K@J&LE]:YEQ8+ MV5:Z[;":0F&GK?)*OJ7.1A:EBM%J&^T?PV$F"NNG#(Y:'4B`CH1.*8 MS"3L&=ZE/LE,\H&$LGN27$(#V^Q0_Q'(O9.P%USS7,(1)L&*^EF/)[]2T(?4 M_03+^M<:W<^]K!=TW_WDR=H.Z^XG5=;*5^A^RF6-`*LC2;X4NO%4GFW9_B== MA*KQ8:1N^?ZM*[X+Y;QJH.1>HG2ACE<#IF;^[KL+M;SVMS9YF+MJ=*57+P?* M"^U"F;#FIBQ)%.Y"Y;`:)HL.!<,.(ND$(F&V,W'150.MH9"@="(Z;;VQ\I%3 M:%VWUO8J\Y!.0U?-.9%\D11E5XTX@0R4%&37C39>7::+KEMFG'?M+KIN/K%R M!%)TJNPDN;L95O)(#B/_'D_YK8PN):5T!"9X"2?[NETGH.;W=`+Q\A@@BH=H M):@_'%E9M$>+O#'^BB(XOWEJWC?L=B4:O>JS<+('$EF5N56YA>VR,W09I=JZ M)30>"]BH+E&24FK`<0`SB&,'M`@`5D-3.<94CM&[L&6'UIVF=KED9I:.X+1KWK7'&F*>T45Y$PECX-R?>BW]W:$SOF` M+S5YI*WP<2'.QT6;?%R*\W&YRX>2N/CC2CP[<*Z=%O'Q^^9E-[E2*!#!3UI M<=@V84\M!,J8""@=8H%NK/#UW@O>PI'ON!C9D9IG$#-9,23SQ[==#^6B<\$> M!4X?<;!R`?;U^B>PRD;^]HGH(2CU%4TFV'V\ONPUN::&4G$9`,H=1XE1/I[> MNSY\8,`=?1BHDF4V`6>"A9MW.42UH?`]&)AH\[$_@EE*5#XO0H])JR2X;4>`CORA M;9,E#1^M=B!<6O] M)H93A94MT8$F^$CV`QP'D+LB7XOXRA4:ZH'G$:.%Y3IW[R0%5UQH[#0SP87Q M1,'QD'4DW)Z@TB,A9Z8E.M`;7\5W7Z,CC?`RCOAR.%D=Z(VOWGKJY@MI^Z'- M9KBDJN(A\&V8T9B5:6:O+E7,`7P'-D).>(^#>:;(1V+2<%!6--(`QZ8B"SE=BH'(M5"-8'.[ MD*M5(8"#W4XU&OI1E+Y_R*-6S3F<-.G!^3[`E"UQ\TBV%]5(DV/:HX6CM>!' M4VBB`L,36/?Q[.8J,95`*&NA-`4BZ[L52=XHT)LT&1T23AI\+BXN)_CH67ZY M6<4A5L+W M9\4;RQLOT[QQ?HM5DQ-?XH@\H87"Z"4@;#QB%Q3-HF#([=^?BKW5T&.#!P\` M:S,6H%!*BB$SNE`$[%!S5')B[4)-L4--4WDHAOKZ9/K,%.=2+ITB?;.R#C5% M,GA1/X>L&(G%V[9.I&SV/`L[-[-=2*K ML>$Y*$0U="+QL?E)*`1#="(]LN%Y*`N@,,F4AU_?^M?!V76NNBSIPML?S<^$ MD).\"T^$-#\U1:]Z%][]:'X>./=977@/I!7)D;^FZ,+K(>#FE^ M-^0N1[OP:$@S4R`3?]:%]T;JQR<)O=Z@K^7<#/!V7%%=>+NDL8TC'/ZG_K$3 MN41KWKUXSMG&\%HI/Y>8>AZ-OVU37P1D3B$*YSYVH MIE9S!J0BI92746MS*S"+072BI%AMQ(SB$YVH,28/N)F\D$Z4)&M`$,B'(*JO M9M;JMA$OA-"%&N/7(.[[#2XF3(5B'.\R#4Q"A3HTR-,C7*M*UW M7"I%EM&KNNG5!_26&CZ/&-HL8?GBV,5C4*XZ*C&.PA=:"H;6%VIGU*Q1LT;- M'H>:%1,41M?JIFO)O;$;YP4,?8=$H<#Z(2!"8:-'VOT>DI#@D"TA)3LQ_F9S M1#:ZV^CNH]?==86L4>2Z*?)[R\4T:C)=K^,[+=>7Q>73PQ;-Y6V,5C9:V6AE MHY5;U,H50LLH8=V4<#91)Y/-T.Q16B^5?%S*3&8!V9I#I@>CKHVZ-NKZ:-2U ME/`PRELWY4W2RS3Q>?-884L_'K7Q8NMH8A@%;!2P4<"M*&"NV#3*5CMENUTF M6K*4E#6GV6.)#47?P:#E'ZZMD)A4ZZ;"O_90RGNRS%'>>_9JE+Q1\D;)&R7_ M^U'R^XIA8PSH9@S0LB6O@0?LAW&E9D)KG.9&V>FG[`[*I^AGP8,@VMZH3GY21$ORWAGW>KAOSE1I$91=:Y@S/W,^"PS*4W:MBH M827/>G`WL%&Z?*7[^8P,,;%"!/_GOU!+`P04````"`#K?;)`!*^TH(@O``"1 M:0(`%0`<`&-T:7@M,C`Q,C`S,S%?;&%B+GAM;%54"0`#2:>V3TFGMD]U>`L` M`00E#@``!#D!``#=??MOY#B2YN\+[/_`JUM@>@"[*J5\UTS/(OWJ25R5T[#= MW;-7.!1D)=/6CE+*D90N>_[ZY4-OD12EE$C-`3O;+IL,QA>*+_@._OD_W_8N M>(5!Z/C>SQ^,CZ,/`'JVOW6\YY\__/IPOGJX7*\__.=?_OW?_OR_SL_!]=4O MJWNP\5S'@V!]_A5&@?,&_F9#%P96!,&C]>9[_OX=?+&>H!N"+X[W]RYO]S[1V_[&4QGYA1N=Y-S:%K;\\G.,,Z?=M`\W\X6NYEACV;V MSL[5N@R@%2&!8(LT_@S,D6&>CZ;GQN+1F'R>C#]/1O\W7]H_O`?.\TL$?K+_ MB`JCDJB&4;#$&5A[]D>PV`T#F]L*?/^2@OST% M[D<_>/Z$9(\_)04__/N_`5KX\UOH%"K\&"?%C4]_^_KEP7Z!>^O<\<+(\NQ" M12R,5=58+I>?R%]IZ=#Y'!(I7WR;F$9"0<`M@?]UGA0[Q[\Z1Q8>&Q_?PNV' MO^`&_QSX+KR'.T!T^!R]'^#/'T)G?W#AA_AW+P'I%"+A&'XZAN?/EG6@0ESLIXFH#Y^H>N27V'4+ M"L*W"'I;+)G^%M<7&(J*QS8F0K%8WRX(=+&U_8`)F$3$9BHC#WO$W2C M%`3QQ?.1D8"/?_U]9=N(&U%X9[U;3RZ\/`8!]**D)8+OYP\UA3^E>N/B!#HROD^FT^5T M_MWX;GSX2R(%Q&)`+.?/M.UNX40H*L$O?6(R"Y@.5,P9<#S;/>+X#`+H8J]% M?PJB]Z1`"/P=^`_C;+:(!VY+Q"]YUEF%50 M=%(KL!.`Z,<:R\0E/MD^BD2'Z+SPS7>!OZ]UNJ1M7\J0G_13ZYY^A#OT#1P8 M-B(:NZH^VC'UD7+8R70Y'W-(&$L%L=A!D?)4Q!R*LHDY(+8)G5;`/;Z]-#$Q M.,+M%\=ZT@J&$>GE<%/`PG4ME_:"YMP\F\Z3/M!8GDV7P^H!Q>Y;(J+`N%K8M]TZ M>*Y@N7>6LUU[E];!B2RN6P6Y$=G(6"QBWJ5B`):#IGX@EJ2)=B?# M,DNP#AB6XP&;#TL91\1.5F"(P`X#XL=7N'^"0;-O&=?1SQ6JB)QKC6?+6L:` M;U3B_QL4=1JC+!,(2SMWA'%!,X&*7BA!HYQ-])#IOX]AM$?]71B/01_]1^OM M=R=Z>?%=/#*X\8.'%RN`%WB=\=+?XZ$#67!_Q]-@?$XI-_S@ZH1/!!QB\.C:\@X'C;^^A[3][ MCMPXH=?6!Q8H.H`D-X`V)V;C,,,;?@"B'X@5!*F&(%814!U!3LGA!BNU7X"$ MNG48'O$>,HYS)+8!G[8T].C6(?V;QL:N/I/VR(H5\FS'A;? MK'T@#*']\=E__;2%#HV!Z(=RZ$._^KY"6F^QYC>N]5SRR.K?%0292J-R#::CE\BO*FG/)]84C]"I"?(;5IY M,`%9=`JN@E:[1TM%Z7)971[>*-Q-%I.YP?+T@<3N]IA("+\LN+W>-1N10W'] M7WMDO[!")]SLXC/B:#3/^5S5<@K]O]*XY&AUMAQ1WR<"\#PS$Z''ZT]!0G>R MZ:P+;Z!%5D0FDEK#/==_\B[/1MW,W>W(><-.;*(!''5A_)OOEWBORW7C.>E= M`%\=_QBZ[W@;C&SG[..-'++'4YXGMA+1L>-O??N(/R/KH%L;_:0\:C9;FLOO M8Q)#<^+Q2D76`*`M`-I$O#%+&^F%/:P0T+,%C(H%-DHLT/B87,]V6+`\(212 M@$-M$/CQ;_YHXZ`HWRSW"D[X]E3#8($74D_1,8S%N%:-( M&P,-44WQMXE0'>#O.4`UM4)]?!I^3"I0NWE(RDS60T22'1T-8@C4H'=;3)8C M3@S1/Y!IC(,9"WK$P9W.=`'&K(`AQ]4&PF.I`43WHP1R'.W2]Z+`>3IR@VRE ME'H^EE606WQ?+";3A(WT&*B=B0!/[\#:[1S70=W+1]7$/`&0D0>4$Z&%DR?@ M,)D?!C-S&&?E:SB2(RG3"+U05)(@/9P.;TQ2Z_GH'KVRNPN0%WU_?K MS56/`!XB*X@ZA##-(%Q<_[*^O5W?_M(SD-J-A8803)'?J-H[R-,NOUV08M$5 M"^CMCK5G!]`*X16D_Q58GE-!<=Q@:R&9`V$Z'F?1)+EDE<@"B3`]!R0Z`4=. M2]Q>/X+U[>7]]>KA&OQT=4U_^B/Z'<"$ULT&L>.5.2(PB1;FN%88HDDQGB1< M^7O+X5W'9!14R91*Z])90A*&8`EDZ86LMGZC4C2=HS@)CIG!\67@*.,"UY4* M'&!#U^+[_G[OT)LT*V^+![6.]PP]VZDLJLK44,D&OAIR1Q-FXWE\]S6T>&9EEV'3AE7ZEVO0)H:DPR,/5=.:+M^>`S@(WR++I`2?V_^ MK5E"AL$QAF9RCCD>+^<2M`-9`^`;;@*0-G3U57T9@LG0VO@S`(8*W%N2M#S# MZ>*Q[Y%N>27,D<C\JD8.#6[/@7LHY_H=7Q+QIXRF0^,:<,Q[\8CN,WAY-S_(LA.OZ%E.-? MM'9\WOY6=N"$GD!Y]%?V/XY.`"^.H8,3:'&.BMXL-7.-,1E0LRP8KWR;J%:NB'6K.;UBU>,X>79DV*3[WN_`!8-DW^P]DW M5+.EUH"7V1Z;K)'T]9E$.8DN,U].>8^9:UPR#_YT83`X-(3NLAT6LXQ%?R_) M\)QJ)UE&J]G1[ZQ@$Y"+.UMRG/,.TJRJ]5^,6U,/&7CJ2*;B7>;7#%-Z(*%@ M$]"+35MZB!EO1-$3CMHYTP'D2B]SAM_``*^\X]H:"%7GH1R*"8VCF73TE.;J M&+WX@?-/;@)J40T])"NK(3>MGRS2>TW56TL@DZ:=4"?`8Q`IO@Q@"?%I(!3/ M^SA$8AIE$`2B(TC9SQJ7UDD&B0;"-(;%)XN^FS.27B8D M20SQQ?C%`;?1@^ M*.10V2Z:B<2Z_]3=)EUKS;0F*PDR#2 MM.S0%2Q&Q_5:_Z54+V0SR<-:O*Z:04\_E5U5V>QN?0^I!R,K>*<9G1[]2Z2> M$^$W=C?!L^7%F5)K%K=/D:FT!SQ!4=EW+"?I\8K/VT1 MY)O4OLJNQE!FQ5`^TU`1UU!Z._`.N%3L[4\U>T=#`^\5>0A1XG<>VOCTB;-S[#2?QH\$+XHX^+6<2,O#W,U8F!MLR%A(TZ@#:18Y*'!=P:=( MG(.74UCM.(&A@=P\TS1FTSR3B!2`Q?2;GU>B2S\-DUG&M(5/2,(1KR2=);E[ M-7?'`B'T9(F'J#G^,%5:K;Z.S1M).@9D\JJ)^5P\^EX-,T/ M4*G#4?$@DY^[1:-CB-H#YDKX$&'6>'.H7RM40DTF6//8M2F/2P/91K;2TV^' MY"K3]1M^;E-P2;943&DO76Q;\CK:/-OS">,;>8D$3TOSO1`332;61OL":2M#X_ M4>=D(F8H?KHSGC/>H.[(>U+/H\YGR090^)W M2J@@@"4!)`I@6>I?^NP`E=D&5=]0]EMHC/-=,5P6RQ/94,,M&`R@:&GEZF!^AF M"MU.\4;^8*ZN-O7??(?4R%JZR"F?B8176C'U6J?4F!BC28YI@U@(Z`X8Y=$1 MXGVYS6[GV'J2&4NZ5IDF0YK$7\%7Z/H'3-"'R'J&UQ[Z?(?`P;GHD%V=:&7; MQ_W1Q;>"KHX!&BN7:W`_\LF"E7+M5&TE5\='D[0#3.L#(@!D;8*X49!K%=!F M0:6>XC="M%AL02U&C6+EC+*E1MGFC!+RC*(N&G1%J6+@Z,3>G>Q3G*X+\T!= MM[)5[VUTI;C2 MLJYVOG2B5)5CO=-4E;SBC/]#XTTV]=KL0+Y!$+<(Z!([:1.01D'2ZA!F:\K, M1=_'(#Z(49[^K>7WEH[(&RLFXZG0R,Z?Q:W2)3'`.TA^QP](&0*Z%OG?,^(.L?N`; M!?@YX1JPUPR4^C&`V>GW5S,B:D'S;-33U(S];T$FJM#M'_J.P@WZ7?DD%KN<8EX4&I<-HTD6B-1CXO&#OO-9I$QF$1Z?=,1RH[?!6Y.D]_ M1&(%'X7\6;%?XS:EOW\YON/*^GRXH>JFE.HJ_37O#F4W3<%I68L_PD<_7O"[ MLX+(@:'XU6X$W2$!*OX=>?DNL49 M"&*@!R3W'3AX[PB&=-6(',,E[T%;KMZU[EJG+"QCBZVE@U775N`YWG.:;>C" M"AU[A3HBQSWR#[34U5+(KQI59-$'L57C!-Q648L0"222QVQ3#U4ZPXHX1M% M966HP!<_I`FSN(G`5+%*TBGSU)*QCA9^[0^N_PYAS/HOCO7DN$Y]YU5?3R7' MZI21=;YIO#*;"$P[LYQ(O1U:EU`+_5IHN5:`X6'*':QWI(X+(NM-[\5":?Y8HS)BW]7-(P)M56?5-6 M?15S&:9C)).9*D)%GOI^B:@16.[:V\*W_P/?>=:OE%/IN>7&9>>RXUG.@]]! M+`40,0#)T>3))\`QF$1YMD\1RIX.!.Y,D^7SQ4O64DM!TY.ISZ:);D]$P\: M4MKXSI&:'*1GDE`54D*@^]<5P87*(YP;,?\(/COXO)X7W5I[[DRS7$RI9Q?; MEG6(^;3@VID0@*7H\NW66,QF6-1Y-]N!BN[-0-W)D?5KDIOXTD)JNBXY4\$X MTB`JJ?H8.EL-R=M7D[%)#YQ3*2`OYJR_\PTL8M,(26C0:JCK\_^!XY?,Z8+(C+JMQ08"D@^5#9?#XJ MDB*1HFE"T14FLS$F99L$(MVDU62>5L*#0O>1/0 M2!*NQ7Z3R""=@^(3WMV@H?<:L]X`R]#7'TBX4M7_J]`'X/T^ZJ,"FE:JYA%V MB8KZN,'01O(-H=%BRJ$*D9GD3]/\_GJG<,M)$JO'ISZGNAFNI:Z"?623+)\G0YJI`0;@&1#%+1X")' MSV]8O-8A7:?HS7KT3U+HU;-4SJG97)6PGP[&WEA.0!Y+S1(,U&;O$-=1R$VA M(I+OI9N+^#8(%D9?ZLWE/QQ"2HVN4)HEE/X.W#@>\D#';L\LJI!93`=FC"PW)6W76WWCD>V.2+G%<8)^7E?M*:6RG@@5D6N&YJ:R4-$ ML3ARIZ`H,'E<05.,Z`RFF8>)NU6K(%`KA^2$02M7;2K?V[ MT&^WLY4.0J\]V]]#/&2_089`$2=RO".*/?&S6[X77L"='T!:[A'?&_OJ>'Y` M,-";T0AH40J%^!5&+_ZV?M*M4@.%(40A++G9YM1(8@\52I<(L%B0:06.)4A(6&0RY<(:5W'9]D\]DD>8E],I@(FBA)?#862 MG9C@7R#W51N_%I.VQG+#(&^\6.,]7UH')[+<^A4.60%:BQ]"&LCG1O`'HUDVR1A&@B"/P4MI4=D'0SK_X\+/K6>;:8O$+[#82ZT0L, M[J$-G5<\!I?O;2L5]5*UI(WLE9:Q:"9)A(*<5'V+,MW!)>LS%%F0"A@8Z3@^ M64,VEDV&0;*[`!XL9RL^FUA;32O!BKI(;H4M%Q,!O6*1W9Q/[)!]/I(AW33,A&+Q MKGV\IY#L)^3%`B17U]BR4\1F`7%,M7./C4X=V^0=M,@X2=MH85UZ*U:0_*-4 M2"63"BW+Q>K%*'G^(KL3J37-1VL0IC0(91Q@NDO!VZM@.SGGGLHEC[[3UX^, MD'U25:*"ZC/N0FUD4R&9,WK"/4M$0*0E[U?V>-&4QM5-TA@@=Z!N>^'![ M5QA-\1?4=LY=BF#I*?=Z:_3&>M/;-F-]5F$(K$^UD?:9N9#U2-Z`6-\&G8CU M)N@;7G/6M\$H8CV2-RC65P@F9'W1&KVQ?APT9'U680BL3[61]IF%D/5(WH!8 MWP:=B/5CT#>\YJQO@U'$>B1O4*RO$$S(^J(U>F/])'IIQOJLPA!8GVHC[3-+ M(>N1O`&QO@TZ$>LGH&]XS5G?!J.(]4C>H%A?(9B0]45K=,KZQ\#R0LL6)9OF M%=7%])(>4AZR,,;+$L?/0$Z0AGS3I\,IDEH)&CDFMX>4)4($,+X"JCG'=`U1 M*KQE8=>QPHP^DA^LO&U\PDF\2K2%2R`7+Y-2>UBPM M)X,B=-CL=HZ-FOI#>B"O=#A/Y\JTV,WR*]0"8_3_.L@7^&RY]/4&1EY/5@E% M;X*4FI5^'R9Q>%P=)"\=:4C`>1H&LP$&%6^`<-PD>?Z#!51+;*\]QJWIE';S M$\C+9/NA]^/5=5?>V^E.KJ0_8MGYXY9:([+X+/00CCKG=,`Y/_"#?2^^NT4Q MAMXQK_]"[&IZ/)VIB^35SNEL7'%_FN,F)S%.#J&=%J<"97.%C&;"G-P_@"U$ M(Q[V95T-+!*Z*(=:?%,-D6\U%PNDJP^(?\W.U$\7HXDT#[7?*.@!NUG&;I6P M_P%<#9^4HFL$C8RFF:27QR"`G@0=DX)ZB!>W+N=FIKE@='6Q".U=6W,HN<[, MII4'.``L.1*'#WGPP_!\^0ZI7$$K$QH%WNEXEER383!B2)U,>W3TFEJ5'EJO MH]6[FY@GVGN*6RLZ!G"SRY)Y<;XAHZ!"?E1;ESR*OIS%QQ2H!+#9Y9+LZ6'# M25@("RXL^^_/@7\DR?]V?K`G8G3R@.]&>?_G(-?B]S"ZM,(7D@5I"[<7[[^& M<+OVXG=`O.>5'3FOHE6Q!@)4\D1:*\G\L-/DJ1B<*A&+!HEL_%X3EH[OB:7R M0=:`GG%8+P9(/ MZ]_6C^OK!ZW#S?;>WX[F^H>G;%73K`UMNVF6`/WT9F@E^Y;16(;664*3@7;3 MIQF@V$T?,>AB.I,A=]$"EY;@+L]PP^9LNRY:)&B0'&ZVV#&=CXR67!YJ%]V- M39A=].;N^G[U./PN6L+[V]%\"%UTEMN=[Q>Y,FI)FC4L>6U[/!]G_,L]KJ"- M4JT0F/GW#;1U\JU4G]6IKI#+5=#8BE@TQ\O^<1:H<-O1C`3`R0I+@'D0]\>J=`:T?= MW(\+W7A#8^F@:CKTKQULLTHJI!ZC>=E;*LOX_'8VM^U]^%TWACT-#1G)DH?9 ML+\F2U&32)[QL/XS"L^2$G%8&2;EC@4SUQAD0KVZ1"=I0*U=/ M/[LR921SH2^GXSJ"93('Q;%64&MHYD+4:R6G40]^H/N$D;2K2M"N9*].UFQ( M4Y?8=BLON9!:'J$)"JI>E6%J(7FY?C:?TF482A0BA1SROQ8D5.YOT>54*$89 MRJIO*.(UE5/Q$&+?H4F,E^;=U;9D(F1%ND;"1ZRM4\0AP@I?"@E_14&965YU M)\A20G*V,C'-/!%B2:5,U9KROW>!C21^O\1)-5R7!$7@[^A-0?+^91B_%:^] MAQ/Y7:5GX]I$&VURCSO@+$;(H46`6D2 M&!H9W+^5",<`DI^T<_]$ZE2BPRF6 MUA$_[I`LB$(8O81\9P6;@#P9OR6ZWB%`./\9Q[9S^8IVL!* M^LE(=`E7Q^C%#YQ_\)6O'/`+JN6354%),]>C,;CE$_YQY7U[A2(/`7/I>%#A/QPAN+ZV#$UG\CR>LI)08(DUD\S%D#*'2`!8'GVG$.J1!C`T@;!J);PS`(\0B$[!V\+GU!D/P:Z^Z5:%Q00J6(9 MW2Q*GJK!VV+[O>^1D:3$5V;7T\0HIC*RR>#!4UXTPX6HT\*CT^A'3@'W2?J:YR,QY2R'73SX\YZ)[>I;_R`J":? MPK.I%$U\DE!-TB'1_[%XEC0`4`LQZ=0E]&Q"P6XM$9^3)R)+!YP&DGV]I9OS MF"MK/MV,SEW!?I>0SM.K6%S[RA6RJB^)%E60&Z6O%C,Q_1^ M9+F^XHN1)ZAOL-37_>@SEQN:U]?-5Y%R8R7MB+I1=2!#SZ?:Y82'.](^C, M.*`'>K-`T1%^DXD?!9(?5'H('"_R`>3"UA)/9$C-C36UEM,QQLT/MG,WH@7F\A].8F-=E$-I7SDJB&;]RU9R\E$Q7=*.]QH;YU+H1M\ M"XIO"_>'I$,:V>,:407U`VR!-E+^ M,YLMQ_-D1)T(P_Z3WR0_BP_FJQY"=P/.*($KG0#H$UO=&+D;@&;UZ^7/`>!' M5Q`]/4AOU?]PHI?\WLI/Z,_TX+26U!'R-,R-D.OLUF=L8%TJJ"\_D,@@?S1_ M-C-&X_K`T-^E@Z9QH2FTNK#0`;+&HX(N\2U.B0I#BP25*Q-REM(SU`XA0ONR M\K97\!6Z_@$;5)RR3%Q'Z7!;H(CDM3?D?0FYJ#"2P"\GKIOT9>VGM]U`-`L0 M\66C;2;N##P'FA]+D?+#XH"[SC`==:N"9FYAM-F1/%:C;JZC;F`P/9WV*_2.$)\C848??CFEG7.I<N$!VN25GRM_;SGE$5=]>85.S%5" M7#3O/Y_6`:+ON+WVMD+_;P=A@B%/@0LF21'))X M@D!>>]OLR*+>ZLWAC5WXY56Z.T\)N5@Y-J?Q3E4JB+Y=B">Z=$'Z&Y:FJR?H M`!W-KD`P^?68E#&BSMD*]!":02M7Z(&P2W]_\#V\:2[#%V8='9QA*2(Y(UR. MIF7>4&D@$S<,ZIP(TBR`/&N$4CF91-[()!37.%I)]<7QX!K]6,NDK*`.^J2M M2PY2EI-*7_,-RP!$B&Z>M$%C-D.CG`\51V*2H(AKFR&D82VSQ&V!4SAR! M(S(YQ+.,9C;%=[LM]\X/';R+*,\J?E4][.+J(_N&T7C"8%DJ%21BA\2V+C!7 M6=<8LP;VU3HNAX5BBVEFXT.6QR^D(T]Y.@KJZN$C7R')]TG&XQF#D'FQR61C M0(SL!'65DGFQ?Y"#K8&4]?[+866-U;32,EE=EUFY*)350;N\`I*[(>:R0K-T MSV<0"Q0M,947)B1`*:<,R[>8%*G80"LE'O&[B'6?C1;200+2LN0;/>.I65ES M(/5U>WU3$.6E!CX(Y5Y>F>V=@]?AUN??A?IQ*0:7^76Y=:>K8X!&.7=D M2!4_M6DCG>GJ)7]%0K:^:FK**"7GFZ/EU,A1,SZ6!ZAH0&6G[\GFI&LD9L?@ MS=RA1/AFOZ#RR`".1QYD?\4:`2N33#;4H.O:\!@Y;W>HVMXZ`U?0AOLG&(#9 M&4!PYH,Y$MB4`16"2QM[<`2G>45"DF4KEV/D`=JHJ"!3^8E"AQ(*:C65G&(9 MB[%L?,B:+"?AR5H=8-SHTE+T'&0Q_5"5R-!I&`X0%O2DJBS M7UM(1L6>;-$N_TB_%EFD0ZET)$63CU1'3&O/_CBX8=.IL2*]$]W6S/T'NZ\P M>(9!8]>(JPTJF%&=)+/F3(T%#5ZW1^)Q.#]U_%!WDJDZ?EIX2TD78H\6BGI!$]G`734^!WL>: MZ0"9S'5X"2ZSS3LT-G>\2"HI^B/BI!DYAU-$@=V(*)U&G/\7O"R?#&2L$\=-B8.<'((3!JV.3 MM84];I4,M\ZR7P?0V$`UT,"47^)9MGX%AU>BH@"Y^DXC"/:7/^M$!M92W$ M.SZ%\!]'G/[K%2?]JKT'P2VODGX\)23OD$[-^'F43!"@DH9PJZ$#<"83G%:" MU/E9@2-"$^BAR>%`GV6RW"2YT=I#H6MOR602DJRME$)2*DGFULDN#N7$9AFM M0$ZR_FMZG2.G;/OU[N[+]=?KV\?5%W"U?KC\LGGX]?X:;&[`[>;V_'+U\%=P M\V7S.[A9WZYN+]>WOX#5Y>/ZM_7C^OI![]V^9KY=)*J\+;M9-\HU>(/`.B@^ M0)P&%K])>O&>?P>8.8EO4%WY2I*\;K)/T,WCPW0%5N9DX^5=+!UP< MFQ!XLUO9=H!F,FL/?5P81H\^5N4.3:QMYV#5?N?&\G1&HZ;*2GOIC!&>RHUA MIL;-@:0]\.A3]J9-Z@M8/1JG&L$&9!SYF-:CA>)7?4I&09'.BHWB)$:)?.#A M"^P'ZYVL')"%!-;[[(.(CVW##3-@MK*_CDE6.LVKF4Y5RRF<.%4:ESPCNS3B M!?1L@4'[5.@4+&8C+*KF,EP7RL]:V+#;>WP([8_/_NNG+72HLZ,?RCZ.?O7] M,;!P$J>']_V37_XDU;\K\.E*HY+W\6>SN'.**P-:6ZT3GZ*\*:=\WU[+=0KL MK6Q\G8QL61\)7O)K(Z<5U3U>)2CA^11GXEITJ%F3@S`3H@0PL@\;CO=%0-3V1I&Z[5<"@=B8DLT@N937DRFP,AL]G02\8\ M,IL#(7-S0!PR]PRH&9F;HSKYG--@Z&U*TMOLF]YC>7J/!T+O<4._F?#H/1X( MO9L#XM"[9T#-Z-TGWRP;#[[$DO\>M^=W1&DD`K?`8O)-C),Q0("JIJM1"E6[PF%4\6I=)^%Y46"CA8-;N^/YZH4Q57=3@Z"/Y\)Z9I(4L<266"K!80.4"*EAQ.J.>,),41I/&2K_X9(*>LD0:R&;+W,Z$W`BZ6D& MPXWFX,SZOJ0NE\0@%VUD/BTMJ"M" MD-8E!V+&_0>7Y!GV6%(IGU#&GZQ@LK=.PKQSVB/U!*;HY1 M&%GD+2/6DE0+*:H7-YNK*)L#<3RBZYY)"R!N`F2Y,.,^-R<<_'B!`01$`>*@ ML18`K[GCB^&AM:>GG0)X\$G6%@LY+0A171<"!*^?VV;[6>([$=ME-BG M:DH-2["]&L,L&,.*C>&ESI2D[J&&.(9TZ?8I]:1M;*D#*DX*`=MR[2,=-FB9 M/9P8:=)%W99FIZ$F!OX%243_1O]"/R"C0?2/_P%02P,$%`````@`ZWVR0"PS M^;4>&0``Y!("`!4`'`!C=&EX+3(P,3(P,S,Q7W!R92YX;6Q55`D``TFGMD]) MI[9/=7@+``$$)0X```0Y`0``[5U=<^.XE7W>J9K_H#@O255D6W9W9Z:K.RE_ M=KFVVW+9GLSLODS1)"1S0Y$:@G+;^?5[`5(B*0(@0)$"!2$/2<<"R(M#X.+@ M?N'3/U]GP>`%Q=B/PL\'H\/C@P$*WAF!G M._CJA_]^`/_UV?O]U<'(X&@R>DV3^\>CH^_?OA\B;.O$PHD\_ M=*/9T6`X7+[Y7ZF,'P#=&)XPW?34:C MX=,$G0R]#S]-/HSCGQY'[SZ^._WX M[OA_BZVC^5OL3Y^3P5_'43P]@F>?'BT;'OSXPR!M_/$5^Z4.WT^7S4=' MOWW[^N`^HYDS]$.<.*%;ZD@>QNHZ^OGGGX_HKVEK['_$]"E?(Y="(R'@@-N" M_+_ALMF0_&D(")^.#E^Q=_`/\L)/<12@>S094!D^)F]S]/D`^[-Y@`ZROSW' M:/+YP$W\5P+WR?%IVO_/EY&[F,'T6OZO$WI78>(G;S?A)(IG5/J#`7G^+_G),TI\UPG:'Q>LZ6B&SH($Q2%, M@!>TV4"JCVM'8M!!TKSZH\%S."ST!L#2/%%-)O#3RC$\.Y4 MF,T&I/8J[8-M82ZJOZ^[V7GAX.?K(/J.;T+/CY&;;#:TZN/:D?@V2A!^C%:K M>/5*?.LDBQB-)^,Y(1"PL'&#$2@]ONL1G3O8Q^/)F>L"+TF`1[4ZH.K3NQ[/ MEPC>V/6H06W-_(3^$S09P$^$@5.`CW#7'USQU5TC<>WX\;^<8('REW?TX<5O MZGJ<]RB`?Q+JE+P]QDZ('9^VO].K.9\+B":,_%O#/JY?NU@/_+=GXY@73&;&< ME08*C5'H$IFI35J4G^\KO,YSE[PDGLD(->23CU_MWCNA0C M1>L.Q7[D7X;$"L>C/W4M#URB<>!Z=IX`E3OGW+12ECWB\2(CSPZ,F%YZPHD[;DOPRFCE^R)4Q^WE;TES[`8HO M8-U-HYC_E8IL\RPNR^;$[O)!\,\*U2P[_+(61W-J\1ZZSWZP M8JF3.)HUX2A+:2*6(AQ$,9R>J-,:_G,P@)%,$-`S[VLZ:*ZD5,P$#EZ(MB0] MX>P!(GP^.#D8+#",,IH3.1P].,GN]TM8RKM9CLIHKU%9.V7DL)SL-2P<:I;# M68#8A[HN')Z?]AH> MOHTN1^CGO4:(>9I;@3/:;XHL8S+(L3*/.#--3$MP*J=9DP]60B3$4VH)R_&Q MB'=>XEDPRA;6S1F3CXB4*RP,.IX\Q3LPX*$KS\ MR[I])_OS[UFL$+YSWLCTS3;%-6-/3>/FEJB-Y(X7,#M\Y\D/Z/*K%9W37HOT MGN>G<_+.\;V;\,*9^XFS;F.K:ZU%7/M1GUP<5R:GD3XY:^9JJ8UV M*:5`76^K0VH2:\P1DOZD12:BW<<3RA"97AI!0RWR\L,G>8(+>N@:0;:KGGU# MLR<4"P1?:ZA/7OK=:?BF4-I",SVRKL*K2""B6(UQ&O=`[MLH=%5$+[37(?TE M>D%!-"=+#(CD%`%Q1C'07`S"37S73X#<+&8+&OQXN8AA^:WWX`RSA0?KP.-J M-@^B-X2R>$]I#EC?;]_\]=OT.C?_WH4/Q?FRQ1::)80]L!J)6R\VNUL?QU)# M!Z6[:QZ;6%7TY)Q8%4,>_3XPH&.$-$M3U1A1 MTZE'XZAE2O7]M(WF'KG(?R$3!]^B&JXJZ*!#_KNE];/V6,!JJ4GBN>-[5Z\D M&Z?&C,ANJT/JE5VV>/IF,*'Z]EJEKSBI>&)_;2%BNP5Y&5;PFGU-JJO6,;%" MK3F-],@IR4E[PD*5>6?/F.9CC!R\B-]J%3BCH0Y_G=B.3EQV-;;AE?_NQ*Q0 M+55@BD@TB.R+YF M:GI'&[A)6(M,3?]H`SZ!.]+4I)"65^NFJ2']W_DVFU^"(`Y3DT?:`$[4VM2T MDI97)L?_N5G6R4XM5QD6SXFZ-37SI#%*/+>:J5DHS8"2"(@Q-16E&6!U7ML< M+>.YOP1:2E[\'#KC>;^,"903,)FC9#S-ET!)O`3-Y/>UKN?2-&*8P4RWZ_"] MVU5[*(.EC\QDZ7*HR'/Y'"\SO0\J,0?EDV#9K[\WJVV_\WGKX9#0WQDX)Q:< MHI8R-]=9/F9ES1U%M.42BD__>0"2T@I]T?>SO;9&+ M\O55^BM>K!FT5.I?L+O:+'-3<[2I&.>R\IYKEY=^99B=XY@N38_JZ3L4TTI5 MP@&(>VH>45IHZVR1/(,*_$^NK?@CJ?3HQ0AN,%[(2Y^U[H7D_+KH4EU:N=FB M>#:@_@GVO!:WU9+-OT"/DI#OGKY9*^H@"4[ZQ^7I!JNZ=27 M<0B5L:!#7^2O5\EUO6S^96/I*[X8FW^Y]3'U//^R9#!)%Q]'6%;+'4_!,#2" M7AF9\RHR9@7)V.04&^71292'E,W.]-P).:Q$YTM3[]-00TCV?&9ZID03M*JG M/M/S(IJCM#Q3FGKCQN8(L6]+,#3Y00Q3C5'3](0'N3DDY=

XML 32 R10.htm IDEA: XBRL DOCUMENT v2.4.0.6

Going Concern
9 Months Ended

Mar. 31, 2012

Going Concern

3.         Going Concern

The accompanying financial statements have been prepared assuming the Company will continue as a going concern. For the period since June 20, 2007 (date of inception) through March 31, 2012, the Company has had a cumulative net loss of $14,698,226and a working capital deficit of $7,057,183 at March 31, 2012.  As of March 31, 2012, the Company has not emerged from the development stage. In view of these matters, the ability of the Company to continue as a going concern is dependent upon the Company’s ability to generate additional financing. Since inception, the Company has financed its activities principally from the use of equity securities, debt issuance and loans from an officer to pay for its operations. The Company intends on financing its future development activities and its working capital needs largely from the issuance of debt and the sale of equity securities, until such time that funds provided by operations are sufficient to fund working capital requirements. There can be no assurance that the Company will be successful at achieving its financing goals at reasonably commercial terms, if at all.



The economic downturn and market instability has made the business climate more volatile and more costly.  If the current equity and credit markets deteriorate further or do not improve, it may make necessary debt or equity financing more difficult, more costly and more dilutive.  Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on the Company’s growth strategy, financial performance and stock price and could require the delay of new product development and clinical trial plans.  Currently, the Company has not made any additional arrangements for equity or any other type of financing.

These factors raise substantial doubt about the Company's ability to continue as a going concern. The accompanying financial statements do not include any adjustments relating to the recoverability of the recorded assets or the classification of liabilities that may be necessary should the Company be unable to continue as a going concern.

X

- Definition

Going Concern Disclosure [Text Block]

+ References

No definition available.

+ Details

Name: ctix_GoingConcernDisclosureTextBlock

Namespace Prefix: ctix_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.6 Html 124 128 1 false 17 0 false 4 false false R1.htm 101 - Document - Document and Entity Information Sheet http://www.cellceutix.com/taxonomy/role/DocumentDocumentandEntityInformation Document and Entity Information true false R2.htm 103 - Statement - Balance Sheets Sheet http://www.cellceutix.com/taxonomy/role/StatementOfFinancialPositionClassified Balance Sheets false false R3.htm 104 - Statement - Balance Sheets (Parenthetical) Sheet http://www.cellceutix.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical Balance Sheets (Parenthetical) false false R4.htm 105 - Statement - Statements of Operations Sheet http://www.cellceutix.com/taxonomy/role/StatementOfIncomeAlternative Statements of Operations false false R5.htm 106 - Statement - Statement of Changes in Stockholders' Deficit Sheet http://www.cellceutix.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome Statement of Changes in Stockholders' Deficit false false R6.htm 107 - Statement - Statement of Changes in Stockholders' Deficit (Parenthetical) Sheet http://www.cellceutix.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical Statement of Changes in Stockholders' Deficit (Parenthetical) false false R7.htm 108 - Statement - Statements of Cash Flows Sheet http://www.cellceutix.com/taxonomy/role/StatementOfCashFlowsIndirect Statements of Cash Flows false false R8.htm 109 - Disclosure - Background Information Sheet http://www.cellceutix.com/taxonomy/role/NotesToFinancialStatementsNatureOfOperations Background Information false false R9.htm 110 - Disclosure - Financial Statements Sheet http://www.cellceutix.com/taxonomy/role/NotesToFinancialStatementsBasisOfAccounting Financial Statements false false R10.htm 111 - Disclosure - Going Concern Sheet http://www.cellceutix.com/taxonomy/role/NotesToFinancialStatementsGoingConcernDisclosureTextBlock Going Concern false false R11.htm 112 - Disclosure - Recent Accounting Pronouncements Sheet http://www.cellceutix.com/taxonomy/role/NotesToFinancialStatementsNewAccountingPronouncementsTextBlock Recent Accounting Pronouncements false false R12.htm 113 - Disclosure - Commitments and Contingencies Sheet http://www.cellceutix.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock Commitments and Contingencies false false R13.htm 114 - Disclosure - Fair Value of Financial Assets and Financial Liabilities Sheet http://www.cellceutix.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock Fair Value of Financial Assets and Financial Liabilities false false R14.htm 115 - Disclosure - Related Party Transactions Sheet http://www.cellceutix.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock Related Party Transactions false false R15.htm 116 - Disclosure - Due To Officer Sheet http://www.cellceutix.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock Due To Officer false false R16.htm 117 - Disclosure - Stock Options and Warrants Sheet http://www.cellceutix.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Stock Options and Warrants false false R17.htm 118 - Disclosure - Equity Transactions Sheet http://www.cellceutix.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock Equity Transactions false false R18.htm 119 - Disclosure - Convertible Debentures Sheet http://www.cellceutix.com/taxonomy/role/NotesToFinancialStatementsConvertibleSeniorDebenturesDisclosureTextBlock Convertible Debentures false false R19.htm 120 - Disclosure - Subsequent Events Sheet http://www.cellceutix.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock Subsequent Events false false All Reports Book All Reports Warning: The equity rendering routine was not applied to 106 - Statement - Statement of Changes in Stockholders' Deficit. None of the elements feature the 'periodStartLabel' preferred label role. Process Flow-Through: 103 - Statement - Balance Sheets Process Flow-Through: Removing column 'Mar. 31, 2011' Process Flow-Through: Removing column 'Jun. 30, 2010' Process Flow-Through: Removing column 'Jun. 30, 2009' Process Flow-Through: Removing column 'Jun. 30, 2008' Process Flow-Through: Removing column 'Jun. 30, 2007' Process Flow-Through: 104 - Statement - Balance Sheets (Parenthetical) Process Flow-Through: 105 - Statement - Statements of Operations Process Flow-Through: Removing column '0 Months Ended Jun. 30, 2007' Process Flow-Through: Removing column '12 Months Ended Jun. 30, 2011' Process Flow-Through: Removing column '12 Months Ended Jun. 30, 2010' Process Flow-Through: Removing column '12 Months Ended Jun. 30, 2009' Process Flow-Through: Removing column '12 Months Ended Jun. 30, 2008' Process Flow-Through: 106 - Statement - Statement of Changes in Stockholders' Deficit Process Flow-Through: Removing column '3 Months Ended Mar. 31, 2011' Process Flow-Through: Removing column '9 Months Ended Mar. 31, 2011' Process Flow-Through: 107 - Statement - Statement of Changes in Stockholders' Deficit (Parenthetical) Process Flow-Through: 108 - Statement - Statements of Cash Flows ctix-20120331.xml ctix-20120331.xsd ctix-20120331_cal.xml ctix-20120331_def.xml ctix-20120331_lab.xml ctix-20120331_pre.xml true true